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SUMMARY
The lite ra tu re  re la ting  to the ontogeny o f the opioid system and to the tox ic  
e ffec ts  o f lead in both man and animals w ith  pa rticu la r reference to neurochemical 
and behavioural to x ic ity  o f lead is reviewed.
The e ffe c ts  o f perinata l lead exposure on the development o f several aspects 
o f opioid function has been studied using a dosing model o f lead (as the acetate) in 
the m aternal drinking w ater from  conception un til postnatal day 14 or 21. This 
model o f low level perinata l lead exposure in rats had no tox ic  e ffec ts  on growth 
and produced blood lead levels close to the safety lim its  set fo r human exposure
and s im ila r to those tha t have been recorded in some children.
The ontogeny o f morphine antinociception using the ta il immersion test and 
ketocyclazocine in the paw pressure test was studied in 10, 21 and 30 day old rats. 
Perinata l lead exposure decreased the antinociceptive a c tiv ity  o f both morphine 
and ketocyclazocine in 10 day old rats. Recovery o f morphine antinociception 
occured by 21 days and ketocyclazocine antinociception by 30 days.
Radioligand binding studies w ith  t^H lD A G O  were used to study the
ontogeny o f p-opioid receptors in 10, 21 and 30 day old rats. Perinata l lead 
exposure was w ithou t e ffe c t on equilibrium  dissociation constant or m axim al 
binding capacity.
Radioligand binding studies w ith  t ^H l DPDPE were used to study the
ontogeny o f 6 -opioid receptors in rats between 13 and 30 days. The a ff in ity  o f the 
6-opioid binding site fo r [^H ] DPDPE was reduced by perinata l lead exposure but 
w ithou t accompanying changes in binding capacity. This e ffe c t o f lead on <5 -opio id 
receptors was persistant and was observed in rats aged 15-50 days.
Basal plasma corticosterone levels (measured flu o r im e trica lly ) were elevated 
by perinata l lead exposure in 45 and 60 day old rats but not in 30 day old rats. In 
addition the modulatory e ffe c t o f morphine on stress induced elevations o f 
corticosterone levels was also a ffected  by lead exposure. A reduced e ffe c t of
morphine was seen in 30 day old animals w hilst an increased e ffe c t was seen in 60 
day old animals.
Locom otor a c tiv ity  (measured by photocell detection) o f 10, 21 and 30 day 
old rats was recorded over 1 hour during the dark phase o f the ligh t/da rk  cycle. 
Exploratory locom otor a c tiv ity  was reduced in lead exposed animals at postnatal 
day 10 and the hypolocomotor e ffe c t o f morphine was also increased in 10 day old 
lead exposed animals.
The opioid system is pa rticu la rly  sensitive to perinata l low level lead 
exposure and this is manifested in several aspects o f physiological function. 
Possible mechanisms by which lead a ffec ts  the development o f the opioid system 
are discussed.
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1. INTRODUCTION
1.1. Historical perspectives of the opioid system.
The pleasant psychological e ffec ts  o f the extracts  o f opium poppy seed heads 
have been known fo r thousands o f years. The ancient Babylonians are known to 
have used opium, the ju ice  extracted  from  unripe seed capsules, as early as 4000 
BC and its  use continued throughout h istory o ften as a sleeping draught although its  
benefic ia l e ffec ts  in the case of diarrhoea was reported in Chinese m edical texts  in 
the 11th  century.
The iso lation o f morphine from  opium did not occur un til the beginning o f the
ii
19th century when a German sc ien tis t S e rtu rner successfully extracted  the pure 
compound. From this tim e the opium alkaloids were used extensively fo r many 
ailm ents un til the problems o f misuse and dependence were exacerbated by the 
invention o f the hypodermic syringe. The use o f opium alkaloids is now res tric ted  
and closely supervised, but is s t il l o f great value to re lieve visceral and traum a tic  
pain and to  re lieve anxiety in the dyeing or in serious or frigh ten ing  disorders. 
They are also used in small doses to contro l diarrhoea and suppress cough.
The unwanted side e ffec ts  o f tolerance and dependence o f morphine resulted 
in much work on the production o f analogues tha t reta ined the pow erfu l analgesic 
a c tiv ity  o f morphine but did not possess the unwanted side e ffec ts . This resulted in 
the production o f a series o f powerfu l analgesic compounds and also compounds 
w ith  antagonist properties. Studies o f these compounds which were very potent, 
and stereoselective indicated the possib ility  o f an endogenous receptor site and 
receptor binding studies were demonstrated in discrete brain regions associated 
w ith  pain pathways.
Subsequently the presence o f an endogenous ligand fo r the opioid receptor 
was demonstrated. In it ia lly  extracts  o f pig, rabb it, guineapig and ra t brain was 
shown to  have inh ib ito ry  a c t iv ity  on the e le c tr ica lly  evoked tw itc h  o f the mouse 
vas deferens s im ila r to tha t o f morphine tha t was also naloxone reversib le . 
P u rifica tion  o f this compound from  pig brains yielded a peptide in 1975 (Hughes,
1975) tha t was named enkephalin from  en kephalos (in the head) (Hughes et al., 
1975).
During the fo llow ing 12 years the physiology, pharmacology and biochem istry 
of th is endogenous pain system has been studied extensively and the d ive rs ity  and 
com plexity o f the system w ith  at least 20 d iffe re n t peptides id en tified  and 6 
d iffe re n t receptor subtypes proposed has been revealed. Current e ffo rts  continue 
to  make use o f molecular biology techniques to isolate and sequence the receptor 
subtypes and to determ ine the m olecular actions o f opioids.
As w ith  other neurochemical systems the understanding o f endogenous opioid 
ontogeny has been preceded by a good deal o f experim ental study in the adult. 
App lica tion  o f methodology established fo r the adult is o ften d if f ic u lt  in the 
neonate and in th is respect endogenous opioids are no exception. Nevertheless, the 
enormous s c ie n tific  e f fo r t  that was made in th is area in the la te  1970's resulted in 
the publication o f ontogenetic studies from  several laboratories by 1980, only five  
years a fte r the in it ia l iso lation o f a morphine like  substance from  pig brain 
(Hughes, 1975). This in troduction  covers the lite ra tu re  on ontogeny o f the opioid 
system since 1976 and in addition includes earlie r whole animal studies on the 
ontogeny o f morphine antinociception and to x ic ity . Sections cover the ontogeny of 
opioid peptides, receptors and pharmacology. Studies o f a h isto log ica l nature and 
ontogeny o f opioids in tissue cu lture  are beyond the scope o f th is in troduction  but 
i t  should be recognised tha t there is also extensive lite ra tu re  in these areas. 
Ontogenetic studies have yielded in fo rm ation  on in terre la tionships between opioids 
and various physiological functions such as peripheral and centra l pain perception, 
behavioural contro l by the lim b ic  system and neuroendocrinological con tro l. Much 
experim enta l work has been d irected at determ ination o f levels o f endogenous 
opioids and the d is tribu tion  and k ine tic  parameters o f opioid receptor binding. In 
addition the link between opioid ontogeny and behavioural and physiological 
development in the whole animal has been studied using various pharm acological 
tests.
I t  should be noted that there are several methodological constraints 
associated w ith  developmental studies. L im ita tions  imposed by the size o f foe ta l 
and embryonic brains are pa rticu la rly  a problem in small animal species. In 
addition short gestation periods and rapid postnatal development in small animals 
necessitates accurate determ ination o f the tim e o f conception and b irth . I t  is also 
worthy to note the differences in re la tive  m a tu rity  between animal species during 
the perinata l period. For example the guinea pig at b irth  has its  eyes open, 
exhibits many adult responses and in brain tissue, ce ll p ro life ra tion  is com plete. In 
contrast the newborn ra t is im m ature, eye opening occurring only a fte r two weeks 
and cell p ro life ra tio n  in the brain continuing beyond th is tim e.
1.2. Opioid Peptide Ontogeny.
1.2.1 In troduction .
As would be expected levels o f opioid peptides in the developing neonate are
considerably less than in the adult and this has necessitated sensitive assay
techniques. Some of the early studies employed radioimmunoassays w ith  su ffic ie n t
sens itiv ity  but re la tive ly  poor se le c tiv ity . Thus results were expressed as
enkephalin or endorphin equivalents. More recently  HPLC (Bailey & K itchen, 1985;
Dahl e t al., 1982; Epstein & Dahl, 1982; Seizenger et al., 1984; Winder e t al., 1984)
or gel f i lt ra t io n  chromatography (Hovious & Peters, 1984; Sandman et al., 1979;
Weissman et al., 1983) combined w ith  radioimmunoassay or bioassay (Bailey &
K itchen, 1985; Winder et al., 1984) have allowed measurement o f specific  opioid
peptides. Tbis is extrem ely im portant since there may be upto 20 opioid peptides
derived from  the three opioid peptide precursor molecules serving d is tinc t
physiological functions (fo r review  see K itchen, 1984). In b r ie f, there are three
opioid precursors; proopiom elanocortin which produces 8-endorphin; proenkephalin
which is processed to y ie ld four major enkephalin peptides, [M e t!-enkepha lin ,
[ Leu ] -enkephalin, [ M e t]-enkepha ly l-A rg^-P he^ and [ M e t]-e n ke p h a ly l-A rg ^- 
7 8Gly -Leu ; and prodynorphin which is processed to various dynorphin peptides and
a and 8 -neoendorphin a ll o f which are extended sequences of 1 Leul -enkephalin.
I t  should also be noted tha t the sens itiv ity  o f the assay determines the l im it  
fo r earliest detection since levels in foe ta l animals are extrem ely low. Expression 
of results is also im portan t in the comparison o f studies. Levels may be expressed 
per brain region, per g wet weight of tissue or per mg protein. Levels per brain 
region invariab ly increase w ith  age u n til adulthood whereas concentrations per wet 
weight tissue or per mg prote in w ill vary and are dependent on the re la tive  
increases o f both the opioid and the prote in content o f the brain region. This has 
the most marked e ffe c t on peak levels; i f  results are expressed per brain region 
then the peak is usually seen at the oldest age studied or in adult animals, whereas 
i f  results are expressed as a concentration the peak may occur at d iffe re n t times 
during ontogenesis.
The m a jo rity  o f ontogenetic studies have been carried out in the ra t centra l 
nervous system (CNS) (Table 1). Foetal studies have confirm ed tha t a ll opioids are 
present in the CNS w e ll before b irth . W ith the exception o f the cerebellum , the 
peak level of endogenous opioid peptides appears to occur during the th ird  
postnatal week, but as discussed previously th is is dependent on whether results are 
expressed per brain area or as a concentration. This progression o f development is 
m irrored by the ontogeny o f opioid receptors (see Section 1.3).
The early work o f Garcin and Coyle (1976 & 1978) showed the ontogeny o f an 
endogenous morphine like  fa c to r in the ra t CNS which was capable o f inh ib iting  
naloxone binding. A t embryonic day 17 levels o f th is fac to r were 20% o f tha t 
found in the adu lt increasing to  46% a t b irth . During the f ir s t  postnatal week 
levels remained constant before increasing to adult values and showing some 
para lle l to the receptor development. In the fo llow ing years more se lective assays 
have been employed to investigate the ontogeny o f the various opioid peptides and 
this is described in the fo llow ing sections.
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1.2.2. Proopiom elanocortin products
8 -Endorphin can be detected as early as embryonic day 13 in ra t whole brain 
(Ng e t al., 1984). Bayon et al. (1979) and Bloom et al. (1980) measuring 
8 -endorphin in separate brain regions at embryonic day 16 found the d is tribu tion  to 
be s im ila r to the adult pattern  although levels were only <2% of the amounts found 
in 23 day old animals. H isto log ica l studies have also demonstrated the presence o f 
8 -endorphin im m unoreactiv ity  at embryonic day 14 in the spinal cord (Haynes, et 
al., 1982) though th is immunofluorescence disappears abruptly by postnatal day 28, 
and is absent in the adult.
Ng e t al. (1984) demonstrated tha t 8 -endorphin content of several brain areas 
increases w ith  age, but absolute concentrations in the forebra in and hindbrain 
increased only m in im a lly  a fte r  embryonic day 18 which re flec ted  large increases in 
the protein content o f these areas. A s im ila r observation has been made by other 
workers (Bayon et al., 1979; Bloom et al., 1980); w ith in  the telencephalon, 
hippocampus and s tria tum  levels o f 8 -endorphin increase less rap id ly than prote in 
concentrations between embryonic day 16 and postnatal day 6 and accordingly 
8 -endorphin levels are seen to fa ll.  However, true decreases in 8 -endorphin 
content have been shown in the mediobasal hypothalamus during the second 
postnatal week (Hompes et al., 1982). Subsequent to these early postnatal 
fluctua tions most workers have found tha t levels increase to adu lt values, w ith  the 
exception o f Tsang & Ng (1980b) and Tsang et al. (1982b) who reported peak levels 
o f 8 -endorphin in the forebra in at 13 days, in the brainstem at 20 days and at 
3 days in the cerebellum followed by decreases in content to adult values (Tsang & 
Ng, 1980b; Tsang et al., 1982b). In addition 8 -endorphin in the p itu ita ry  remained 
constant un til the second postnatal week before increasing rap id ly  to adu lt levels 
at day 20 (Tsang & Ng, 1980b; Tsang et al., 1982b).
Most recent studies have shown increases in 8-endorphin im m unoreactiv ity  in 
the hypothalamus, amygdala, pons m id-brain, cortex and p itu ita ry  between 10 and 
80 days (Kapcala, 1986). Only the hippocampal regions showed a decrease between
29 and 80 days. There are also indications o f a d iffe re n tia l a c tiv ity  o f processing 
enzymes fo r proopiom elanocortin which are both age and brain region dependent 
(Kapcala, 1986).
Alessi et al. (1983) have demonstrated a d iffe re n tia l development of 13- 
endorphin in the an terio r and in term ediate lobe o f the p itu ita ry . In contrast w ith  
the work o f Tsang & Ng, (1980b) and Tsang et al., (1982b) levels o f 8 -endorphin 
increased in both areas from  b irth  to adulthood. However, the ra te  o f increase in 
the two areas varied a fte r postnatal day 7, increasing more rapid ly in the 
in term edia te  lobe than in the an terio r lobe where levels did not rise u n til puberty 
(days 35-42). In addition N -ace ty la tion  o f 8 -endorphin occurs in both lobes o f the 
p itu ita ry  at b irth  (Alessi et al., 1983), but n -ace ty l 8 -endorphin constitutes a much 
higher proportion o f to ta l endorphin in the in term edia te  lobe (70%) than in the 
an terio r lobe (25%). The proportion in the an terio r lobe decreases to adult levels 
of < 5% by day 42 whereas in the in term ediate lobe n -ace ty l 8 -endorphin increases 
to 90% of to ta l endorphin. Again, there is c learly  a d iffe re n tia l m etabolic 
ac tiva tion  which is age dependent.
As can be seen from  the preceding discussion there are marked regional 
differences in the postnatal development o f 8-endorphin and some disagreement 
between studies. The question o f whether 8-endorphin develops in para lle l w ith  its  
pu ta tive  receptor (the p receptor) must remain open since binding studies w ith  
selective ligands show rapid postnatal development o f th is receptor to day 21 and 
on th is point there is good agreement between laboratories (Section 1.3.4.). 
However in the only study where 8-endorphin levels and receptor binding were 
monitored in para lle l (Tsang et al., 1982b) there was some accord in the 
developmental p ro file .
Mechanisms fo r the stim ulated release o f 8 -endorphin are im m ature at b irth . 
Spontaneous or potassium stim ulated release o f 8 -endorphin from  hypothalam ic 
slices is low at 10 days and does not reach postpubertal levels u n til day 20 (Hompes
L it t le  work has been carried out in man due to d iff ic u ltie s  in obtaining 
m ate ria l though measurements o f 8-endorphin have been made in a lim ite d  number 
of cases. 8-Endorphin can be detected in the p itu ita ry  at 8 weeks o f gestation 
(Celio e t al., 1980). Levels o f 8-endorphin in plasma show a wide varia tion  
although increases are detected in both the mother and child at b irth  (Moss, et al.,
1982). Further increases are seen in the cerebrospinal flu id  o f children i f  apnoea is 
present (Burnard et al., 1982) which accords w ith  studies in rabbits. The increased 
levels detected around b irth  remain high fo r approxim ately 4 days and then fa ll to 
adult levels (Moss et al., 1982). I t  has also been noted tha t the ra tio  o f 8 -endorphin 
to 8-lipo trop in  is higher in neonates than in adults which like  the studies in rats 
probably re fle c ts  d iffe re n tia l processing o f the precursor peptide (Vuolteenaho et 
al., 1983).
1.2.3. Proenkephalin products.
[M et] - and [ Leu ]-enkephalin  have been detected at s im ila r tim e  points to 
8-endorphin. Dahl e t a l. (1982) observed tM e t ] -  and [ Leu ]-enkepha lin  like  
im m unoreactive form s at embryonic day 13. However, HPLC separation revealed 
th a t the enkephalin measured was due to m u ltip le  im m unoreactive form s. O f the 
[ Leu ] -enkephalin im m unoreactiv ity , measured at embryonic day 16, 70% was due 
to a form  tha t eluted ea rlie r than the I Leu] -enkephalin found in adult animals. 
This was decreased to  30% at 1 day and only 19% at 14 days postnata lly . The 
m u ltip le  form s o f tM e t 1 -enkephalin were only detected prenata lly. These m u ltip le  
form s have also been detected in embryonic gut samples and lim b buds and i t  has 
been suggested tha t they may be due to sulphated groups in the enkephalin 
molecule (Dahl, et al., 1982). Others have not been able to de tect enkephalin 
im m unoreactiv ity  un til embryonic day 16 (Bayon et al., 1979; Bloom e t al., 1980) 
and even then only at 0.08-2% o f levels found in 25 day old animals. In addition, 
the d is tribu tion  o f enkephalin does not resemble adult patterns.
H isto log ica l studies have detected enkephalin im m unoreactiv ity  at embryonic 
day 15 in the m idline from  the ventra l pons to the cerv ica l spinal cord (Palmer et 
al., 1982). In the lower brain stem (Senba, et al., 1982) [ Leu I-enkephalin
im m unoreactiv ity  can be detected at embryonic day 16 w h ils t enkephalin like  
im m unoreactiv ity  can be detected at embryonic day 18 in the centra l perikarya and 
processes (P ickel e t al., 1982). In the neostriatum  however [ M et!-enkepha lin  
a c tiv ity  is not detectable u n til embryonic day 20 (Pickel et a l., 1981). The 
hippocampal form ation appears to develop ra ther la te r as [ Leu ] -enkephalin like  
im m unoreactiv ity  is not detectable un til postnatal day 4 (Gall, 1984; Gall et al., 
1984). In the North Am erican Opposum, which is born a fte r only 12 days gestation 
and completes its  development in its  mothers pouch, enkephalin like  
im m unoreactiv ity  is present at b irth  and increases to adult like  d is tribu tion  
patterns by 30 days (Di T irro  et al., 1983).
Peak levels o f enkephalin determ ined by radioimmunoassay have been shown
to occur in the f irs t  postnatal week in the cerebellum, the second postnatal week in
the brainstem and at the th ird  week in the forebra in, indicating a caudal to ros tra l
sequence of development (Tsang, et al., 1982b) although in contrast consistent
increases in enkephalin levels in a ll brain regions up to postnatal day 25 have been
reported (Bayon et al., 1979). A more detailed ontogenetic study o f the opioid
peptide products o f proenkephalin has been reported by Bailey and K itchen, (1985)
w ith in  the s tria tum . A peak in [M e t3-enkephalin levels is observed a t postnatal
day 21 but the extended enkephalins [M e t!-enkepha lin  A rg^ Phe^ and [ M et] - 
6 7 8enkephalin Arg Gly Leu and [Leu ]-enkephalin remain constant between 10 and
6 7 830 days. [M e t]-enkepha lin  Arg Gly Leu in hippocampal regions is not detectable 
at embryonic day 20 and shows a slight decrease from  day 1 to day 7 but then 
increases rapid ly by day 14 (Zam ir et al., 1985).
As fo r 8-endorphin i t  is d if f ic u lt  to answer the question as to whether the 
proenkephalin system develops in para lle l to its  puta tive  receptor type (the 6 - 
receptor). Binding studies w ith  selective ligands agree th a t 6 -sites appear la te r in
postnatal development and are fu lly  developed by day 28 (Section 1.3.4.) but again 
there are in te rlabora to ry  differences in postnatal development. Nevertheless, 
where binding sites and peptides have been measured in para lle l the ir ontogeny 
shows s im ila r ity  (Patey e t al., 1980).
Although the m a jo rity  o f work has been concentrated on the ra t CNS, some 
studies have been carried out in the periphery. Adrenal [M et]-enkepha lin  content 
increases 10-fo ld  from  b irth  to  adulthood while [ Leu]-enkephalin  increases only 4- 
fo ld  (La Gamma et al., 1983b). The reverse is seen in the superior ce rv ica l 
ganglion where [Leu ]-enkephalin increases 10-fold w hilst [ Met] -enkephalin 
increases 5 -fo ld  from  b irth  to adulthood. Epstein and Dahl, (1982) and Epstein et 
al. (1981 and 1983) have reported the ontogeny o f t Met! -enkephalin in various 
areas o f embryonic chick gut. I t  is f irs t  detected at 5 days o f incubation in the 
rectum  and duodenum. Levels in the rectum  increase u n til 9 days o f incubation and 
then remain constant w h ils t levels in the duodenum increase 4 -fo ld  by 13 days o f 
incubation and then decrease to levels found in the 4 week old chick. [M e t] - 
enkephalin is f irs t  detected in the ce ll bodies o f the ganglion o f Remak at 6 days. 
These ce ll bodies increase in number and produce processes in to the gut w a ll by 9 
days and varicosities o f ganglion cells are present by 13 days o f incubation. 
[M e t] -enkephalin is not detected in the m idgut u n til 9 days and increases 2-fo ld  by 
13 days o f incubation. White e t al. (1985) detected [Met] -enkephalin in the 
c ilia ry  ganglion o f stage 32 chick embryos. Levels increase 3-fo ld  to a peak at 
stage 37 and then decrease un til the adult levels are reached a fte r hatching.
[ Met] -enkephalin levels in the brainstem nuclei o f rabbits between day 3 and 
day 21 is unchanged w ith  the exception o f the nucleus tractus so lita rius where 
there is a tw o -fo ld  increase. (G inqras-Leatherman et al., 1986).
1.2.4. Prodynorphin products.
Dynorphin and a-neo endorphin im m unoreactiv ity  in the neuro interm ediate 
lobe o f the p itu ita ry  develop in para lle l (Seizinger et al., 1982). During the f irs t
th ir ty  postnatal days both dynorphin and a-neoendorphin im m unoreactiv ity  
increase, w ith  levels o f dynorphin im m unoreactiv ity  being s ligh tly  higher. A more 
detailed study o f the products o f prodynorphin shows tha t dynorphin A, dynorphin- 
(1-8), dynorphin B, a-neo-endorphin and 8 -neo-endorphin a ll progressively, increase 
in the ra t p itu ita ry  from  b irth  to adulthood (Seizinger e t al., 1984). Studies o f the 
molecular weight pattern  o f the prodynorphin products indicate tha t the 
neurointerm ediate lobes o f the p itu ita ry  o f neonatal rats have the a b ility  to cleave 
two basic lysine-argin ine residues o f prodynorphin to produce dynorphin-A. 
However, the production o f dyno rph in -(l-8) by cleavage at a single arginine residue 
from  dynorphin-A is not as w e ll developed (Seizinger et al., 1984). This is 
evidenced by the concentrations o f dyno rph in -(l-8) and dynorphin-A which are 
found at equimolar levels in the neurointerm ediate lobe o f adults but in newborn 
rats the concentration o f dynorphin-A is 3 tim es as high as dyno rp h in -(l-8). Also 
a-neo-endorphin, which is converted to 8 -neo-endorphin by cleavage o f a lysine 
residue at the C te rm ina l, is in equimolar concentrations w ith  8 -neo endorphin in 
adults but is 4 tim es more concentrated in the neurointerm ediate lobe o f newborn 
rats. Thus i t  appears tha t processing enzymes involved in cleavage o f single basic 
amino acid residues o f these peptides are not fu lly  developed at b irth .
Another study o f prodynorphin ontogeny (Gall, 1984) reported th a t 
dynorphin A and 8-neoendorphin in the hippocampal form ation, develop la te r than 
seen in other CNS areas, levels not being detectable u n til postnatal day 6 and 7 
respective ly. This contrasts w ith  dynorphin A, dyno rph in -(l-8), dynorphin B and a - 
neo-endorphin which are detectable at embryonic day 20 (Zam ir e t al., 1983).
The question o f para lle l development o f prodynorphin products w ith  its  
puta tive  receptor (the < receptor) has not been d irec tly  addressed in any o f the 
ontogenetic studies. However the rapid postnatal development w ith  peaks in the 
peptide levels at the th ird  or fou rth  week shows s im ila r ity  w ith  the receptor 
binding p ro file  (Section 1.3.4.).
1.3. Opioid Receptor Ontogeny
1.3.1. Theoretica l aspects o f receptor binding assays.
The study o f the binding o f a va rie ty  o f neuro transm itte r molecules and drugs 
to pu ta tive  pharmacological receptors has been made possible w ith  the a va ila b ility  
o f rad ioactive ligands o f high specific a c tiv ity  which can be used to measure 
binding to sites in ce ll or membrane preparations. The methods employed are 
re la tive ly  simple and are analogous to enzyme-substrate kinetics. However many 
a rte fac ts  may influence results obtained from  ligand binding experiments unless 
suitable controls are employed and the basic c r ite r ia  fo r receptor id e n tifica tio n  are 
fu lf il le d .
Binding assays employ radio labelled ligands fo r binding to  the receptor under
study. T ritium  and carbon 14 labelled compounds are most commonly used because
such labelling does not a ffe c t the b io logical a c tiv ity  o f the ligand or its  behaviour
in ana ly tica l techniques. In addition they can be obtained at high specific
125a c tiv itie s  and have a long ha lf life . The use o f I I I  is a poor a lte rna tive  as 
although i t  can be incorporated easily to very high specific  a c tiv ity  i t  can only be 
used when an arom atic hydroxyl group is present. In addition iodinated compounds 
may undergo damage during production or su ffe r radiation-induced destruction o f 
m olecular s tructure  and b io logical a c tiv ity  may also be a ffected  p a rticu la rly  i f  d i- 
or tri-iod ina ted  compounds are produced. Due to very low equilibrium  dissociation 
constant o f most receptor sites the radio labelled ligand must have a su ffic ie n tly  
high specific  ra d io ac tiv ity  to perm it detection o f the compounds a fte r  binding, 
o ften in as l i t t le  as fem tom olar concentrations. The radio labelled ligand must also 
be at least 90% pure due to the small proportion of radioligand tha t is bound, i t  
must be stable throughout the incubation period and must re ta in  b io log ica l a c t iv ity  
(Yamamura et a l., 1978).
Binding o f radioactive ligands even at low concentrations is not only to  the 
receptor o f in terest (specific binding) but also to non-receptor prote in and lip id  
sites (non-specific binding). Non-specific binding is determ ined by para lle l
incubations w ith  a 100-1000  fo ld  excess o f an unlabelled compound which also binds 
to specific  binding sites. This displaces a ll the specifica lly  bound radiolabelled 
ligand the remaining binding representing non-specific sites, and is subtracted from  
to ta l binding in order to calculate the specific  binding. Ideally the compound used 
to determ ine non-specific binding should not be chem ically re la ted to the 
radio labelled ligand so tha t binding w ill only be displaced from  specific binding 
sites and not from  other non-specific sites where binding is a ttribu tab le  to 
chemical s tructure . Non-specific binding may occur not only to the membrane 
preparation but also to physical components o f the assay system, fo r example some 
opioid compounds have been shown to bind to glass fib re  f ilte rs  (Snyder et al., 
1975). '
Membranes fo r binding assays are prepared from  a tissue believed to contain 
the receptors. C entrifugation  is employed to wash the membranes free  from  any 
endogenous substances which may in te rfe re  w ith  the assay. Some assays employ 
subcellular frac tiona tion  techniques to increase the concentration o f binding sites 
in the preparation.
The results o f the binding assay are dependent on the conditions during 
incubation. Ideally optim al conditions o f pH, ionic strength and com position, 
tem perature and optim al concentrations of tissue and ligand should be employed. 
However compromises are often made between producing incubation conditions as 
near to that found in the whole animal and to m inim ise metabolism or breakdown 
o f the ligand. As w ith  enzyme kinetics measurements o f binding are made at 
equilibrium  thus when lower temperatures are employed to preserve the ligand in 
its orig ina l form  then incubation times must be suitably extended to  a llow  fo r 
equilibrium  to occur.
Once equilibrium  is reached the bound ligand must be separated from  the 
remaining free ligand so tha t measurements o f bound ligand can be made. This can 
be achieved by a varie ty  o f methods, the most popular is f i lt ra t io n  under vacuum 
through a glass fib re  f i lte r .  Washing o f the f i l te r  removes any free  ligand. I f  the
dissociation ra te  is too fast fo r f i lt ra t io n  methods then membranes . can be 
harvested by cen trifuga tion  which does not disturb the equ ilibrium , however non­
specific  binding is higher due to quantities o f ligand not bound but trapped w ith in  
the membrane pe lle t. Other methods o f separation include equilibrium  dialysis, or 
gel f i lt ra t io n  where the receptor preparation is soluble.
To obtain the k ine tic  parameters of equilibrium  binding constant and 
apparent maximum number o f binding sites fo r a given radioligand and tissue 
preparation, k inetics s im ila r to those o f classic enzyme-substrate in teractions are 
used. The basic ligand binding model involves the reversible in te rac tion  o f ligand 
(L) w ith  a single class of receptor (R) fo llow ing the law o f mass action:
R + L = k _1 = K d
k i
where k^ is the ra te  constant fo r association and k^ the ra te  constant fo r
dissociation. Therefore at equilibrium
[ R ] [ L ]  = k_x = K d
[RL]
K1
where [ R ]  is the concentration o f receptors, [ L ] is the concentration o f ligand,
[R L ] the concentration o f receptor-ligand complex and the dissociation
constant. The to ta l number o f receptors B can be defined asmax
[ R ] + [ R L ]  Bmax
Thus by substitu tion w ith  the dissociation constant equation i t  is possible to 
obtain
£ RL] = B™=,v [max
K d + [ L ]
As [ RL] is the amount o f ligand bound to the receptor B, and [ L ] is the 
concentration o f free ligand F the equation becomes
B =■ B F max
k d  + f
which can be transform ed to the Scatchard equation (Scatchard , 1949)
B/F = B - B max
K D
However several assumptions are made when using this equation to determ ine
B and K n  from  a series o f incubations at various ligand concentrations. These max D a
include:
a) tha t the proportion o f ligand bound to  receptor sites is small - less than 10%
b) the binding o f the ligand is reversible
c) the receptor consists of a homogenous, non-in teracting class o f binding sites.
An a lte rna tive  approach is the use o f inh ib ition  or displacement studies where
the membrane preparation is incubated w ith  a fixed  concentration of radio ligand in 
the presence o f increasing concentrations o f another, unlabelled, substance whose 
a ff in ity  fo r the labelled site is o f in terest. From such binding data a H ill p lo t can 
be drawn tha t is a p lo t o f log B/(Bmgx- B) against the log concentration o f 
displacer ligand. From such a p lo t the concentration of unlabelled drug which 
inh ib its  50% o f the specific binding o f the radioligand can be determ ined (IC^g).
The inh ib ito ry  constant (K j) fo r the unlabelled displacing drug is calcula ted from  
the K p  v 
equation
alue fo r the radio labelled ligand (3HL) and the from  the fo llow ing
K I -  IC50
. 1 +  [ 3HL] /K D
If  the slope o f the H ill p lo t is un ity> im plying tha t the binding o f the
unlabelled compound is non-cooperative, and tha t the in te rac tion  o f the radio ligand 
is w ith  a single site , then the K j fo r the unlabelled compound approximates to its
dissociation constant K ^ .
However the presence o f a binding s ite  is not ind ica tive  o f binding to the 
appropriate receptor s ite . For such an assumption to be made several im portant 
c r ite r ia  must be met. The three basic c r ite r ia  are tha t the binding site is 
saturable, tha t the d is tribu tion  o f the binding site is in agreement w ith  the 
presence o f appropriate neurotransm itters and responses and that the 
pharmacology o f the binding site is in agreement w ith  the receptor pharmacology.
For more detailed aspects o f receptor binding the reader is re fe rred  to 
review artic les (Yamamura et al., 1978; Joseph & Waddington, 1987; Cattabeni & 
Nicosia, 1984).
1.3.2. Opioid receptor binding.
Ligand binding studies have p rim arily  been employed to fo llow  opioid 
receptor development in foe ta l and neonatal animals. Binding studies using 
membrane fra c tio n  homogenates o f brain tissue has been the main method 
employed, though the use o f hypothalam ic slices as an a lte rna tive  has suggested 
tha t homogenisation reduces the number o f viable binding sites (Bhanot & 
Wilkinson, 1983).
Binding studies in the adult have indicated at least three d is tinc t types o f 
opioid receptor (p, 6 and k ) and the ir ontogenetic p ro file  has been examined.
Since the early experiments o f Coyle and Pert (1976) who used t 3H1 naloxone as a 
binding ligand the development o f opioids more selective fo r the subtypes o f opioid
receptors has allowed a more detailed and accurate analysis o f receptor ontogeny.
2ID -A la  , G lyol ] enkephalin (DAGO) has been used as a selective ligand fo r the
2 5p binding site. 6 receptor binding has been demonstrated by using[D -A la , D -Leu ] 
enkephalin (DADL) though suppression o f p binding w ith  an excess o f DAGO is 
necessary because of the lack o f se lec tiv ity  o f this ligand. Opioids selective fo r  k 
binding sites have been slow to emerge and < ligands such as e thylke tocyclazocine 
and brem'azocine bind also at the p and 5 sites and accordingly p and binding
must be suppressed w ith  excess cold DAGO and DADL respective ly. The 
benzodiazepine compound tifluadom  has been shown to have se le c tiv ity  fo r the K 
receptor (Burkard, 1984) and the k -se lective Upjohn compound (U 69593) may 
prove to be a useful ligand in the fu tu re .
Studies tha t have used less selective ligands w ithout suppression o f binding to 
other sites make data in te rp re ta tion  d if f ic u lt  (Magnan et al., 1982 and Wood et a l., 
1981). Although morphine and m orphiceptin are re la tive ly  specific  fo r p binding 
sites both dihydromorphine, and naloxone in addition bind at both <5 and k sites 
(James & Goldstein, 1984), w h ils t 1 M et! -enkephalin, [Leu] -enkephalin and [ D- 
A la , M e t] -enkephalinamide (DALAM ID) bind at both the 5 and p sites w ith  
s im ila r a ffin it ie s . Studies w ith  these ligands have revealed l i t t le  about the 
development o f the receptor sub-types. Naltrexone, diprenorphine and etorphine 
bind to a ll 3 types o f receptor and therefore studies using such ligands can only 
indicate to ta l opioid receptor binding.
Comparison o f data is hampered by the va rie ty  o f methods used to express 
results. For example w ith  respect to maximal binding capacity data may be 
represented per brain* per mg wet weight or per mg prote in. This may produce 
apparent differences in the tim e o f peak levels and anomalies in rates of receptor 
increase.
As was seen w ith  endogenous opioid levels the study of opioid receptor 
ontogeny has p rim a rily  been carried out on the ra t centra l nervous system 
(Table 2). Prenatal receptor ontogeny studies have used only whole brain 
homogenates due to problems associated w ith  size o f foe ta l brain regions, 
dissection and accum ulation o f su ffic ien t m ate ria l.
Only a few groups have carried out complete saturation curves in postnatal 
studies, and most studies have employed a single concentration o f ligand to 
measure binding to receptors. This lim its  the amount o f in fo rm ation  tha t can be 
obtained as no measure o f a f f in ity  or receptor concentration can be made. Those
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tha t have carried out saturation curves are in general agreement tha t increases in 
binding w ith  age are due to increases in the concentration of receptors (Bmax) and 
not the a ff in ity  o f the receptor fo r the ligand (K ^ ) (Bardo et al, 1982; Bhanot & 
Wilkinson, 1983; Clendeninn et al, 1976; Coyle & Pert, 1976; Garcin & Coyle, 1976; 
Gibson & Vernadakis, 1982).
1.3.3. Receptor Ontogeny in the ra t: Non Selective Ligands.
Binding o f naloxone in ra t wholebrain can be detected as early as embryonic 
day 13 (Coyle & Pert, 1976 and Garcin & Coyle, 1976) and in the spinal cord binding 
o f diprenorphine can be shown at embryonic day 16 (K irby, 1981). Using 
h isto log ica l techniques Kent et al. (1982) f irs t  detected naloxone binding in the 
stria tum  between embryonic day 12 and 14 and at embryonic day 16 in the 
pa leocortica l o lfac to ry  areas and the medial septum. Enkephalin binding could not 
be detected u n til embryonic day 20 in the s tria tum  and these findings corre la te  
w ith  the f irs t  appearance o f endogenous opioid peptides as described in section 1 .2 .
As was seen w ith  most of the opioid peptides, receptor binding increases w ith  
age to a peak during the th ird  postnatal week except fo r the cerebellum  which 
shows a peak in [M e t! -enkephalin binding (Tsang & Ng, 1980a,b; Tsang e t al., 
1982a,b) and naloxone binding (Tsang et al, 1982b) during the f irs t  postnatal week. 
Some disagreement appears here since Torda (1978) found peak naloxone binding at 
1 month in rats.
The regional d is tribu tion  o f binding is dependent on the age o f the animal. 
Naloxone binding studies (Bardo et al, 1981) have shown marked regional 
d ifferences between 7 and 21 days. Regional d ifferences in naloxone binding 
between the newborn and adult have been confirm ed in other laboratories (Garcin 
& Coyle, 1976, 1978; Torda, 1978; Tsang et al., 1982b) and fo r o ther ligands such 
as [ Met ] -enkephalin (Tsang & Ng, 1980a,b; Tsang et al., 1982a,b) and 
dihydromorphine (Recht et al., 1983).
3Autoradiographic studies w ith  [ H I naloxone (Moon, 1984; M urrin  & Ferrer,
3 1 ?S1984), [ H] etorphine (Van der Kooy, 1984), [ I ] DAGO (Moon-Edley &
Herkenham, 1984) describe the form ation o f clusters o f opioid receptors as patches
which appear in s tr ia ta l regions in the f irs t postnatal week and persist in to
adulthood as opposed to the diffuse labelling seen from  prenatal day 14 (Moon-
Edley & Herkenham, 1984). These patches are in topographical register to the
patches o f -dopamine fluorescence tha t are seen in the stria tum  from  prenatal
day 19 to postnatal day 16. Patches of opioid receptors are also observed in the
caudate putamen at postnatal day 3 (Van der Kooy, 1984). Naloxone binding has
been detected in the accumbens nucleus in the form  o f patches from  prenatal
day 18 but in contrast this is not in close association w ith  dopamine fluorescence
patches (Moon-Edley & Herkenham, 1984). Autoradiographic studies w ith
dihydromorphine show binding in the hippocampus and. o lfac to ry  bulb at postnatal
day 2 (Unnersta ll e t al., 1983). Maximal densities o f dihydromorphine binding are
detected at day 14 in the caudate, hippocampus, amygdala and hypothalamus but
are not obtained u n til day 21 in the medial thalamus and quadrigeminal p late.
Highest levels o f binding are detected in the interpeduncular nucleus fo llowed by
the habenula, hypothalamus and periaqueductal gray (Recht et al., 1985). Sex
d ifferences have also been shown in studies o f the autoradiographic loca liza tion  o f
opioid receptors using [^H ] naloxone. In the medial preoptic area there is an
increase in opioid receptor density from  day 3 to  day 10 in the fem ale which is
absent in males (Hammer, 1985).
1.3.4. Receptor Ontogeny in the ra t: Selective Ligands.
The use o f re la tive ly  selective ligands has allowed the d iffe re n tia l 
development o f opioid receptor subtypes to be studied. Koch et al. (1980) 
demonstrated tha t the low a ff in ity  binding site fo r naloxone was not present at 
postnatal day 1 but at subsequent ages both high and low a ff in ity  sites are present. 
DADL binding has been compared w ith  dihydromorphine and w ith  naloxone (Leslie 
et al., 1982; Wohltmann et al., 1982). Leslie et al. (1982) showed stereospecific
binding to both dihydromorphine and DADL at 6 days and adult, but the p ligand 
m orphiceptin inh ib ited DADL binding in the neonate but not in the adult. Thus it  
appears tha t in the neonate both dihydromorphine and DADL bind to p receptors. 
In older animals as m orphiceptin no longer inh ib its  DADL th is  probably re flec ts  
binding to $ receptors.
Wohltmann et al. (1982) obtained s im ila r results using DADL as a ligand. 
DADL binding was lower than naloxone binding but increased at a para lle l ra te  t i l l  
day 12. Thereafter, DADL binding increased at tw ice the rate o f naloxone binding 
un til day 26 when the adult 1:1 ra tio  was obtained. Naloxone binding could be 
com plete ly displaced by morphine in neonates and adults. In contrast DADL was 
only com plete ly displaced by morphine up to postnatal day 12. A t la te r ages only
J
pa rtia l displacement was observed leaving some specific  residual binding o f DADL. 
These results suggest tha t DADL and naloxone bind to a s im ilar site during the f irs t  
two postnatal weeks but then DADL binds to two d iffe re n t sites, probably p and 6 .
H ill e t al. (1984) using ethylketocyclazocine showed specific  binding from  
day 1 increasing to adult levels by 28 days. T ifluadom , a specific  k receptor 
agonist, was 3 tim es as e ffe c tive  at inh ib iting  ethylketocyclazocine binding to the 
cortex o f neonates than in adults indicating tha t in the neonate there is a higher 
ra tio  o f k to p receptors in the cortex than in the adult. The p receptors must 
therefore  increase more rapid ly during development to reach adult ra tios o f k to p 
receptors where tifluadom  would be less potent in inh ib iting  ethylke tocyclazocine 
binding.
A study using etonitazene in varying doses to surpress the p and 6 binding o f 
[ ^H 1 D ALAM ID  in the ra t forebra in produced contrasting results (M illigan  e t al., 
1987). Unlike the other studies*presented here M illigan et al., (1987) report p- 
receptor binding to be constant throughout the developmental period from  day 3 to 
day 43, whereas 6 -receptor binding was in closer agreement w ith  the other reports 
w ith  binding undetectable before day 3 and increasing to a maximum at day 43.
A com parative study o f the ontogeny o f p, <5 and k receptors has been
reported by Spain et al. (1983) using DAGO to fo llow  p and DADL and 
ethylketocyclazocine w ith  suppressor ligands to fo llow  6 and k binding
respective ly. DAGO binding was found to decline fo r several days a fte r b irth  but 
then increased 2-fo ld  over the subsequent two weeks to reach adult levels. 6 -  
Receptor binding did not appear un til the second postnatal week and increased 3- 
fo ld between postnatal day 10 and 28. k -  Receptor ontogeny using ethylke to  
cyclazocine was low at b irth  and had only increased 2-fo ld  by the f i f th  postnatal 
week. A s im ila r pattern  o f development was reported by P e tr illo  e t al., (1987) w ith  
DAGO binding increasing 3-fo ld  to reach adult levels by 21 days and 6 receptor 
binding not detectable before day 7 and not reaching adult levels by day 21. Some 
varia tion  was seen w ith  k receptor binding which may be due to the use o f [^H  1 
bremazocine ra ther than ethylketocyclazocine as < receptor binding was shown to 
increase 2-fo ld  to adult levels by day 14. I t  is thus clear tha t the receptor subtypes 
exh ib it a d iffe re n tia l ontogeny. However, there is d isparity in the lite ra tu re  fo r 
the k receptor ontogeny. Peak binding being reported as la te as day 35 (Spain et 
al., 1985) and in a more recent study as early as day 16 (Barr et al., 1986) using 
ethylketocyclazocine as a binding ligand or day 14 (P e trillo  et al., 1987) using 
bremazocine. There are indications tha t e thylketocyclazocine binds to more than 
one site in the neonate (Spain et al., 1985) even where experim ental measures are 
taken to suppress p and 6 binding and th is may contribu te  to the differences 
observed between laboratories.
1.3.5. Receptor Ontogeny in other Species.
Several groups have studied opioid receptor ontogeny in species other than 
the ra t. The ontogeny o f opioid receptors in chick has been reported by Gibson and 
Vernadakis (1982), Geladopoulos et al., (1987) and Bardo et al. (1982). Gibson and 
Vernadakis (1982) detected etorphine binding in chick embryos as early as 4 days 
incubation. By day 10 o f incubation binding a c tiv ity  was confined to neural tissue. 
Scatchard analysis showed the increase in binding to be due to increases in receptor
concentration and not changes in receptor a ff in ity . Geladopoulos et al., (1987) 
using dihydromorphine to detect p receptor binding and DADL to detect .<5- 
receptor binding during embryonic development o f the chick showed that both p 
and 6 receptor sites could be detected as early as day 5 o f embryogenesis. A t th is 
age both high and low a ff in ity  sites were detectable but la te r in embryonic 
development only a single high a ff in ity  site remained. Bardo et al. (1982) fo llowed 
post-hatch development o f naloxone binding in the midbrain and forebra in o f the 
chick and found numbers o f binding sites increased in both areas but to a greater 
extent in the forebra in. However, the density o f receptor sites showed decreases 
in both areas and this was more marked in the m idbrain. Again, there were no 
accompanying changes in receptor a ff in ity .
DAGO binding in the mouse increases markedly between 3 and 13 days and 
shows fu rth e r increases when measured at 10 weeks (Tavani et al., 1983). 6-  
binding using DADL w ith  p binding suppressed could not be detected at 3 days and 
showed increases in sites at day 15 and at 10 weeks o f testing. This accords w ith  
the la te r development o f 6 -sites in the ra t. k binding using bremazocine w ith  p and 
6 -binding suppressed was detectable at 3 days and increased w ith  age.
2 5The regional d is tribu tion  o f naloxone and [ DA la Met ] enkephalinamide
binding in the lamb has been described (V illige r et al., 1982). Highest levels o f 
2 5naloxone and [D A la  Met ] -enkephalinamide binding are found in the s tria tum  and 
hypothalamus fo llowed by the m idbrain, thalamus, tem pora l cortex, occ ip ita l 
cortex, pons medulla and hippocampus. A ll areas show an increase in binding from  
68 days gestation to b irth  at 147 days gestation, except fo r the pars medulla where 
a decrease in binding is observed. A fte r  b irth  binding plateaues or decreases 
s ligh tly  to adult levels.
In sheep p and 6 receptor binding has been shown in foe ta l and m aternal 
brain regions. In the fro n ta l cortex and hippocampus dihydromorphine binding to p 
receptors is higher in foe ta l sheep brains 118-127 days gestation (Dunlap et al., 
1986). This d iffe rence, however, is not observed in the cerebellum a region rich  in
dihydromorphine binding sites at a ll ages. 6 -  Receptor binding demonstrated by 
DADL binding also shows peak levels in foe ta l brains 118-127 days gestation 
(Dunlap e t al., 1986). The studies in th is species demonstrate a more fu lly  mature 
receptor system at b irth  than is observed in rats and mice.
1.3.6. Peripheral Receptor Ontogeny.
Peripheral opioid receptor development has been reported by G in tz le r et a l. 
(1980). D iprenorphine binding in the enteric  nervous system o f the guinea-pig was 
detected at 23 days gestation. Concentration o f receptors remained fa ir ly  
constant between 25 and 50 days gestation except fo r a transient fa ll a t 30 days. 
The amounts o f ligand bound increased throughout the period, the transient fa ll 
being due to rapid increases in prote in concentration.
1.4. Pharmacology of the opioid system during ontogeny.
1.4.1. In troduction .
Much o f the pharmacology o f morphine and its  anologues during development 
preceeded work on receptors and on levels o f endogenous opioids. As early as 1911 
the increased sens itiv ity  o f neonatal rabbits to morphine had been reported (Dobeli, 
1911) and in 1938 s im ila r e ffec ts  in rats were shown (Gibbs & Bobb, 1938). Since 
these early reports many studies have been carried out on various aspects o f opioid 
pharmacology in the neonate. These studies p rim a rily  in the ra t include 
antinociception, pharmacokinetics and to x ic ity  (Table 3). Some work on isolated 
tissue responses to opioids, taken from  neonatal animals has also been reported.
1.4.2. An tinoc icep tion .
Several antinociceptive tests have been used including ta il f lic k  (Aud ito re  et 
al., 1983; Hamm & Knisely, 1984; Pasternak e t al. 1980; Zhong-Zhang & Pasternak, 
1981) ta il immersion (Auguy-Valette et al., 1978; Barr et a l, 1986) paw immersion 
(Giordano & Barr, 1987), paw and ta il pressure (Giordano & Barr, 1987), hot p la te
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(Huidobro & Huidobro, 1973; Johannesson & Becker, 1972 & 1973), u ltrasonic pain 
s tim u la tion  (Nicak & Masnyk, 1966) and e lec tr ic  algic stim ula tion (Nicak & Kohut,
1978), and in the guinea-pig dental pulp stim ula tion (Frommal & Joye, 1964). The 
m a jo rity  o f studies have used morphine as the antinociceptive drug, though e ffec ts  
o f phenoperidine, pethidine and ketocyclazocine have also been reported (Huidobro 
& Huidobro, 1973; Nicak & Kohut, 1978). The peak antinociceptive e ffe c t usually 
appears during the second or th ird  postnatal week. D ifferences have been reported 
in the ontogenetic p ro file  o f the antinociceptive e ffec ts  o f morphine and 
ketocyclazocine (Barr e t al., 1986; Giodarno & Barr, 1987) where there are 
indications tha t ketocyclazocine antinociception is observed about 4 days earlie r 
than fo r morphine raising the possib ility  tha t functiona l k -sites are operative 
before p-sites. I t  has also been reported tha t tolerance to analgesic e ffe c ts  of 
morphine is present in neonates (Huidobro & Huidobro, 1973; Nicak & Kohut, 1978) 
and tha t peak tolerance occurs at 21 days.
The development o f nociceptive responses o f neonatal ra ts have been 
reported by Hamm and Knisely (1984) who used the ta il f lic k  assay and found no 
d iffe rence in nociceptive threshold in 10 days, 28 days and 3-7 month old rats. 
N ociceptive responses in mice were shown to decrease w ith  age and morphine had a 
greater antinociceptive  e ffe c t in 14 day old mice compared to mice 21, 28 and 70 
days old (A lieva & Laviola, 1987).
The analgesic action o f morphine in guinea-pigs (Fromm el & Joye, 1964) show 
it  to be less e ffe c tive  against dental pulp stim ula tion in four to five  week old 
animals than in 10 week and adult guinea-pigs. Thus although CNS m a tu rity  in this 
species appears to be more advanced than in the ra t and rabb it, as evidenced by 
walking and feeding behaviour, opioid system function lags behind by several 
weeks.
1.4.3. Locom otor A c t iv ity .
Locom otor a c tiv ity  is a simple gross behavioural measure. Its s im p lic ity
results in only general measures o f ambulation and in form ation on stereotyp ic 
responses (eg. sn iffing  and grooming), co-ordination and muscular r ig id ity  cannot 
be recorded. I t  is w e ll known tha t po ten tia lly  useful in fo rm ation  goes unrecorded 
(Krsiak et al., 1970). Many external factors such as novel environments, housing 
conditions (singly or in groups), ava ila b ility  and qua lity  o f food and the period of 
the ligh t/da rk  cycle w ill a ll a ffe c t a c tiv ity  (Aschoff, 1981; Smith, 1972; P e tit and 
A lfano, 1979; L ilien tha l et al., 1986). The in fo rm ation  gained from  these 
locom otor studies should therefore be viewed as only a basic measure o f a ltera tions 
in behaviour and too detailed in te rp re ta tion  o f the results should be avoided.
Modulation o f a c tiv ity  by opioids in adult animals is variable and dependent 
on the dose level, in general low doses increase locom otion while high doses depress 
a c tiv ity  although th is  is species dependent (Olson et al, 1983). This also appears to 
be the case in neonates w ith  both hypo- and hype ractiv ity  reported, other facto rs 
including age may also play a part in the varied results obtained.
Using a c tiv ity  meters, methadone produces hypoactiv ity  in animals less than 
25 days o f age and th is is prolonged in neonates 12 days old or less (Shah & Donald,
1979). However, in rats older than 20 days post-partum  morphine adm inistered 
in traperitonea lly  produces hype ractiv ity  which is most marked at la te r ages (K a tz ,
1980). Using line crossing as a measure o f a c tiv ity , 10 day old neonates exhib ited 
hypoactiv ity  a fte r morphine adm in istra tion (Caza & Spear, 1980). As fo r 
methadone la te r ages exh ib it a d iffe re n t p ro file . In 17 day old neonates, low doses 
o f morphine (0.5mg/kg) produce hype ractiv ity , but doses o f 5 m g/kg produce 
hypoactiv ity  and by 24 days no s ign ifican t e ffec ts  on a c tiv ity  were observed at any 
doses (Caza & Spear, 1980).
In m ice, 1 mg/kg morphine has no e ffe c t on a c tiv ity  except at 20-22 days 
where a c tiv ity  is depressed. A fte r  10 mg/kg mice show hype ra c tiv ity  except at 
20-22 days when hypoactiv ity  is observed (F ilibeck et al, 1982). In contrast A lieva  
and Laviola, (1987) report tha t morphine caused hypoactiv ity  in 14 day old m ice 
was in e ffec tive  at 21 days and at high doses only caused hype rac tiv ity  in 28 day old
mice. Thus in both neonatal rats and m ice, i t  appears tha t age o f testing and dose 
o f opioid used are im portant determ inants o f the a c tiv ity  changes.
1.4.4. T o x ic ity .
Changes in metabolism and d is tribu tion  are also re flec ted  in the to x ic ity  of 
opioid drugs in rats. Morphine-induced catalepsy reaches a peak at 20 days (Katz,
1980) whereas the hypotherm ic e ffe c t o f methadone peaks at 8 days post-partum  
(Shah Sc Donald, 1979). The LD^q o f morphine is re la tive ly  constant a t 50 mg/kg 
during the f irs t  two weeks a fte r b irth  but then at 16 days the LD^q value rises to 
adult levels o f 220 mg/kg (Kupferberg Sc Leong-Way, 1963). This may be due to a 
com bination o f the development o f the blood brain barrie r from  day 14 and the 
appearance o f the various metabolising systems which appear m ainly during the 
second postnatal week, but may also be re la ted to the ontogeny o f receptor 
subtypes which do not develop in para lle l (Spain et al., 1985) (see Section 1.3.4.).
Rabbits have also been used to study the neonatal to x ic ity  o f morphine. 
Eddy, (1939) and Schlossman, (1937) reported tha t the le tha l dose o f morphine 
increased from  b irth  u n til two to three months indicating an increase in 
metabolising enzymes and a decrease in the sens itiv ity  to morphine. Eddy, (1939) 
also reported tha t the dose causing convulsions was close to  the le tha l dose in 
young rabbits but became lower than the le tha l dose in older animals.
1.4.5. Respiration and Cardiovascular system.
The involvem ent o f the opioid system in ontogenesis o f resp ira tory con tro l
has been investigated. In rats the respiratory depressant e ffe c ts  o f morphine,
2 . .
[D -A la  Met]-enkephalinam ide or 8 -endorphin are s im ila r between 2 and 14 days o f
age (Pasternak et al., 1980; Zhong-Zhang & Pasternak, 1981). However, in rabbits
a ltera tions in opioid function show abnormal e ffec ts  on respiration in the neonate.
Hazinski et al. (1981) demonstrated that infusions o f naloxone increase resp ira tion
by 140-180% in the m a jo rity  o f pups less than 4 days old while in pups greater than
5 days old this response is only observed in a m ino rity  o f animals. Naloxone 
adm inistered during hypoxia also stim ulates respiration but this response decreases 
w ith  age (Grunstein et al., 1981). In addition the adm in istra tion o f DADLdecreases 
ven tila tion  in rabb it pups and this e ffe c t is inversely proportional to age (Grunstein
6  Grunstein, 1982). Naloxone was also shown to increase phrenic nerve m inute 
output (a neural index o f resp ira tory output) by 122% in piglets less than 10 days 
old but only increased output by 54% in piglets aged 20-34 days (Long & Lawson,
1983). In te rm itte n t hypoxia in 21 day old rabbits causes a decrease in
[ Met ] enkephalin levels in brain stem nuclei, but was not a ffec ted  in 3 day old 
rabbits (Gingras-Leatherman et al; 1986). Thus i t  appears tha t resp ira tory contro l 
in neonates is partly  under the contro l o f the opioid system but tha t th is  e ffe c t 
diminishes w ith  age and is species dependent.
The e ffe c t o f [ M et] -enkephalin on the c ircu la to ry  responses in sheep have 
been reported (La Gamma et al., 1983a) in foe ta l and newborn lambs, and in 
pregnant and non-pregnant ewes. [ M et] -Enkephalin adm inistered i.v . causes 
decreased heart ra te  and blood pressure in foe ta l and neonatal lambs. In contrast 
in pregnant ewes however this is preceded by an in it ia l increase in heart ra te  and 
blood pressure.
1.4.6. Isolated Tissues.
In the ra t vas deferens age does not a ffe c t the potency o f 8 -endorphin to 
in h ib it fie ld  stim ulated muscle contraction (Huidobro-Toro & M iranda, 1981). 
However, the po tentia ting  e ffe c t o f morphine in this tissue, which is not naloxone 
sensitive, increases w ith  age to a maximum at 2 months. Rat duodenum responses 
to [ M et]-enkepha lin  alters during development (Furukawa et al., 1982). From 
day 8 there is a sustained re laxation o f the tissue to [M e t] -enkephalin reaching a 
maximum at 18 days. This response can be blocked by te trodo tox in  or naloxone but 
by day 40 it  is no longer te trodo toxin  sensitive. This indicates a change from  
neurogenic to myogenic a c tiv ity  o f opioids during development o f the gut.
1.4.7. Plasma corticosterone levels; e ffe c t o f stress and modulation 
by opioids.
Synthetic opioids are capable o f exerting a profound influence on the release 
o f various hormones from  the p itu ita ry  and other endocrine organs. In pa rticu la r 
opioids a ffe c t stress responses indicated by a modulation o f stress induced 
corticosterone levels in rats and e ffec ts  o f stress on opioid peptide levels (Torda, 
1978).
1.4.7.1. Ontogeny o f corticosterone responses to stress.
There is general agreement tha t neonate animals do not show normal stress 
induced rises in plasma corticosterone levels (Hening, 1978; Kakihana et al., 1974 
and Bartova, 1968). Plasma corticosterone levels have been reported to be low 
during the f ir s t  two postnatal weeks but during the th ird  week rise rap id ly to  a 
peak at 24 days (Henning 1978). This pattern  o f development also occurs fo r stress 
induced rises in plasma corticosterone levels. The response to histam ine stress is 
not observable u n til a fte r postnatal day 11 in m ice (Kakihana et al., 1974). This 
lack o f response is not due to a lack o f ACTH in the p itu ita ry  or unresponsiveness 
of the adrenals to exogenous ACTH but i t  has been corre lated w ith  brain levels o f 
corticosterone (Butte et al, 1973) suggesting tha t high brain corticosterone levels 
in h ib it ACTH release from  p itu ita ry  in the neonate.
1.4.7.2. Opioid modulation o f corticosterone levels.
Adm in is tra tion  o f opioids have been shown to elevate plasma corticosterone 
levels in both mice (Gibson et al., 1979) and rats (Kokka et al., 1973; Eisenberg,
1985). In agreement Bailey and K itchen (1987) also found corticosterone levels 
were potentia ted by morphine, fentanyl and buprenorphine in adult rats but this 
e ffe c t was not observed in neonates up to 45 days o f age. As was discussed in the 
previous section the corticosterone response to stress is late to develop an adult 
response not being obtained u n til postnatal day 30 but the m odulation o f th is  
response by opioid compounds matures by day 40-45 some 20 days a fte r  a stress
induced rise in plasma corticosterone can be detected. Some m odulation o f stress 
induced rises in plasma corticosterone by morphine and fentanyl were observed at 
postnatal day 40 but modulation s im ila r to tha t observed in adults and m odulation 
by buprenorphine could not be measured un til postnatal day 45. These e ffec ts  are 
naloxone reversible and are therefore  mediated by opioid receptors (Bailey and 
K itchen, 1987). The la te  development o f opioid modulation o f stress induced rises 
in plasma corticosterone levels is unusual in comparison w ith  many physiological 
e ffec ts  o f opioids which para lle l opioid receptor development and CNS opioid 
peptide levels which reach m a tu rity  by postnatal day 21-30 (Spain e t al, 1985 and 
Bailey and K itchen, 1985).
The e ffe c t o f stress and pain on the development of the opioid system has 
also been studied. Footshock has no e ffe c t on binding but produces an analgesic 
e ffe c t as evidenced by an increase in nociceptive latency (Bardo e t al, 1981). In 
addition Hamm and Knisley (1984) have reported tha t analgesia induced by 
footshock is less in 10 day old rats than in 28 day and 5-7 month old animals. 
Recurrent pain re lated stress, s tim u la tion  o f periaqueductal grey m a tte r or 
repeated placement on a hot p late, has been shown to increase opiate receptors and 
enkephalin levels in neonates (Torda, 1978) and chronic stress during the f irs t  
month post partum has also been found to increase the sensitiv ity  o f the adu lt to 
morphine analgesia (Larson, 1982).
In addition hot plate stress fo r 1-2 hrs per day in preweanling ra ts causes a 
25% reduction in naloxone binding in the m idbrain, hypothalamus and s tria tum  
(Torda, 1978). Thus i t  appears that the opioid system is involved w ith  responses to 
stress and tha t stress during these im portant stages o f development can a ffe c t the 
development o f the system. I t  should be noted tha t opioid modulation o f stress 
induced rises in corticosterone is absent in rats in the early postnatal period. This 
e ffe c t matures ex traord ina rily  la te  at about day 45 (Bailey & K itchen, 1987).
1.5. Summary.
The understanding o f opioid system function in the adult has progressed 
markedly in the last decade. This in turn has led to an increased knowledge of how 
opioid function  develops in the embryo and in the postnatal period.
W ith respect to the ontogenetic p ro file  o f the opioid peptide products o f the 
three opioid precursors, a ll are detectable during gestation and the ir development 
in rodents is not completed un til well a fte r b irth , the th ird  postnatal week o ften 
exhib iting the most marked increases. There is not exact paralle l development o f 
the precursors and there may be regional fluctuations fo r some of the peptides in 
the postnatal period. A ll o f the indications are tha t the ontogenesis o f the three 
precursors occurs independently, and tha t th e ir opioid peptide products have 
d is tin c t ontogenetic profiles (Section 1.2.2 -  1.2.4). Indeed in a com parative 
im m unocytochem ical study fo r dynorphin A and enkephalin (Gall, 1984) the 
patterns o f development in the hippocampal fo rm ation  were dissim ilar. In addition 
the differences observed in ontogenetic patterns fo r the precursor products may 
w e ll re fle c t d iffe re n tia l ac tiv itie s  o f the processing cleavage enzymes in the 
developing animal. Indeed a com parative ontogenetic study o f ACTH and 8- 
endorphin (Kapcala, 1983 & 1986) showed a d is im ila r p ro file  during early 
development in ra t brain and p itu ita ry . W hilst these may be due to d iffe re n t 
processing patterns, the possib ility  o f d iffe re n tia l release, secretion or degradation 
o f these peptides cannot be excluded and may be independent o f the synthesis o f 
the precursor.
There is also a d iffe re n tia l ontogeny o f the opioid receptor subtypes and the 
recent evidence w ith  highly selective binding ligands has provided a clear pa tte rn , 
p and k sites are the f irs t  to appear though 6 -receptors are absent u n til the 
second postnatal week in the ra t. In th is species the fu ll development o f p and 6 
sites occurs in the th ird  and fourth  weeks respective ly.
There is s t il l some argument about the ontogenetic p ro file  fo r  k -sites 
though, like  the 6 -receptors, fu ll development is probably la te r than fo r the p-
sites. Ontogenetic p ro files o f opioid receptors have also been demonstrated in the 
chick, sheep and mouse.
Too few studies have looked at peptide and receptor development in para lle l 
and i t  is s t il l unclear i f  specific peptide development is d ire c tly  linked w ith  
development o f a single receptor site.
The postnatal development of both opioid peptides and receptors is m irrored 
by pharmacological actions o f opioids which d iffe r  in the neonate. Their 
pharmacological e ffe c ts  are not solely dependent on the number o f receptors but 
also on the ontogenetic pattern  o f the metabolising enzymes and on blood brain 
barrie r development. There are some anomalous responses to opioids in the 
neonate and these include locom otion, respiratory depressant a c tiv ity  and e ffe c ts  
on corticosterone release.
1.6. Historical perspectives of lead toxicity.
Lead has been used and its  to x ic ity  known fo r thousands o f years. I t  is a 
useful m eta l because o f its  heavy, pliable and corrosion resistant properties. There 
is a p le n tifu l supply o f lead containing ores from  which i t  is easy to  e x tra c t by 
sm elting. Evidence o f the earliest use o f lead was found in Turkey where beads o f 
m e ta llic  lead have been found which have been dated at 6500 BC. Evidence from  
ancient w ritings o f the early Egyptians, Hebrews ad Phoenicians from  2000 BC 
describe the use of lead as ornaments and coinage. The Greeks made more 
extensive use o f lead as solder, in alloys, fo r coinage, building construction, 
gutte ring  and cisterns. I t  was also used in the home fo r w ater vessels, pots, 
pigments, cosmetics and paints and i t  was even added to food as a seasoning and 
preservative.
The Romans greatly  promoted this m etal and i t  was considered as a sign o f 
wealth. Thus the aristocrasy made much use o f the m etal especially in th e ir 
enthusiasm fo r bathing as well as fo r cooking, lead gave a sweet flavour to the food 
compared to the b itte r  flavour obtained by cooking in bronze containers. One o f
the major sources of exposure resulted from  the Roman habit o f producing 'saga' 
obtained by boiling grape syrup in leaden vessels. Saga was used to sweeten and 
preserve food and to make wine. Studies fo llow ing the Roman recipes fo r making 
saga have found the resulting syrup contains up to  1000 mg lead per l i t re  of syrup 
(Eisinger, 1977). Use o f such a syrup on a daily basis could easily resu lt in chronic 
lead to x ic ity . Lead poisoning could have been the cause o f co lic , gout and insanity 
during Roman tim es and i t  has been suggested tha t lead was the cause of the fa ll of 
the Roman empire due to the excessive consumption o f lead ta in ted wine by the 
Roman aristocracy (G ilfilla n , 1965). Since the Roman era the association between 
lead and tox ic  symptoms such as persistant and painfu l constipation, abdominal 
pain, jo in t pain (gout), paralysis o f the extrem ities sta rting  w ith  w ris t drop, 
headache, insomnia, blindness, m ental disturbances extending to  insanity, s te r ility ,  
m iscarriage and s till-b ir th s  have been reported.
The use o f lead subsided a fte r the fa ll o f the Roman Empire but cases o f lead 
induced co lic  s t il l appeared in the middle ages due to lead ta inted wines and cider. 
The Industria l Revolution again increased the use o f lead and i t  is s t i l l  used today 
in e le c tr ica l insulation, rad ia tion shielding, batteries and lead compounds which are 
used in paint, p lastic, ceram ics, glass and of course as an antiknock agent in petro l 
(Fig. 1). During the 19th century the e ffec ts  o f industria l exposure were realised 
and leg is la tion was introduced to l im it  exposure. Nowadays acute or chronic lead 
to x ic ity  is rare but due to the ine rt nature o f lead and the excessive use o f the 
m eta l -over 274,000 tonnes/year in this country alone (Royal Commission Report,
1983), the environment is contam inated and i t  is estimated tha t daily in take o f lead 
is 100-fold higher than in prehistoric man. Current in te rest is now focused on 
exposure to low levels o f lead pa rticu la rly  in children and the possible behavioural 
de fic its  this may cause. Therefore this part o f the lite ra tu re  review  w ill 
concentrate on the e ffec ts  o f low level lead exposure.
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Fig. 1. Use o f m e ta llic  lead and lead compounds in the U K  in 1982.
Figures in thousand tonnes. Total 283 thousand tonnes.
*  This figure is for the m anufacture o f anti-knock compounds, about 80% 
o f which are exported.
{Royal Commission Report, 1983)
1.7. Human exposure to lead.
1.7.1. Sources o f exposure to lead and levels measured in humans.
Environm ental contam ination by lead is widespread and has increased rapid ly 
during the 20th century. I t  arises from  both natural sources and from  its  extensive 
long-term  use by man (Royal Commission Report, 1983). Natura l contam ination 
results from  weathering o f rocks containing lead ore and results in contam ination 
of the surrounding soil and local water. The more im portant contam ination of the 
environment is due to the anthropogenic sources o f lead resulting in airborne lead, 
and contam ination o f soil, water, m icroorganisms, plants and animals and therefo re  
human food. Lead is released in to the environment during m ining, sm elting and 
re fin ing  to produce the m eta l and also during production, recycling and disposal o f 
lead based products. These may be in the m etal fo rm  as sheet and pipe, ba tte ry  
castings and grids or cable sheathing, solder or shot or from  lead compounds which 
are mainly used as antiknock agents in pe tro l or ba tte ry  oxides but are also used as 
pigments, in paint or as stabilisers in plastics (Fig. 1).
A irborne lead is almost wholly a ttribu tab le  to exhaust from  pe tro l engines 
due to the use o f a lky l lead compounds as antiknock agents. 75% of the 9.7 m illio n  
tonnes o f lead used in pe tro l in 1981 was em itted  in to the atmosphere (Chamberlain 
e t al., 1978). This airborne lead depending on its  physical and chem ical form  is 
deposited on soil, vegetation or in water or on man-made surfaces resulting in 
contam inated dust.
Lead finds its  way in to freshwater from  various sources, these may be 
airborne lead or leaching from  soil or mine waste. However th is is not the m ajor 
source o f lead found in tap w ater as in the natural environment the lead becomes 
absorbed onto pa rticu la te  m a tte r and is d istribu ted throughout sediments. 
Contam ination o f tap w ater occurs in the household and is a ttr ib u ta b le  to lead 
piping. The degree of leaching from  lead pipe is dependent on the softness and 
ac id ity  o f the water, the tem perature, the contact tim e and the qua lity  o f the lead 
pipe (Royal Commission Report, 1983). Lead also finds its  way in to sewage from  
domestic and industria l waste and from  run o ff, the m a jo rity  o f the lead remaining
in the sludge which is o ften reapplyed to agricu ltu ra l land.
Contam ination o f the soil w ith  lead is also widespread w ith  natural sources o f 
lead as well as human ac tiv ites  contribu ting, including atmospheric po llu tion, mine 
waste, addition o f sewage sludge, run o ff  o f contam inated water to blame. O ther 
m inor sources include flakes o f lead containing paint - often used to  prevent rust 
and lead shot a ll adding to the contam ination. Gardens pa rticu la rly  o f older 
housing show higher soil contam ination than agricu ltu ra l samples, th is is 
a ttrib u ta b le  to coal ash, eroded paint, burning o f old painted tim bers, vehicle 
exhaust and local industries (Royal Commission Report, 1983).
Thus it  is impossible to com plete ly avoid exposure to lead although location 
w ill g rea tly  a ffe c t the degree o f exposure. Lead can enter the body by various 
routes, although uptake o f th is m etal is very low. Inhalation o f lead is dependent 
on the size and so lub ility  o f the lead, approxim ately 30% being reta ined in the 
airways although only 5% is absorbed the remainder being sequestered by alveolar 
cells or via the lym phatic system to the lymph nodes (Winder, 1984). D ie ta ry  
intake via food and water is estim ated at 300 yg/day but again only 5-10% is 
absorbed (Kehoe, 1960) although in children the uptake is several fo ld  higher. 
O ther d ie ta ry components can a ffe c t lead uptake. Calcium, phosphorus and iron a ll 
increase absorption and to x ic ity  o f lead while zinc, alum inium and selenium have 
been found to be p ro tec tive . A combination o f v itam in C and zinc has been shown 
to reduce blood lead levels o f ba tte ry  workers continually exposed to lead by 25% 
(Papaioannou et al, 1978).
The d is tribu tion  o f lead once in the body is extensive and tim e  dependent but 
is not a ffected  by route o f absorption (Chamberlain, 1985). In it ia lly  there is a 
rapid attachm ent o f lead to red blood cells from  plasma. Subsequently and more 
slowly lead is red istribu ted to the live r, so ft tissues and bone. O f the normal whole 
body lead burden o f non occupationally exposed individuals (0.4-2 mmol) only 2% is 
in the c ircu la tion  (Fell, 1984) from  where i t  is excreted in the urine, in the faeces, 
via b ile and pancreatic flu ids or from  soft tissues eg. sweat, ha ir, nails etc. Post
mortem studies show bone pa rticu la rly  dense bone contains highest levels o f lead 
while non glandular tissues like  fa tty  adipose tissue, collagenous skin and fa c ia l 
tissue and muscular tissue have the lowest lead burden. Glandular tissue such as 
the live r, kidney and pancreas have in term edia te  levels (Gross et al., 1975).
Due to the continually changing pools o f lead i t  is d if f ic u lt  to obtain an 
accurate index o f exposure. Blood lead levels are the most common measurement 
made but only re fle c t recent exposure. Lead content of hair (Rockway et al., 1984) 
and deciduous teeth (Grandjean et al., 1986) have been measured and are reported 
to give a more accurate p ic tu re  o f past exposure depending on when the m ate ria l 
was la id down.
1.7.2. C lin ica l and subclin ical to x ic ity  o f lead.
Once clear c lin ica l tox ic  symptoms had been associated w ith  exposure to 
lead, m ainly in the work place, government legisla tion was introduced to l im it  
exposure in industry. O vert c lin ica l to x ic ity  to lead is now a rare occurrence but 
does occasionally occur in workers in heavy lead using industries and in children 
exposed to point sources o f lead like  flaking lead paint or lead toys. O vert to x ic ity  
a ffec ts  many systems such as the haemopoetic system resulting in anaemia, the 
a lim entary system and the most im portant e ffec ts  on the nervous system. Lead 
causes a centra l encephalopathy which may be fa ta l and a peripheral neuropathy, 
an overview of c lin ica l lead poisoning is given by Krigman et al. (1980) and Winder 
(1984).
G reatly improved industria l hygiene has almost e lim inated cases o f c lin ica l 
lead poisoning in the western world. The World Health Organisation have 
recommended tha t in order to p ro tec t against lead to x ic ity  blood lead levels should 
not exceed 40 pg/d l fo r men and women over reproductive age and 30 pg/d l fo r 
women of reproductive age (WHO, 1980). However in this country Government 
recommendations indicate tha t steps to reduce exposure should be taken i f  blood 
lead levels exceed 25 pg/dl especially in children. Studies o f industria l exposure
resulting in blood lead levels o f 40-50 jjg /d l have shown that neurobeha.vioural 
function and nerve function are both a ffected  by these lead levels (W illiamson and 
Teo, 1986). Im pairm ent o f neurobehavioural function including visual sensory 
function, slower performance o f psychomotor tests and de fic its  in sensory store 
memory, short-te rm  memory and learning ab ilities  have been reported (Williamson 
and Teo, 1986). In addition nerve conduction ve locities o f the median and posterior 
tib ia l nerves are decreased while d ista l la tency and somatosensory evoked 
potentia ls o f these nerves are prolonged in lead exposed workers (Jeyaratnam et 
al., 1985).
Most a tten tion  has now been turned to childhood lead exposure due to the 
increased absorption o f lead and the sensitiv ity  o f the developing system to the 
e ffe c t o f low levels o f lead.. Neurophysiological e ffe c ts  o f lead have been reported 
in 5 year old children w ith  blood lead levels in the range of 6-30 pg /d l where 
measurements o f nerve conduction ve loc ity  were shown to be slower (O tto  et al., 
1985). In te rest has been concentrated on the behavioural and in te lle c tu a l 
development o f children exposed to lead. However the results are generally 
inconclusive, due to the many variables involved, some examples are given in Table 
4. A part from  the experim ental variables such as age o f testing, lead level, 
method o f measuring lead level, and test used, there are many variables in the 
childs environment tha t can a ffe c t behavioural and in te lle c tua l development. 
D ie trich  e t al. (1985) reported tha t children w ith  higher lead levels generally lived 
in less adequate developmental environments as evidenced by Home Observations 
fo r the Measurement o f the Environment scores. Needleman &. Landrigan (1981) 
also describe many o f the confounding variables tha t can a ffe c t child development 
such as socioeconomic group, parental in te lligence, undernutrition , increased 
occurrence o f in fection , poor education and poor health care. G enerally i t  is 
believed tha t there may be a causal relationship between low concentrations o f 
lead and neuropsychological e ffec ts  in children and to try  and con tro l some o f the 
many variables and e th ica l constraints associated w ith  human experim enta tion
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supportive evidence has been sought from  animal studies.
1.8. Experimental exposure of animals to lead.
1.8.1. Anim al models o f exposure.
Due to the concern about children exposed to lead via the environment many 
animal studies have concentrated on the e ffe c t o f lead on learning and behaviour 
and also the neurochemical and neurological aspects of low level lead to x ic ity  
during development. These are reviewed in section 1.8.2. and 1.8.3.
Anim al studies, although easier to contro l than human studies, s t i l l  have 
many inherent variables tha t make comparisons between studies and extrapo la tion 
to man d if f ic u lt .  Variables such as species, age, dose o f lead, chem ical fo rm  of the 
lead used, the route o f adm in istra tion and the duration o f exposure can a ffe c t the 
results obtained. Many studies only provide the exposure regime as an index o f 
lead exposure and as w ith  humans there are many variables tha t can a ffe c t 
absorption and re ten tion  of the lead dose. Blood lead levels give a be tte r 
indication o f body load but again as in humans does not always re fle c t past 
exposure.
Early models o f lead exposure involved dosing adult animals and produced 
variable results. I t  was not u n til Pentschew and Garro (1966) reported a lead 
dosing model, which involved adm in istra tion o f lead to nursing mothers so tha t 
th e ir pups would be exposed to lead via the mothers m ilk , did more in fo rm ation  on 
the developmental aspects o f lead to x ic ity  emerge. I t  provided a good model as 
the neonate was more sensitive to lead insult than the adult and paralle led in many 
respects, exposure in children. The route o f adm in istra tion to the neonate was 
ora lly  and the exposure period was during the c r it ic a l period o f brain growth which 
in the ra t is the preweaning period from  b irth  to postnatal day 21 and in children is 
during the f irs t two years.
There are various methods o f adm in istra tion o f lead via the oral route , these 
include the d ie t, drinking water, by gavage adm in istra tion or via the m aterna l m ilk
supply o f a lead dosed dam. The nu tritiona l composition of the d iet and m ineral 
content o f drinking water w ill a ffe c t absorption o f lead from  the gut (Conrad.and 
Barton, 1978). Gavage adm in istra tion provides a more accurate estim ate of 
exposure than addition o f lead to the d iet or drinking water as there is no waste, 
spillage or leakage and in developmental studies does not necessitate in tox ica tion  
o f the dam, however i t  does cause problems in tha t i t  is a pulse o f lead and 
therefore  has a short trans it tim e through the gut and i t  involves stressing the 
animal.
Studies which dose the dam w ith  lead in order to expose the neonate during 
the perinata l period often involve weaning the neonates onto the same d ie t or flu id  
tha t has been given to the dam, th is may result in a 100 -fo ld  increase in exposure. 
Many o f the methods and dosing regimens are reviewed by Winder and K itchen 
(1984) and Winder (1984).
There seems to be a general consensus on the d is tribu tion  o f lead w ith in  the 
body w ith  accum ulation in bone, kidney, live r and brain (Table 5), the levels o f lead 
in each tissue dependent on exposure.
. Lead uptake from  the gut is mainly from  the duodenum (Henning and Leeper,
1984), but is dependent on age w ith  greater uptake occuring in young animals 
(Kosita l et al., 1971). The uptake in to embryonic animals is also dependent on age 
w ith  uptake lim ite d  to blood in early stages but as the foetus develops uptake o f 
lead occurs in the liv e r and cartilagenous skeleton and la te r uptake in to ca lc ified  
bone can be detected (Danielsson e t al., 1983). Variations in regional d is tribu tion  
w ith in  the brain occur and are dependent on the dose o f lead adm inistered (Collins 
et al., 1982).
1.8.2. E ffec ts  o f low level lead exposure during development on behaviour.
As has been described in humans, overt lead to x ic ity  a ffects  many systems in 
animal models of to x ic ity . These include the e ffec ts  on the nervous systems 
(Gombault, 1880 and Pentschew and Garo, 1966) as well as e ffec ts  on brain grow th
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(Krigman and Hogan, 1974; Maker e t al., 1975; Harry a t al., 1985 and Edwards and 
Beatson, 1984), conduction along nerves (Maehara et al., 1986 and Spence et, al.,
1985) and changes in the m icroc ircu la tion  o f the brain (Maxwell e t al., 1986 and 
Press, 1985). Lead exposure has also been shown to a ffe c t the reproductive 
system. Many o f the e ffec ts  o f high levels o f lead have been associated w ith  
undernutrition  which its e lf can cause histopathological brain lesions. When the 
nu trition a l e ffe c ts  in the Pentschew and Garro model are contro lled the lesions 
w ith in  the brain disappear although a behavioural d e fic it does remain (Michaelson 
and Saueroff, 1974). The l im it  below which undernutrition is m inim al is reported to 
be 1000 ppm (Carm ichael e ta l. ,  1981).
As lead exposure during developmental periods in children has been 
associated w ith  childhood hype rac tiv ity  and d e fic its  in in te lligence and classroom 
performance (Section 1.7.2.) much a tten tion  has been focused on possible paralle ls 
in animal experiments. Anim al models have been extensively used to find a d irec t 
association between lead exposure and the suspected e ffec ts  on behaviour and 
in te lligence observed in children as many o f the confounding variables tha t occur in 
the human s ituation can be contro lled in animal experiments. There are s t i l l  
lim ita tions  o f animal models mainly due to the varie ty  of exposure models and 
testing schedules used and in many cases no in te rna l index o f exposure is given. 
Rodents have been used extensively fo r experiments on simpie behaviour and 
a c tiv ity  although some more complex behavioural tests have been carried out. 
More re levant to the human situation is the ba tte ry  o f behavioural tests tha t have 
been carried out in primates often several years a fte r the te rm ina tion  o f dosing 
(see Section 1.8.2.2.).
1.8.2.1. Behavioural and a c tiv ity  studies in rodents.
Due to the hype rac tiv ity  that is o ften  associated w ith  lead exposure in 
children many studies have been carried out in rodents to try  and reproduce this 
e ffe c t. Table 6 summarises some o f these experiments perform ed in rats.
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H yperac tiv ity , hypoactiv ity  and no e ffe c t on a c tiv ity  have been reported fo r 
various exposure paradigms in various aged rats. Many reports use a m od ifica tion  
of the method described by Pentschew and Garro (1966) where exposure is via the 
maternal system, th is may be prenata lly, postnatally or both. Blood lead levels are 
often not reported so comparison between d iffe re n t exposure models is d if f ic u lt ,  
often retarded growth is reported, an indication o f high body burdens o f lead which 
its e lf may a ffe c t behavioural development.
The e ffe c t o f perinata l lead exposure on other indices of development have 
also been described. Perinatal exposure to very low doses o f lead via the dam 
have been reported to delay the appearance o f the righ ting  re flex  and eye opening 
although no e ffe c t o f lead was observed on the s ta rtle  re flex  (R e ite r et al., 1975). 
In contrast perinata l exposure to a much higher lead dose had no e ffe c t on the 
surface righ ting  re flex , negative geotaxis, eye opening or aquisition o f a simple 
r ig h t le f t  d iscrim ination test (Rabe et a l., 1985).
More complex behaviour has been reported by using various behavioural tests, 
these are summarised in Table 7. Again the p icture  is confused w ith  various 
d iffe re n t measures o f behaviour, although overall they indicate an im pairm ent o f 
learning ab ilities  in lead exposed rats. In addition the e ffe c t of lead on other more 
complex behaviours have been described. Play figh ting  determ ined by crossing 
over and pinning down a matched naive animal (Holloway and Thor, 1987) and social 
and sexual investigation (Donald et al., 1986) are both increased by postnatal or 
perinata l lead exposure respective ly. O f im portance when studying exposure via 
lac ta tion  is the e ffe c t o f postnatal lead exposure on the decrease in in it ia tio n  o f 
nursing by the pups and delayed attem pts at feeding on solids (B a rre tt and Livesey, 
1983). Visually evoked responses measured from  the brain were also a ffec ted  by 
postnatal lead exposure (Fox, 1970).
In mice i t  has been reported that perinata l lead exposure causes retarded 
growth, increased a c tiv ity  and increased aggression (Dolinsky et al., 1982). The 
e ffec ts  o f lead have also been shown to be modified by housing conditions, both
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group housing (Vickers and Paterosn, 1986) and enriched environments (P e tit and 
A lfano, 1979) were shown to m odify the e ffec ts  o f lead on behaviour.
1.8.2.2. Behavioural studies in prim ates.
The m a jo rity  o f the studies summarised in Table 8 employ postnatal lead 
exposure models and testing does not occur un til the monkeys are at least 1 year 
old and often does not take place un til several years a fte r exposure has been 
term inated. Blood lead levels o f these animals are measured a fte r term ination  o f 
exposure or during the testing period and are found to be s im ila r to those found in 
children. The models o f exposure and testing used in prim ate studies are probably 
more re levant to the problem in children than the rodent models used. Exposure in 
children is almost ce rta in ly  postnatal and the e ffec ts  o f early lead exposure are not 
observed u n til several years la te r, o ften at school, when exposure may have ceased 
and blood lead levels are low.
Most o f the tests employed in prim ate studies involve learning tasks and in 
general lead has a de trim enta l e ffe c t. This may be exhibited as slower acquisition 
o f the task, general im paired a b ility  to  perform  the task or slower response tim es. 
Thus although lead exposure produces no overt symptoms o f in tox ica tion  i t  can s t il l 
a ffe c t the learning a b ility  o f monkeys o ften years a fte r  exposure has ceased and 
blood lead levels are approaching controls.
1.8.3. Developmental neurochemical to x ic ity  o f lead.
1.8.3.1. Classical neuro transm itte r systems.
In an a ttem pt to elucidate the m olecular mechanisms o f lead to x ic ity  in the 
centra l nervous system much a tten tion  has been focused on the neurochem istry o f 
tran sm itte r systems of lead exposed animals. Some work has looked at the e ffe c ts  
o f lead exposure on the neurochem istry of adult rodents (Hong et al., 1983 and 
Bondy et al., 1979, 1983) o ften  using high exposure levels and also in v itro  systems 
have been used (Silbergeld and A lder, 1978). But the m a jo rity  o f work has used
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developmental models o f lead exposure to study the disruption of neurochemical 
systems as a possible cause o f la te r neurotoxic e ffec ts  resulting in behavioural 
disorders.
Classical neuro transm itte r systems have been studied in de ta il (acetylcholine, 
catacholam ine, gam m a-am inobutyric acid (GABA) and 5-hydroxytryptam ine) 
although some in te rest in more recently  iden tified  neuro transm itte r systems such 
as the peptidergic systems have been shown. H is to rica l and m ethodological reasons 
account fo r the re la tive  emphasis o f research in terest.
The cholinerg ic system has been studied extensively w ith  not only levels o f 
the tran sm itte r acetylcholine being measured but also levels o f precursors, a c tiv ity  
o f synthesis enzymes (choline acetyltransferase), turnover o f the tran sm itte r and 
its  breakdown by cholinesterase enzymes in lead exposed animals. Many studies 
have used high lead dosing models and results from  d iffe re n t groups are 
con trad ic to ry . A summary o f the e ffec ts  o f lead exposure on the cholinerg ic 
system is given in Table 9, a more extensive review o f the e ffec ts  o f lead on the 
cholinerg ic system is given in Winder and K itchen (1984). The cholinerg ic system is 
an unlike ly ta rge t fo r specific neurochemical to x ic ity  induced by lead as reports 
indicate tha t nonspecific changes occur due to a decrease in energy metabolism 
(Sterling e t al., 1982) although lead exposure does have an inh ib ito ry  e ffe c t on 
cholinerg ic metabolism (Shih and Hanin, 1978). More recent studies using lower 
lead exposure levels have reported an in it ia l increase in : muscarinic receptor 
binding capacity in the cortex and s tria tum  (Moingeon et al., 1984) but more 
prolonged perinata l exposure results in decreased capacity o f muscarinic receptors 
in the s tria tum  (Rossouw et al., 1987).
Many of the early studies o f lead exposure on the catecholam inergic systems 
used re la tive ly  high lead dosing models which caused a va rie ty  o f changes in 
tran sm itte r levels, synthesis and metabolism o f these transm itte rs  and are 
summarised in Table 9. E ffec ts  o f lead exposure on the dopamine system are o f 
pa rticu la r relevance due to the involvement o f the dopaminergic system w ith
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skeletal muscle contro l and movement. A general inh ib ition o f this system has 
been reported and recent studies using low levels o f lead exposure have also 
reported a decreased a ff in ity  o f D2 receptors which is accompanied by an 
increased capacity a fte r postnatal exposure (Rossouw et al., 1987).
GABA a major inh ib ito ry  neuro transm itte r in the CNS appears to be 
unaffected by lead exposure but uptake and release o f GABA are inhib ited 
(Silbergeld e t al., 1979), these e ffec ts  are summarised in Table 9. The e ffec ts  o f 
lead exposure on the indolamines are inconsistent w ith  both increased and 
decreased levels reported (Table 9).
1.8.3.2. Peptidergic neuro transm itte r systems.
The e ffe c ts  o f perinata l lead exposure on opioid peptide neuro transm itte rs 
has been recently  studied (Table 10). Increases in both s tr ia ta l (Memo et al., 1981) 
and hypothalam ic (Baraldi et al., 1983) enkephalin levels have been reported as w e ll 
as decreases in 3 -endorphin levels (Baraldi et al., 1983). These studies used high 
levels o f lead exposure fo r long periods o f tim e. Studies using lower and shorter 
lead exposure models have reported decreased levels o f s tria ta l [M e t! -enkephalin 
(Winder et al., 1984 and Bailey and K itchen, 1983) as w e ll as the extended 
enkephalins (Bailey and K itchen, 1985). These e ffec ts  on s tr ia ta l enkephalin levels 
appear to represent a delay in ontogeny as some recovery o f levels is observed 
la te r in development (Winder et al., 1984 and Bailey and K itchen, 1985). Baraldi et 
al. (1985) have reported an increased capacity o f opioid receptors, w ithou t e ffe c t 
on receptor a f f in ity  in the hypothalamus, brain stem and stria tum  o f 40 day old 
animals exposed perina ta lly  to lead.
1.9. A im s o f study.
The possible link  between low level lead exposure during development periods 
and childhood behavioural disorders has prompted work in animal models. 
A ttem pts to corre la te  lead exposure w ith  behavioural and neurochem ical
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abnorm alities in experim ental animals have yielded results which are often 
con trad ic to ry . An association o f lead exposure has been made w ith  abnormal 
locom otor a c tiv ity  although there is va ria b ility  in the lite ra tu re  which may in part 
re fle c t high levels o f lead exposure in some animal models. In addition studies o f 
lead e ffec ts  on dopamine in the brain have also indicated a link w ith  a c tiv ity  
because o f the involvem ent o f this neuro transm itte r in centra l contro l o f skeleta l 
movement. With the discovery o f endogenous opioids in the CNS, th e ir possible 
role in modulating dopamine and the ir e ffec ts  on behaviour, the opioids are a 
po tentia l ta rge t fo r the tox ic  e ffe c ts  o f lead. In addition, there have been reports 
o f altered levels o f opioids in various brain regions (Memo et al., 1981, and Govoni 
et al., 1980) and on the e ffe c t o f lead on morphine seeking behaviour (Schwartz and 
Marchok, 1975) at high levels o f exposure. Carm ichael et al. (1981) developed a 
perinata l lead dosing model which attem pts to para lle l low levels o f lead exposure 
in man producing blood lead levels tha t are below the 'safe l im it ' fo r human 
exposure. Using th is model lead delays the ontogeny o f proenkephalin products in 
the s tria tum  o f neonatal rats (Bailey and K itchen, 1985) an e ffe c t not observed fo r 
other neuro transm itte r systems (Bailey and K itchen, 1986).
The aim o f th is p ro ject is to use this model o f low level, perinata l lead 
exposure and examine its  e ffec ts  on various aspects o f the developing opioid 
system. Studies have included work on the whole animal looking at the e ffe c t o f 
lead ’ exposure on responses to pain and on a c tiv ity , and m odulation o f these 
reponses by opioid drugs. In addition biochem ical studies on receptor development 
and endocrine function  in these lead exposed animals have been examined.
METHODS.
2.1. Lead dosing model.
Lead was adm inistered to animals according to the method o f Carm ichael et 
al (1981). W istar albino rats o f the University o f Surrey strain were used in a ll 
experiments. Throughout the study animals were maintained at a constant 
tem perature o f 22°C, hum id ity o f 45-55% and on a 12 hour ligh t dark cycle (lights 
on at 7.00 hrs, o f f  at 19.00 hrs). Spratts expanded laboratory d ie t No. 1 was fed ad 
lib itu m . Two v irg in  female rats (170-250 g) were caged w ith  one male ra t from  
Monday to Thursday. Conception was determ ined by the presence o f sperm in 
vaginal smears obtained by introducing 0.1 ml o f 0.9% w /v saline in to  the vagina 
and then w ithdraw ing and examining under a Phase contrast ligh t microscope 
(m agnifica tion x 10). Females w ith  a positive smear were transfe red .to  individual 
breeding cages and introduced to a lead treated drinking solution. Four trea tm ent 
groups were used (0 , 100 , 300 and 1000 ppm lead acetate) prepared according to the
fo llow ing protocol 
0 ppm -
100 ppm 0.183 g Lead acetate + 0.8 m l g lacia l
>
300 ppm 0.549 g Lead acetate 1 acetic acid /1
1000 ppm 1.832 g Lead acetate /  d is tilled  water
Female weight gain and flu id  consumption were recorded tw ice  weekly. 
Close to pa rtu rition  (at 22 days a fte r conception) females were checked daily fo r 
lit te r in g . On the day o f b irth , designated day 0, dams and litte rs  were weighed and 
the number o f pups recorded p rio r to cross fostering. L itte rs  born on the same day 
were randomly cross fostered w ith in  the same trea tm ent groups. E ight pups were 
randomly assigned to each dam. Any l i t te r  w ith  less than 6 pups or which 
subsequently fe ll to less than 6 pups due to neonatal m o rta lity  were removed from  
the study. Dams and lit te rs  were weighed, counted and flu id  consumption recorded 
tw ice  weekly.
Two schedules o f lead adm in istra tion were used (Fig. 2):
1) Dosing from  conception to weaning
2) Dosing from  conception to day 14
L itte rs  on schedule 2 adm in istra tion at day 14 were weighed counted and 
flu id  consumption measured before the drinking solution was changed to tap water. 
A t day 21 a ll lit te rs  were weaned, pups were weighed and counted, flu id  
consumption measured and the dam a fte r weighing was removed form  the li t te r .  
A ll l i t te rs  were subsequently maintained on tap water.
A t the end o f experim ental procedures trunk blood was collected in lead free 
polythene vials and frozen at -20°C fo r subsequent determ ination o f lead levels by 
atom ic absorption spectroscopy.
2.2. General Experimental Conditions.
The experim ental laboratory was windowless and maintained under the same 
conditions as the animal house w ith  a constant tem perature o f 22°C, hum id ity  o f 
45-55% and on a 12 hour ligh t dark cycle (lights on at 7.00 hrs, o f f  at 19.00 hrs). 
The laboratory was maintained at a m inim al noise level.
Test lit te rs  were introduced in to the laboratory at least 24 hrs p rio r to 
testing to equ ilib ra te  and a ll experim ental procedures carried out a fte r 
equ ilib ra tion .
During experiments carried out in the dark phase o f the lig h t cycle a red 
25 W ligh t bulb was the only illum ination  in the testing room.
2.3. Antinociceptive Testing.
2.3.1. Ta il Immersion Test.
Nociceptive testing and the antinociceptive e ffec ts  o f morphine were studied 
using the ta il immersion test. The method was adapted from  tha t o f Auguy-Valette  
et al (1978).
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On the morning o f testing the pups were weighed and marked, the mean 
weight being used to calculate appropriate morphine dose, calculated as mg of 
morphine sulphate sa lt. Morphine solutions were made up in 0.9% w /v saline and 
in jection  volumes o f 0.05 ml were used fo r 10 day old pups and 0.1 m l fo r 21 and 30 
day old animals. C ontro l animals were treated w ith  0.9% saline. In jection volumes 
were adjusted i f  weights o f individual animals varied from  the mean. In jections 
were made subcutaneously in to the s c ru ff o f the neck.
A ll testing was carried out between 13.00 hrs and 16.00 hrs. Ta il immersion 
procedures were carried out by holding the pup upright in the hand and immersing 
the te rm ina l 3 cm (10 day rats) or 5 cm (21 and 30 day rats) o f the ta il in a 
waterbath maintained at 50°C (Fig. 3). Nociceptive reaction tim es were 
determ ined w ith  a hand held stop-watch and were taken as the point when the tip  
o f the ta il was w ithdrawn from  the surface o f the water. A maximum c u t-o ff  tim e 
o f 10 sec. was employed to prevent tissue damage.
Nociceptive reaction times were measured 15 mins p rio r to in jection  and 15, 
30 and 60 mins. a fte r in jection  (Fig. 4). 10 day old pups were removed from  th e ir 
mother 5 min prio r to in jection and nociceptive testing, and returned im m ediate ly 
afterw ards to minimise stress to the pups and mother.
P ilo t experiments to determ ine dose re lated e ffec ts  of morphine and its  tim e 
course o f action were carried out in 10, 21 and 30 day pups.
Doses o f morphine chosen fo r study in each age group were varied according 
to the antinociceptive a c tiv ity  determ ined from  p ilo t experiments. 
A n tinoc iceptive  e ffec ts  o f morphine were measured in 0, 300 and 1000 ppm 
schedule 1 lead treated animals.
To e lim ina te in te r - l i t te r  variations and va ria b ility  between testing days, 
lit te rs  o f 8 animals were divided so tha t 2 animals were used fo r each o f the 3 
doses o f morphine and saline contro l. Drug adm in istra tion was carried out blind. 
Each value is a mean of 8 animals from  4 litte rs  tested on 4 separate days.
Fig. 3. Tail immersion test on 21 day old neonate.

2.3.2. Paw Pressure Test.
Nociceptive testing and the antinociceptive e ffec ts  o f ketocyclazocine were 
studied using the paw pressure test. The paw pressure test was carried out using a 
m odified analgesy-meter (Ugo-Basile), allow ing the pressure to be applied by a 
3 mm bar placed across the fu ll w idth o f the neonate paw (Fig. 5) as described by 
K itchen (1984a). Increasing force was applied using the e le c tr ica lly  operated 
footsw itch o f the analgesy-meter. A nociceptive response was taken as paw 
w ithdraw al or body flin ch . Both hind paws were tested and the mean of these two 
measurements used as a single observation. A maximum c u t-o ff  pressure o f 230, 
500 and 750 g was used fo r 10, 21 and 30 day old rats respective ly to avoid paw 
damage. A ll testing was carried out between 13.30 hrs and 16.00 hrs.
Injections o f ketocyclazocine in 0.9% w /v saline were made subcutaneously in 
the sc ru ff o f the neck in 0.05 ml fo r 10 day neonates and in 0.1 m l fo r 21 and 30 
day animals.
Nociceptive reaction tim es were measured 10 min p rio r to in jection  and at 
various tim es a fte r in jection  (Fig. 6). The tim e course o f ketocyclazocine 
antinociception and the determ ination o f dose ranges were carried out in p ilo t 
experiments fo r each age.
Doses o f ketocyclazocine chosen fo r comparison to lead-treated groups were 
varied fo r d iffe re n t ages according to the nociceptive a c tiv ity  determ ined from  the 
p ilo t experiments. A n tinoc iceptive  e ffec ts  o f ketocyclazocine were measured in 0, 
300 and 1000 ppm schedule 1 lead treated animals.
S im ilar methods were employed to reduce in te r - l i t te r  and in te r-day 
variations as were used in the Ta il Immersion Test (section 2.3.1.).
2.4. Receptor Binding Assays.
2.4.1. Ligand preparation.
P rio r to use a ll t r it ia te d  ligands were pu rified  by HPLC using the method of
Fig. 5. Paw pressure test on 10 day old neonate using 
m odified analgesymeter.
vo
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\2
Bailey and K itchen (1985). Reverse phase HPLC was carried out using a C l8 p- 
Bondapak column (3.9 mm x 15 cm). A linear gradient o f 15-30% ace ton itr ile  in 
6.25% v/v acetic acid, 0.25% v/v  ammonia pH 3.2 over 30 min was employed. A 
flow  ra te  o f 1 m l/m in  was used to purify  [ ] [ D-
A la^ MePhe^ G lyol 1 enkephalin (DAGO) and 0.5 m l/m in  fo r [ ^ H ]  [ D-Pen^ D-
Pen^ ] enkephalin (DPDPE). Peptides were monitored using u ltra v io le t detection at 
280 nm. 3 standard concentrations o f each corresponding cold ligand were 
prepared from  a 1 m g/m l stock solution in d is tilled  water and subsequent d ilutions 
were made w ith  in it ia l gradient solvent.
Before pu rifica tion  [ ^H ] DAGO was frozen at -20°C fo r 2 hrs and freeze-
3dried fo r a fu rthe r 4 hrs to remove solvents. For [ H ] DPDPE solvents were 
removed by a gentle stream of nitrogen. Dried samples were taken up in lQOpl o f 
in it ia l gradient solvent and applied to the column. Fractions Were collected a t 
appropriate re ten tion  tim es determ ined by U.V. detection o f respective cold 
standards. A liquots o f each frac tion  were counted by liquid sc in tilla tio n  counting. 
T ritia te d  compounds were stored at -20°C prio r to use.
From the quantity  o f peptide present in the peak frac tio n  as determ ined by 
HPLC and the ra d io a c tiv ity  determ ined by liquid sc in tilla tio n  counting, taking in to  
account quenching, an estim ate o f pu rity  - tha t is the proportion o f peptide in the 
peak frac tio n  and specific  a c tiv ity  - the amount o f ra d io ac tiv ity  a ttr ib u ta b le  to a 
unit o f peptide, could be made.
2.4.2. Membrane preparation.
Receptor binding, assays were carried out on whole brain homogenates.based 
on the methods o f G illan and K o s te riitz  (1982). The experim enta l protocol is 
summarized in a flow  diagram (Fig. 7).
Animals were decapitated and whole brain was removed and weighed rap id ly. 
Brain tissue was coarsely minced w ith  fine scissors in 50 vol. w /v o f ice cold 50 mM 
Tris HC1 pH 7.4 at 0 ° q  ancj homogenised w ith  a Polytron homogeniser at
I50vo l  Tris
^ S u p e rn a ta n t
Pelle t
5 0 v o l  Tris
2nd1st
50 v o l  Tris H Ligand
Displacing  
^  Ligand
Wash 3 x 5  m I Tris
0*5 ml 2 0 %  Triton X -1 0 0
3-5ml S c in t i l lan t
COUNT
Resuspend
INCUBATE  
25°C 40mins
HOMOGENISE  
P o ly t r o n  45s
3 7 ° C  45 m in s
INCUBATE
CENTRIFUGE  
4 9 0 0 0 g  10mins
F IL TE R  
GFB f i l te r  paper 
under  vacuum
Fig. 7. Protocol for opioid receptor binding assays.
13,000 rpm fo r 43 sec. The homogenate was made up to 100 vol. w ith  bu ffe r and 
centrifuged at 49,000 g fo r 10 min (Beckman U ltra  centrifuge L3-65B, ro to r 45Ti). 
The supernatant was discarded and the pe lle t resuspended in 100 vol. o f ice cold 
50 mM Tris HC1 pH 7.4 at 37°C. This suspension was incubated in a shaking 
waterbath at 37°C fo r 45 min fo r removal o f endogenous opioids.
A fte r  th is pre-incubation the suspension was recentrifuged at 49,000 g fo r 
10 mins. The supernatant was discarded and the pe lle t resuspended in 50 vol. o f ice 
cold 50 mM Tris HC1 pH 7.4 at 25°C by vortexing and a fu rthe r homogenisation fo r 
45 sec. This fina l homogenate was made up to 100 vol. and used fo r a ll receptor 
binding assays.
2.4.3. Binding assays.
Assays were carried out in tr ip lic a te  using a fin a l incubation volume o f 2 ml 
containing 19 mg o f brain tissue. A ll ligand d ilutions and volume additions were 
made w ith  ice cold 50 mM Tris HC1 bu ffe r pH 7.4 a t 25°C. Incubations were 
carried out in a shaking waterbath at 25°C fo r 40 mins in the presence or absence 
o f displacing ligand. The incubation was term inated by rapid f ilt ra t io n  under 
vacuum through Whatman GF/B f i l te r  papers pre-soaked in bu ffe r. The f ilte rs  
were washed in tr ip lic a te  w ith  5 ml o f ice cold 50 mM Tris HC1 bu ffe r pH 7.4 to 
remove any free ligand. The f i l te r  disc was then transferred to a 5 ml sc in tilla tio n  
v ia l and 0.5 m l o f a 20% v/v  T riton  X-100 in toluene solution was added. Tubes 
were capped and le f t  overnight. 4.0 m l o f Unisolve 1 sc in tilla tio n  flu id  was added 
p rio r to m ixing and liqu id  sc in tilla tio n  counting.
E ffic iency  o f counting was determ ined in tr ip lic a te  using 10 p i aliquots o f 
[ ^ H ]  n hexadecane standard both on its  own and w ith  homogenate coated f i l te r  
and T riton  solution.
2.4.3.1. [ ^H ] DAGO binding.
Saturation curves were obtained by incubating 12 concentrations o f t^H  ]
DAGO (40 pM - 11 nM) in the presence and absence o f 1 yM diprenorphine.
Schedule 2 lead dosed animals in 0, 100 , 300 and 1000 ppm groups were 
studied at 10, 21 and 30 days. Pooled brain tissue was used for neonates up to 21 
days, fo r animals greater than 21 days a single brain was used. Binding assays were 
carried out on separate litte rs  and on separate days to avoid in te r - l i t te r  and in te r-  
day variations.
2.4.3.2. [ ^ H ]  DPDPE binding.
[^H  ] DPDPE binding was carried out as described by Cotton et a l. (198-3). 
Saturation curves were obtained by incubating 10 concentrations o f [ ?H 1 DPDPE 
(0.2 -23 nM) in the presence and absence o f 10 yM naloxone.
A fu ll ontogenetic p ro file  o f the binding o f [^H  1 DPDPE was determ ined in 
neonatal animals before studying the e ffec ts  o f lead trea tm ent. Saturation curves 
were carried out in naive animals aged between 10 and 50 days. For neonates up to 
21 days pooled brain tissue was used fo r each binding assay, fo r animals older than 
21 days a single brain was employed.
Schedule 2 lead dosed animals (see 2.1) in 0, 300 and 1000 ppm groups were 
studied at 13, 21, 35 and 50 days. Pooled brain tissue was used fo r neonates up to 
21 days. Binding assays were carried out on separate lit te rs  and on separate days 
to avoid in te r - l i t te r  and in ter-day variations.
2.4.4. Data analysis o f binding assays.
Specific binding was determ ined by subtraction o f the non specific  binding in 
the presence o f displacing ligand from  the to ta l binding. Scatchard analysis was 
used to obtain equilibrium  dissociation constant (K ^ ) and maximal binding capacity 
(Bmax) (Scatchard 1949). A linear regression analysis was perform ed on each 
Scatchard p lo t and corre la tion  coe ffic ien ts  below 0.82 (p<0.001) were excluded 
from  the study.
2.4.5. Time Course Experim ents.
The tim e taken to reach equilibrium  in binding assay incubations was studied 
fo r both DAGO and DPDPE. A series o f tim e point from  5 to 180 mins were used 
to measure binding in tr ip lic a te  at a ligand concentration o f 0.5 in the presence 
and absence o f displacing ligand. Time course fo r [ ] DAGO binding was
carried out in 10 and 30 day animals and fo r [^H  ] DPDPE in 15 and 35 day 
animals.
2.4.6. S tab ility  o f ligands.
In order to determ ine i f  binding at equilibrium  was a ttribu tab le  to the parent 
ligand or to a breakdown product the s ta b ility  o f the ligands was checked using the 
HPLC method described in Section 2.4.1.
Each ligand was incubated in both 50 mM Tris HC1 and homogenate fo r 
40 mins at 25°C in a shaking waterbath. Incubation was term inated by f ilt ra t io n  to 
remove particu la tes and large protein molecules. The f ilt ra te  was frozen at -20°C  
fo r 2 hrs and then freeze-dried. In it ia l gradient solvent (100 - 200 pi) was added 
to dissolve the freeze-dried sample. 100 p i o f the resulting solution was applied to 
the column and fractions collected at one m inute in terva ls. P u rity  o f the 
incubated sample ligand was compared w ith  a tr it ia te d  standard. Unisolve 1 
(3.5 ml) was added to each frac tio n  p rio r to m ixing and liquid sc in tilla tio n  counting.
2.4.7. Protein determ inations.
Prote in determ inations (in duplicate) were carried out according to the 
method o f Lowry et al (1951) on a ll samples o f brain homogenates. Reference 
standards o f bovine serum albumin were used between 0 and 80 pg /m l o f sample 
bu ffe r. 1% w /v hydrated copper sulphate, 2% w /v sodium potassium ta rtra te  and 
2% w /v sodium carbonate in 0.1 M sodium hydroxide were mixed sequentia lly to 
give a fina l ra tio  o f 1:1:100 by volume im m ediate ly p rio r to use. 2.5 m l o f th is 
reagent was added to each o f the blanks (sample buffer), standards and prote in
samples, mixed and le f t  to stand fo r 10 mins at room tem perature. Folin 
Ciocalteau phenol reagent was d iluted 1:1 w ith  d istilled, water and 0.25 ml was 
added to each reaction and vortexed im m ediate ly. Colour was allowed to develop 
over 30 mins and was measured at 750 nm in a C ecil Spectrophotometer.
2.5. Corticosterone Estimations.
Plasma corticosterone was assayed flu o r im e tric a lly  by a m od ifica tion  o f the 
method o f Zenker and Bernstein (1958). Trunk blood was collected in to heparinised 
tubes and plasma was separated by centrifugation  at 4000 g fo r 10 mins at 4°C  
(Beckman J6 centrifuge). 1 m g/m l corticosterone in ethanol was diluted w ith  
saline to produce a standard curve from  0.05 - 0.5 pg/m l. 200pl o f plasma was 
diluted to 1 m l w ith  d is tilled  water and 1 m l o f standard solutions were used fo r 
assay. Samples were vortexed w ith  10 ml ch loro form  fo r 10 .sec. 8 m l o f the 
ch loroform  layer was then mixed w ith  3 ml o f an ethanol: concentrated sulphuric 
acid m ixture (3:7 by volume) fo r 5 secs. Fluoresence was measured in the 
ethanol/acid layer a fte r 90 mins using a spectro fluorim eter (Perkin E lmer LS-5 
Luminescence Spectrometer) set at an exc ita tion  wavelength o f 475 nm and an 
emission wavelength o f 525 nm, s lit widths o f 5 and an in tegrated measurement 
made over 8 secs.
Schedule 2 lead dosed animals (see 2.1) in 0, 100, 300 and' 1000 ppm groups 
were studied at 30, 45 and 60 days. A ll animals were weighed and marked the day 
p rio r to experim entation and were maintained in the experim ental room fo r 24 hrs 
p rio r to the experiment to avoid stress induced rises in corticosterone. Anim als 
were decapitated between 08.00 - 09.30 hrs. Doses o f morphine sulphate in 0.9% 
w /v saline were calculated fo r the mean weight and appropriate adjustment o f 
volume made fo r individual animal weights. Basal, saline and morphine trea tm en t 
was included fo r each l i t te r  on each experim ental day to reduce in te r - l i t te r  and 
in ter-day variations. Animals fo r basal corticosterone determ inations were 
term inated p rio r to in jection o f l i t te r  mates. Remaining l i t te r  mates were
te rm inated 20 mins a fte r in jection  o f saline or morphine.
2.6. Locomotor Activity Studies.
Locom otor a c tiv ity  was measured using a system previously described by 
Francis e t a l  (1983). The a c tiv ity  m on ito r was b u ilt in the B iochem istry Workshop, 
U n ivers ity  o f Surrey and consisted o f 3 testing boxes (18.3 x 11 x 22 cm), each box 
was in tersected 1.5 cm above the box base by 3 in fra -red  beams from  industria l 
grade in fra -red  source which were detected by photocell sensors. Whenever a 
beam was blocked or unblocked a score was recorded via an in te rface  to a BBC B 
m icrocom puter. The software program employed an in te rrup t routine to assess the 
state of the photocells, on or o ff,  every 10 ms and recorded a change in state as a 
score.
Locom otor a c tiv ity  was measured constantly over 60 mins but recorded as 30, 
2 m inute periods so tha t a p ro file  o f exploratory a c tiv ity  (0-10  mins) and to ta l 
a c tiv ity  (0-60 mins) was obtained.
P ilo t experiments were carried out to determ ine the circadian varia tion  of 
locom otor a c tiv ity  between 14.00 hrs and 01.00 hrs in 10, 21 and 30 day animals. A 
2 5 W red lig h t bulb was the only illum ina tion  a fte r the end of the normal ligh t 
period at 19.00 hrs.
Schedule 2 lead dosed animals 0, 300 and 1000 ppm dose groups were studied 
during peak a c tiv ity ; 20.00 - 22.00 hrs in 0, 21 and 30 day animals. 4 doses o f 
morphine or saline were used to  study locom otor a c tiv ity  in contro l and lead dosed 
animals.
2.7. Blood Lead Determinations:
Blood lead levels were determ ined by furnace atom ic absorption 
spectrom etry as described by Bailey and K itchen (1983). Defrosted trunk blood 
samples were sonicated w ith  a Dawe soniprobe (Type 130 A) and 40 pi aliquots 
were dilu ted 1:10 w ith  0.1% T riton  X-100, 0.3% phosphate as (N H ^ H P O ^  prepared
in deionised reverse osmosis treated water. 10 p i o f d iluted blood was introduced 
in to the graphite furnace tube o f an atom ic absorption spectrom eter (Pye Unicam 
SP9). The samples were dried, ashed and atomised at contro lled rates using the 
fo llow ing tem perature programme.
Phase Temperature (°C) Time (s) Ramp
Dry 1 110 40.0 5
2 140 10.0 9
Ash 3 723 30.0 4
Atom ise 4 1430 3.0 0
Clean 5 2830 2.0 0
Absorbance was measured at 283.3 nm and lead concentrations were 
determ ined in duplicate by reference to a standard curve from  whole blood 
standards.
2.8. M ateria ls.
Ammonia solution (Anala R), copper sulphate hydrate (Anala R), hydrochloric 
acid, concentrated (Anala R), lead acetate, tr ihyd ra te  (Anala R), sodium carbonate 
(Anala R), sodium potassium ta rtra te  (Anala R), toluene (Scintran), tr ito n  X-100 
(Scintran) and tr is  (hydroxymethyl) m ethylam ine (Anala R) were obtained from  
BDH Chemicals L td ., Poole. Ethanol (absolute alcohol 100) was obtained from  
James Burrough (F.A .D .) L td ., Waltham. A ce to n itrile  (HPLC grade) and Unisolve 1 
were obtained from  Koch L igh t L td ., H averh ill. A ce tic  acid, g lacia l (Pronalys AR), 
ch loro form  (Pronalys AR), sodium hydroxide (Pronalys AR) and sulphuric acid, 
concentrated (Pronalys AR) were obtained from  May and Baker, Dagenham. 
Ammonium phosphate, bovine serum albumin, corticosterone and Folin C iocalteau's 
phenol reagent were obtained from  Sigma Chemical Company, Poole.
2 4The peptide [ D -A la MePhe G lyol ] enkephalin was obtained from
2 5Cambridge Research Biochemicals, Harston and [ D-Pen D-Pen ] enkephalin was 
obtained from  Peninsula Laboratories Europe L td ., St. Helens.
The radio labelled compounds [ ] [ D -A la^ MePhe^ G lyo l] enkephalin
(55 - 60 C i/m m ol), [ ^ H ]  [ D-Pen^ D-Pen ^ ] enkephalin (25 - 29 C i/m m ol) and
[^H  ] n-hexadecane tr it iu m  standard were obtained from  Amersham In ternationa l 
pic., Amersham.
Morphine sulphate was obtained from  May and Baker, Dagenham.
The fo llow ing drugs were generous g ifts , naloxone hydrochloride (Dupont 
Pharmaceuticals, USA), diprenorphine hydrochloride (R eck itt and Colman, Hull) 
and ketocyclazocine mesylate (Sterling Winthrop Group, Guildford).
2.9. S ta tis tica l Analysis.
Values fo r students t- te s t were calculated from  the fo llow ing form ula:
where 3C = mean
a = standard error o f the mean
Analysis o f variance (ANOVA) fo r m aternal and neonate weight gains and 
e ffe c ts  o f lead exposure on binding parameters was carried out using the SPSS-X 
package on the prim e com puter. Maternal weight gain data was analysed as a 
change from  s tarting  weight to take in to account any variations between lead 
groups o f the sta rting  weight.
S ta tis tica l comparison o f peak antinociceptive a c tiv ity  o f morphine in the 
ta il immersion study was carried out using repeated measurement analysis 
assuming Weibull d is tribu tion  fo r data to account fo r censored values (ie values >
cut o f f  tim e) (K itchen and Crowder, 1985).
Dose response curves fo r ketocyclazocine antinociception in the paw pressure 
study was analysed by s tra igh t-line  regression. A D ^q values (defined as the dose 
required to increase antinociceptive responses to ha lf the c u t-o ff  weight) were 
computed from  the fu ll dose response curve.
Both the e ffe c t o f lead on corticosterone levels and locom otor a c tiv ity  were 
analysed by the M u lti-w ay analysis o f variance (MANOVA) using the SPSS-X 
package. Locom otor a c tiv ity  was analysed using repeated measures to account fo r 
the w ith in  subject fac to r o f tim e.
3. RESULTS.
3.1. E ffect of lead exposure on litte r parameters and blood lead levels.
M aternal and neonatal data and blood lead levels were analysed fo r each 
series o f experiments and are presented in the appropriate results sections.
There were no consistent dose re lated e ffec ts  o f perinatal lead exposure on 
m aternal weight gain, flu id  consumption, l i t te r  size and b irth  weight or neonate 
growth (Figs. 11-14, 20-23, 33-36, 50-53, 58-61 and 70-73).
Maximum dose re lated elevations o f blood lead levels were measured at 21 
days in Schedule 1 dosed animals and at 15 days fo r Schedule 2 dosed animals. 
Once dosing o f the dam was term inated neonate blood lead levels decreased and 
approached contro l levels by 30-50 days (Tables 11, 13, 17, 18 and 20).
3.2. Antinociceptive testing.
The fo llow ing sections describe the results o f ontogenetic studies using two 
antinociceptive tests, the ta il immersion test and the paw pressure test, and how 
perinata l lead exposure a ffected  the general development o f the animals, the ir 
nociceptive and antinociceptive responses.
3.2.1. Tail immersion studies.
3.2.1.1 P ilo t experim ents.
The tim e course o f morphine antinociception in the ta il immersion tes t is 
shown in Figs. 8-10. In 21 and 30 day old rats there was a dose re lated increase in 
nociceptive threshold w ith  increasing doses o f morphine (Fig. 9 and 10) and the 
peak antinociceptive e ffe c t was observed 30 mins. a fte r in jection. In 10 day old ra t 
pups doses o f morphine below 8 mg/kg showed peak antinociception 15 mins. a fte r  
in jection  while higher doses showed peak antinociception at 30 mins. (Fig. 8).
The sensitiv ity  o f the neonate to both the therm al stim ulus and the 
antinociceptive e ffe c t o f morphine were age dependent. 10 day old neonates had 
the shortest response tim e to the therm al stimulus while 21 and 30 day old animals
Fig. 8 . Time course of morphine antinociception in 10 day
old rats using the ta il immersion test.
•  Saline
■ 2 mg/kg morphine sulphate
▲ 4 mg/kg morphine sulphate
O 8 mg/kg morphine sulphate 
□ 16 mg/kg morphine sulphate 
a 32 mg/kg morphine sulphate
Each value is the mean + S.E.M. o f 5 observations, each tim e course 
being carried out on separate animals. Injections o f morphine sulphate were 
made subcutaneously in to  the sc ru ff of the neck.
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Fig. 9. Time course of morphine antinociception in 21 day
old rats using the tail immersion test.
•  Saline
■ 1 mg/kg morphine sulphate
a 2 mg/kg morphine sulphate
O 4 mg/kg morphine sulphate
□ 8 mg/kg morphine sulphate
a  16 mg/kg morphine sulphate
Each value is the mean + S.E.M. o f 5 observations. Each tim e course 
being carried out on separate animals. Injections o f morphine sulphate were 
made subcutaneously in to the sc ru ff o f the neck. Figures alongside standard 
erro r bars re fe r to % o f animals which showed response tim es >10s, fo r 
graphical presentation response tim es >10s are denoted as 10s.
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Fig. 10. Time course of morphine antinociception in 30 day
old rats using the tail immersion test.
•  Saline 
. ■ 2 mg/kg morphine sulphate
± 4 mg/kg morphine sulphate
O 8 mg/kg morphine sulphate
□ 16 mg/kg morphine sulphate
Each value is the mean + S.E.M. o f 3 observations. Each tim e course 
being carried out on separate animals. Injections o f morphine sulphate were 
made subcutaneously in to the sc ru ff o f the neck. Figures alongside standard 
error bars re fe r to % o f animals which showed response tim es >10s, fo r 
graphical presentation response times >10s are denoted as 10s.
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took 2-3 tim es as long to  react to a w ater tem perature o f 50°C. Sensitiv ity to the 
antinociceptive e ffe c t o f morphine increased from  10 to 21 days, as evidenced by 
the AD^q value which fe ll from  23 mg/kg to 1 mg/kg when calculated 30 mins. 
a fte r in jection . The AD^q fo r 30 day old animals was 2.3 mg/kg, only s ligh tly  
higher than tha t fo r 21 day old animals.
3.2.1.2. E ffe c t o f lead exposure on l i t te r  parameters and blood lead levels.
S tarting m aternal weights varied between lead dose groups (Fig. 11) and
accordingly m aternal weight gains were analysed as a change from  s tarting  weights 
(see Section 2.9). Lead exposure caused a s ign ifican t weight gain in dams during 
the perinata l period. Neonate weight gain was s im ila r in a ll three lead dose groups 
except at 30 days where lead dosing increased weight gain and. resulted in a 
s ign ifican t e ffe c t o f lead (Fig. 12). F luid consumption, l i t te r  size and mean pup 
weight at b irth  were unaffected by lead trea tm en t (Fig. 13,14).
Blood lead levels showed a dose re lated increase at a ll ages (Table 11). Peak 
blood lead levels were found in 21 day old rats when lead dosing was term inated. 
By 30 days blood lead levels had fa llen  to approxim ately 25% o f peak levels.
3.2.1.3. E ffe c t o f lead on morphine antinociception.
Perinata l lead trea tm ent had no s ign ifican t e ffe c t on the nociceptive 
response tim e o f neonates at any age (Table 12). However perinata l exposure to 
lead altered antinociceptive responses o f 10 day old neonates to morphine (Fig. 15). 
Treatm ent o f the dam w ith  300 ppm lead resulted in a depression o f the 
antinociceptive e ffe c t o f morphine in 10 day old neonates. Peak response la tency 
was reduced from  7.2 + 1.1s to 4.3. + 0.9s a fte r in jection o f the highest dose o f 
morphine (16 mg/kg). In the 1000 ppm lead trea ted group there was a lack o f dose 
re lated responses to morphine and a ll doses resulted in a s im ila r response tim e.
Morphine antinociception in both 21 and 30 day old neonates did not show the 
depression o f response tim es or the loss of dose response tha t was seen a fte r lead
Fig. 11. Effect of perinatal lead exposure on maternal
weight gain in ta il immersion studies.
Each value is the mean o f at least 7 values o f dams exposed to contro l 
( •  ), 300 ppm ( ■ ) or 1000 ppm ( a  ) lead acetate in the m aternal drinking 
water from  conception to weaning (-21 to 21 days). E rror bars are om itted 
fo r c la r ity  o f graphical presentation. Analysis o f variance between lead 
groups p<0.05. .
F ig. 12. Effect of perinatal lead exposure on neonate weight
gain in ta il immersion studies.
Each value is the mean of at least 3 values o f neonates whose dam was 
exposed to con tro l ( •  ), 300 ppm ( ■ ) or 1000 ppm ( a ) lead acetate in the 
m aternal drinking water from  conception to weaning (-21 to 21 days). Error 
bars are om itted  fo r c la r ity  o f graphical presentation. Analysis o f variance 
between lead groups p<0 .01 .
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Fig. 13. Effect of perinatal lead exposure on maternal
fluid consumption in ta il immersion studies.
Each histogram represents the mean + 5.E.M. o f at least 7 observations 
o f flu id  consumed prenata lly or postnatally by dams exposed to contro l 
300 ppm h d  or 1000 ppm QQl lead acetate in drinking w ater from  conception 
to weaning (-21 to 21 days), t- te s t lead group vs. Oppm p>0.05.
Fig. 14. Effect of perinatal lead exposure on
a) mean pup weight at birth
b) number of pups in litte r at birth 
(ta il immersion studies)
Each histogram represents the mean + S.E.M. o f at least 13 
observations o f pup weight or number, o f dams exposed to contro l E L
300 ppm y j , or 1000 ppm [yvl lead acetate in drinking water from  conception
to weaning (-21 to 21 days), t- te s t lead group vs. Oppm. p>0.05.
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Table 11. Blood lead levels (yg/100 ml) of neonatal rats
used In ta il immersion studies determined by atomic 
absorption spectrophotometry.
Dose o f lead Age (days)
(ppm)
10 . 21 30
0 1.2 + 0.7 3.4 + 1.2 n.d.
300 34.7 + 1.3 118.6 + 8.8  26.0 + 2.7
1000 47.5 + 2.5 163.5 + 15.4 35.1 + 2.6
n .d ., not detectable.
Each value is the mean + S.E.M. o f at least 30 samples. Lead was 
administered as the acetate in the m aternal drinking water from  conception to 
weaning ("21  to +21 days).
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Fig. 15. Effect of perinatal lead exposure on the antinociceptive
activity of morphine in 10 day old neonatal rats using
the ta il immersion test.
•  Saline
■ 4 mg/kg morphine sulphate
*  8 mg/kg morphine sulphate
O 16 mg/kg morphine sulphate
Each value is the mean + S.E.M. o f at least 8 observations and each 
tim e course study was carried out on separate animals from  dams exposed to 
contro l (top graph), 300 ppm (middle graph) or 1000  ppm (bottom  graph) lead 
acetate in the m aternal drinking water from  conception to weaning (-21  to 21 
days). Figures alongside standard e rro r bars re fe r to the % o f animals which 
showed response tim es >10s. For graphical presentation response times >10s 
are denoted as 10s. S ta tis tica l comparison o f peak antinociceptive a c tiv ity  
using repeated measurements analysis assuming W eibull d is tribu tion  fo r data 
to account fo r censored values (ie values > c u t-o ff  tim e) 0 vs. 300 ppm data, 
16 mg/kg morphine P<0.05; 0 vs. 1000 ppm data 16 mg/kg morphine P<0.05.
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trea tm ent in 10 day old neonates (Fig. 16,17).
3.2.2. Paw pressure studies.
3.2.2.1. P ilo t experim ents.
P ilo t studies showed that only one pre-test and one post in jection response to 
paw pressure could be made on one paw as subsequent measurements demonstrated 
habituation to the test.
The neonate paw showed a decrease in sensitiv ity  w ith  age to the noxious 
pressure stimulus as evidenced by pre-test and saline values (Fig. 18 & 19). The 
response to ketocyclazocine was also age dependent. Time course experiments 
(Fig. 18) showed peak antinociception in 10 day old neonates to be 20 mins. a fte r 
in jection  o f ketocyclazocine while in 21 and 30 day old rats peak antinociception 
was observed at 3 mins. The sensitiv ity  to ketocyclazocine antinociception was 
also age dependent as shown by the dose response curves to ketocyclazocine (Fig. 
19). G reatest sens itiv ity  to ketocyclazocine was observed in 21 day old neonates, 
30 day old animals being the least sensitive as shown by the respective A D ^q values 
(Table 15).
3.2.2.2. E ffe c t o f lead exposure on l i t te r  parameters and blood lead levels. 
M aternal weight gains were analysed as a change from  s tarting  weights
(Section 2) resulting in a small but s ign ifican t change in lead trea ted animals due to 
increased weight gain at 14 and 21 days (Fig. 20). Neonate weight gain was not 
s ign ifican tly  a ffected  by lead trea tm ent (Fig. 21). The 1000 ppm group showed an 
increased flu id  consumption during the postnatal period (Fig. 22). L it te r  number 
and mean pup weight at b irth  was not s ign ifican tly  a ffec ted  by lead trea tm en t (Fig. 
23).
Blood lead levels were dose re lated to exposure groups and highest blood lead 
levels were observed in 21 day old neonates (Table 13).
Fig. 16. Effect of perinatal lead exposure on the antinociceptive
activity of morphine in 21 day old rats using
the tail immersion test.
•  Saline
■ 1 mg/kg morphine sulphate
a 2 mg/kg morphine sulphate
O 4 mg/kg morphine sulphate
Each value is the mean + S.E.M. o f at least 8 observations and each
tim e course study was carried out on separate animals from  dams exposed to 
contro l (top graph), 300 ppm (middle graph) or 1000 ppm (bottom  graph) lead 
acetate in the m aternal drinking w ater from  conception to weaning (-21  to 21 
days). Figures alongside standard erro r bars re fe r to the % o f animals which 
showed response tim es >10s. For graphical presentation response tim es >10s 
are denoted as 10s. S ta tis tica l analysis by Wilcoxon non-param etric rank test 
and by comparison o f peak antinociceptive a c tiv ity  using complete dose 
response curves using repeated measurements analysis assuming Weibull 
d is tribu tion  showed no s ign ifican t d ifference.
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Fig. 17. E ffect of perinatal lead exposure on the antinociceptive
activity of morphine in 30 day old rats using the ta il
immersion test.
•  Saline
■ 2 mg/kg morphine sulphate
^  4 mg/kg morphine sulphate
O 8 mg/kg morphine sulphate
Each value is the mean + S.E.M. o f at least 8 observations and each 
tim e course study was carried out on separate animals from  dams exposed to 
contro l (top graph), 300 ppm (middle graph) or 1000 ppm (bottom  graph) lead 
acetate in the m aternal drinking w ater from  conception to weaning (-21  to 21 
days). Figures alongside standard e rro r bars re fe r to the % o f animals which 
showed response tim es >10s. For graphical presentation response times >10s 
are denoted as 10s. S ta tis tica l analysis by Wilcoxon non-param etric rank test 
showed no s ign ifican t d ifferences. Comparison o f peak antinociception using 
complete dose-response curves using repeated measurements analysis 
assuming VVeibull d is tribu tion  fo r data to account fo r censored values (ie 
values > c u t-o ff  tim e) 0 vs. 300 ppm: no s ign ifican t d iffe rence; 0 vs. 1000 
ppm: P>0.05 fo r 4 mg/kg.
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Fig. 18. Time course of ketocyclazocine antinociception in 
10, 21 and 30 day old rats using the paw pressure test.
•  10 day old neonates
a  30 day old neonates
■ 21 day old neonates
0.4 mg/kg 
0.2 mg/kg 
0.8  mg/kg
□  range o f pretest values fo r 10 day old neonates 
KX/ range o f pretest values fo r 21 day old neonatesm
range o f pretest values fo r 30 day old neonates
Each value is the mean + 5.E.M. o f 5 observations, each measurement 
being made on separate animals. Injections o f ketocyclazocine were made 
subcutaneously into the sc ru ff o f the neck. Figures alongside standard error 
bars re fe r to % o f animals which gave response weights greater than the cu t­
o f f  weight (230 g fo r 10 day neonates, 500 g fo r 21 day neonates and 750 g fo r 
30 day rats), fo r graphical presentation response weight > c u t-o ff  are denoted 
as the c u t-o ff  weight.
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Fig. 19. The effect of age on the log dose response curve for 
ketocyclazocine antinociception in the paw pressure test.
•  10 day old neonates
■ 21 day old neonates
a  30 day old neonates
Each value is the mean + 5.E.M. o f at least 7 observations, each
measurement being made on separate animals. Pretest measurements were 
made 10 mins prio r to in jection o f ketocyclazocine made subcutaneously in to 
the sc ru ff o f the neck. Response measurements were made at the 
appropriate tim e a fte r in jection, 30 mins fo r 10 day old neonates and 10 mins 
fo r 21 and 30 day old neonates. Figures alongside standard erro r bars re fe r to 
% o f animals which gave response weights greater than the c u t-o ff  weight 
(250 g fo r 10 day neonates, 500 g fo r 21 day neonates and 750 g fo r 30 day 
rats), fo r graphical presentation repsonse weights > c u t-o ff  are denoted as 
c u t-o ff  weight.
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Fig. 20. Effect of perinatal lead exposure on maternal weight
gain in paw pressure studies.
Each value is the mean o f at least 7 values o f dams exposed to contro l 
( •  ), 300 ppm ( ■ ), or 1000 ppm ( a ) lead acetate in the m aternal drinking 
w ater from  conception to weaning (-21 to 21 days). E rror bars are om itted 
fo r c la r ity  o f graphical presentation. Analysis o f variance between lead 
groups was s ign ifican t, p<0.05.
Fig. 21. Effect of perinatal lead exposure on neonate weight
gain in paw pressure studies.
Each value is the mean o f at least 5 values o f neonates whose dam was 
exposed to con tro l ( •  ), 300 ppm ( ■ ), or 1000 ppm ( a ) lead acetate in the 
m aternal drinking water from  conception to weaning (-21 to 21 days). Error 
bars are om itted  fo r c la r ity  o f graphical presentation. Analysis o f variance 
between lead groups was not s ign ifican t, p>0.05.
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Fig. 22. Effect of perinatal lead exposure on maternal fluid 
consumption in paw pressure studies.
Each histogram represents the mean + S.E.M. o f at least 7 observations 
o f flu id  consumed prenata lly or postnatally by dams exposed to contro l Q ]  , 
300 ppm [Q ]o r 1000 ppm ^  lead acetate in drinking w ater from  conception
to weaning (-21 to 21 days), t- te s t lead group vs. Oppm. *  p<0.05.
Fig. 23. Effect of perinatal lead exposure on
a) mean pup weight at birth
b) number of pups in litte r at birth 
(paw pressure studies)
Each histogram represents the mean + S.E.M. o f at least 13 
observations o f pup weight or number, o f dams exposed to contro l □  > 
300 ppm |[J] or 1000 ppm ^  lead acetate in drinking warer from  conception
to weaning (-21 to 21 days), t- te s t lead group vs. Oppm. not s ign ifican tly  
d iffe ren t.
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Table 13. Blood lead levels (pg/100 ml) of neonatal rats
used in the paw pressure studies determined by atomic 
absorption spectrophotometry.
Dose o f lead 'Age (days)
(ppm)
10 21 30
0 3 + 0.3 1 + 0.2 0.4 + 0.1
300 33 + 1 91 + 12 19 + 1
1000 49 + 2 230 + 19 34 + 1
Each value is the mean + S.E.M. o f at least 30 samples. Lead was 
adm inistered as the acetate in the m aternal drinking water from  conception to 
weaning (~21 to +21 days).
3.2.2.3. E ffe c t o f lead on ketocyclazocine an tinociception.
Lead trea tm ent caused a small but s ign ifican t dose related increase in the 
nociceptive threshold o f 10 day old neonates (Table 14). In 21 day old rats there 
was no s ign ifican t d iffe rence in nociceptive response weights but at 30 days there 
was a s ign ifican t decrease o f the nociceptive response in both 300 and 1000 ppm 
dose groups.
Ketocyclazocine antinociception was also a ffected by lead trea tm en t (Fig. 
24-26). In 10 day old neonates, despite the lead induced rise in nociceptive 
threshold there was a dose re lated decrease in ketocyclazocine antinociception in 
lead treated animals (Fig. 24). The A D ^q value was increased by 48% in the 
1000 ppm lead dose group (Table 15). By 21 days the antinociceptive a c tiv ity  was 
restored in the 300 ppm lead dose group (Fig. 25) but was s t il l im paired in the 
1000 ppm lead dose group w ith  a 56% increase in the AD ^q value (Table 15). 
A n tinoc iceptive  responses to ketocyclazocine in lead treated animals were restored 
to contro l values in 30 day old neonates.
3.3. Receptor binding assays.
The fo llow ing sections describe results o f radioligand preparation and p ilo t
3 2 4experiments fo r two selective radioligands, [ H ] [ D -A la  MePhe G lyol 1
3 2 5enkephalin and [ H ] [ D-Pen D-Pen ] enkephalin. Ontogentic pro files  are
presented fo r both ligands and the e ffe c t o f perinata l lead exposure on the general
development o f the animals and the binding characteris tics fo r the ligands during
postnatal development are presented.
3.3.1. Radioligand preparation.
Both o f the unlabelled ligands [ D -Ala^M ePhe^G lyol ] enkephalin (DAGO) 
2 5and [ D-Pen D-Pen ] enkephalin (DPDPE) gave consistant and reproducible 
HPLC traces (Fig. 27 & 28). Retention times o f 5 mins. fo r DAGO and 21 mins. fo r 
DPDPE were obtained using the conditions defined in Section 2.4.1. Both ligands
Table 14. Effect of lead on nociceptive responses in untreated 
rats using paw pressure test.
Dose of lead Paw pressure response weight (g)
(ppm) Age (days)
10 21 30
0. 41 + 1 97 + 3 162 + 5
300 46 + 2 *  95 + 3 134 + 4 * * *
1000 49 + 2 * *  93 + 3 132 + 4 * * *
Each value is the mean + S.E.M. o f at least 40 observations. The data 
represent pretest values fo r animals subsequently trea ted w ith  0.9% saline or 
ketocyclazocine.
*  P<0.05, * *  P<0.01, * * *  P<0.001 (t- te s t contro l vs. lead treated)
Fig. 24. Effect of perinatal lead acetate exposure on the
antinociceptive activity of ketocyclazocine in 10 day old 
neonatal rats using the paw pressure test.
•  0 ppm lead dose group
■ 300 ppm lead dose group
▲ 1000 ppm lead dose group
□  range o f pretest and saline values fo r 0 ppm lead dose group 
range o f pretest and saline values fo r 300 ppm lead dose group 
E l  range o f pretest and saline values fo r 1000 ppm lead dose group
Each value is the mean + S.E.M. o f at least 7 observations each made on 
separate animals from  dams exposed to contro l, 300 or 1000 ppm lead acetate 
in the m aternal drinking water from  conception to weaning (-21  to 21 days). 
Figures alongside error bars re fe r to the % o f animals which showed response 
weights greater than c u t-o ff  weight (250 g fo r 10 day neonates, 500 g fo r 21 
day neonates and 750 g fo r 3.0 day rats), fo r graphical presentation response 
weights > c u t-o ff  are denoted as the c u t-o ff  weight. For s ta tis tica l analysis 
see Table 15 AD^g values.
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Fig. 25. E ffect of perinatal lead exposure on the antinociceptive
activity of ketocyclazocine in 21 day old neonatal 
rats using the paw pressure test.
•  0 ppm lead dose group
■ 300 ppm lead dose group
a 1000 ppm lead dose group
□  range o f pretest and saline values fo r 0 ppm lead dose group
[(XM range o f pretest and saline values fo r 300 ppm lead dose group
/T-l range o f pretest and saline values fo r 1000 ppm lead dose group
Each value is the mean + S.E.M. o f at least 7 observations each made on 
separate animals from  dams exposed to contro l, 300 or 1000 ppm lead acetate 
in the m aternal drinking water from  conception to weaning (-21  to 21 days). 
Figures alongside error bars re fe r to the % o f animals which showed response 
weights greater than c u t-o ff  weight (250 g fo r 10 day neonates, 500 g fo r 21 
day neonates and 750 g fo r 30 day rats), fo r g raph ica l presentation response 
weights > c u t-o ff  are denoted as the c u t-o ff  weight. For s ta tis tica l analysis 
see Table 15 AD^q values.
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Fig. 26. Effect of perinatal lead exposure on the
antinociceptive activity of ketocyclazocine in 30 day old 
rats using the paw pressure test.
•  0 ppm lead dose group
■ 300 ppm lead dose group
a 1000 ppm lead dose group
□  range o f pretest and saline values fo r 0 ppm lead dose group
J22 range o f pretest and saline values fo r 300 ppm lead dose group
y71 range of pre test and saline values fo r 1000 ppm lead dose group
Each value is the mean + S.E.M. o f at least 8 observations each made on 
separate animals from  dams exposed to contro l, 300 or 1000 ppm lead acetate 
in the m aternal drinking water from  conception to weaning (-21  to 21 days). 
Figures alongside e rro r bars re fe r to the % o f animals which showed response 
weights greater than c u t-o ff  weight (230 g fo r 10 day neonates, 300 g fo r 21 
day neonates and 730 g fo r 30 day rats), fo r graphical presentation response 
weights > c u t-o ff  are denoted as the c u t-o ff  weight. For s ta tis tica l analysis 
see Table 15 AD^q values.
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Table 15. E ffect of lead on ketocyclazocine antinociception in rats.
Dose of lead ^*^50 values
(ppm) Age (days)
10 21 30
0 0.23 + 0.021 0.16 + 0.013 0.42 + 0.039
300 0.31 + 0.020 *  0.20 + 0.023 0.40 + 0.025
1000 0.34 + 0.016 * * *  0.25 + 0 .019** 0.34 + 0.033
AD^g values are the mean dose (mg/kg) + S.E.M. required to increase paw 
pressure response to ha lf of the c u t-o ff weight (125 g fo r 10 day; 250 g fo r 21 day 
and 375 g fo r 30 day). Values are computed from  the fu ll dose-response curves. 
Lead was administered in the maternal drinking w ater from  conception to weaning.
*  P<0.05, * *  P<0.01, * * *  P<0.001 (t- te s t vs. 0 ppm contro l groups)
?
Fig. 27. Elution profile for [D -A la  MePhe Glyol 1 enkephalin
from HPLC
2Trace shows absorbance at 280 nm of 10 yg [ D -A la  MePhe G lyol ] 
enkephalin applied to a C^g \ i bondapak reverse phase column eluted w ith  a 
linear ace ton itr ile  gradient (15-30% over 30 min at 1 m l/m in) in 6.25% v/v 
acetic acid, 0.25% v/v  ammonia, pH 3.2. S = solvent peak P = peptide peak.
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2 5Fig. 28. Elution profile for [ D-Pen D-Pen 1 enkephalin
from HPLC
2 5Trace shows absorbance at 280 nm of 10 pg [ D-Pen D-Pen ] 
enkephalin applied to a C^g p bondapak reverse phase column eluted w ith  a 
linear ace ton itrile  gradient (15-30% over 30 min at 0.5 m l/m in ) in 6.25% v/v  
acetic  acid, 6.25% v /v  ammonia, pH 3.2. S = solvent peak P = peptide peak.
Time (mins)
gave a linear relationship between peak height and quantity o f ligand applied.
P u rifica tion  yields o f radioligands were >80% fo r t ^ H l  DAGO and 60-90% 
fo r [^H  ] DPDPE. P u rifica tion  o f the la tte r  was essential as batch v a ria b ility  o f 
this product was marked. Reassay o f purified  ligands showed m inim al degradation 
under storage conditions described in Section 2.4.1.
3.3.2. p opioid receptor binding using [ ^H  ] DAGO.
3.3.2.1. Time course o f l^H  3 DAGO binding and s ta b ility  of the ligand 
during incubation.
An in it ia l rapid rise in specific [ ] DAGO binding was observed during the
f irs t 20 mins. o f incubation in whole brain homogenates from  both 10 and 30 day 
old rats (Fig. 29). There was a subsequent plateau un til 60 mins. and then a 
gradual fa ll in specific  binding to 30% o f peak binding in 30 day old animals and 
33% in 10 day old neonates by 180 mins. Non-specific binding at both ages 
remained consistently low at 10-13% of the to ta l binding throughout the incubation 
period.
The incubation o f [ ] DAGO in bu ffe r at 25°C fo r 40 mins. and a s im ila r
incubation in brain homogenates did not a lte r the s tab ility  o f the ligand as 
evidenced by HPLC separation (Fig. 30). Approxim ately 70-80% o f the labelled 
ligand from  the incubations or unincubated standard appeared in the same fra c tio n  
collected at 7 mins.
3.3.2.2. Saturation curves obtained fo r [^H  ] DAGO binding.
A typ ica l saturation curve fo r [ '] DAGO binding is shown in Fig. 31.
Specific binding (ie. to ta l - non specific binding) showed a hyperbolic curve. Non 
specific binding was not saturable w ith in  the range o f concentrations used and 
therefore showed a linear increase w ith  increasing concentrations o f labelled ligand 
in the incubation. A t higher concentrations non-specific binding constitu ted  a 
larger proportion o f to ta l binding.
Fig. 29. Time course of [^ H l  D-Ala^ MePhe Glyol
enkephalin binding to rat brain membranes of 
10 and 30 day old rats.
■ 10 day old rats 
•  30 day old rats
Each value is the mean + S.E.M. o f 3 measurements from  separate 
experiments and represent the specific  binding ie to ta l binding - binding in 
presence o f 1 pM diprenorphine o f 1 nM 1 ] DAGO at incubation times of
between 3 and 180 mins at 25 °C .
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Fig. 30. Effect of temperature and incubation with
. rat brain membranes on the elution profile of [ 1 DAGO.
O standard [ ] DAGO
□ [^ H  3 DAGO incubated in bu ffe r at 23°C fo r 40 mins.
a  [ ] DAGO incubated in brain homogenate at 23°C fo r 40 mins.
Trace shows % ra d io a c tiv ity  in each 1 m in. frac tio n  eluted from  a 'C ^  
y bondapak reverse phase column eluted w ith  a linear ace ton itrile  gradient 
(15-30% over 30 mins. at 1 m l/m in) in 6.25% v/v  acetic acid, 0.25% v/v 
ammonia pH 3.2
Time (mins)
Fig. 31. Typical saturation curves obtained for [^H ] DAGO
binding to rat brain homogenate.
Each point represents the mean of tr ip lic a te  estimates of binding o f 
increasing concentrations o f t ^ H ]  DAGO per mg tissue. Non-specific 
binding was measured in the presence o f 1 yM  diprenorphine and specific 
binding is determ ined by subtracting non-specific binding from  to ta l binding 
at each concentration o f [ ^H ] DAGO. Incubations were carried out at 25°C 
fo r 40 mins.
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Scatchard analysis obtained by p lo tting  specific  binding against the ra tio  of 
specific bound to free ligand, gave a linear relationship in 10, 21 and 30 day old 
animals (Fig. 32). The ontogenetic varia tion o f the a ff in ity  o f the receptor fo r the 
ligand (K q) and the m axim al binding capacity (Bmax) is shown in Table 16. There 
was no s ign ifican t e ffe c t of age on the a ff in ity  constant but binding capacity 
increased to a maximum in 21 day old rats. This increase was 3-fo ld  when 
expressed per mg wet weight, 4-fo ld  when expressed per brain and 2.4-fo ld when 
expressed per mg prote in . Protein concentrations were found to increase from  40 
to 66 iig /m g tissue during this period.
3.3.2.3. E ffe c t o f lead exposure on l i t te r  parameters and blood lead levels.
S tarting m aternal weights varied between lead dose groups (Fig. 33) and
accordingly m aternal weight gains were analysed as a change from  sta rting  weight 
(Section 2). There were no s ign ifican t e ffec ts  o f lead on m aternal weight gains 
(Fig. 33). Neonate weight gain was s ign ifican tly  a ffected by lead trea tm ent 
mainly due to the reduced weights observed at 21 days (Fig. 34). There were no 
s ign ifican t differences in l i t te r  size or mean pup weight at b irth  (Fig. 36). F lu id 
consumption was s ign ifican tly  reduced by 11% in the 1000 ppm lead treated group 
during the postnatal period (Fig. 33).
Blood lead levels were elevated in lead trea ted animals compared to controls 
(Table 17), highest levels being seen in 10 day old ra t pups. In 21 day old rats blood 
lead levels in the 100 ppm lead group had returned to contro l values while those of 
the 300 and 1000 ppm lead groups remained elevated. By 30 days only 1000 ppm 
lead dose group showed elevated blood levels.
3.3.2.4. E ffe c t o f lead exposure on [ ] DAGO binding.
Perinatal lead trea tm ent had no s ign ifican t e ffe c t on the a ff in ity  (K ^ )  o f the 
receptors fo r [ 1 DAGO (Fig. 37), although there was a 23-40% reduction in
a ff in ity  constant in a ll lead dosed groups at 21 days. Maxim al binding capacity
Fig. 32. Ontogenetic variation of Scatchard plots for [ ^H1 DAGO
binding in rat brain homogenates.
■ 10 day old rats
•  21 day old rats
▲ 30 day old rats
Each p lo t represents a typ ica l Scatchard p lo t at each age of specific 
binding o f [ ^ H ] D A G O  to ra t brain homogenate against the ra tio  of bound to 
free [ ^H ] DAGO. Specific binding was calculated as the difference between 
to ta l and non-specific binding in the presence o f 1 pM diprenorphine. 
Incubations were carried out at 23°C fo r 40 mins.
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Table 16. A ffin ity  constants (K ^  and binding capacities 
(Bmax) of [ H ] DAGO in the developing rat brain.
Age (days)
10 .
21
30
(nM)
1.8 + 0.60
2.6 + 0.70
1.9 + 0.22
®max
(fm ole /m g
wet w t.)
3.1 + 0.37 
9 .4 + 1 .0 3
8.8 + 0.79
(pmole/brain)
3.3 + 0.46
14.2 + 1.30
14.8 + 1.48
(fm ole/m g
protein)
56.2 + 7.1
133.9 + 15.9
119.8 + 9.8
Values fo r and B are the means + S.E.M. o f 6 Scatchard plots. U max —
Fig. 33. Effect of perinatal lead exposure on maternal weight
gain in [^H ] DAGO binding studies.
Each value is the mean of at least 6 values o f dams exposed to contro l 
( •  ), 100 ppm ( O ), 300 ppm ( ■ ) or 1000 ppm ( ▲ ) lead acetate in the 
m aternal drinking water from  conception un til postnatal day 14 (-21 to 14 
days). E rror bars are om itted  fo r c la r ity  o f graphical presentation. Analaysis 
o f variance between lead groups p>0.5.
Fig. 34. E ffect of perinatal lead exposure on
neonate weight gain in [ ] DAGO binding studies.
Each value is the mean of at least 6 values of neonate weights from  
dams exposed to qontro l ( •  ), 100 ppm ( O ), 300 ppm ( ■ ) or 1000 ppm 
( a ) lead acetate in the m aternal drinking water from  conception un til 
postnatal day 14 (-21 to 14 days). E rror bars are om itted  fo r c la r ity  of 
graphical presentation. Analaysis o f variance between lead groups p<0.01.
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Fig. 35. Effect of perinatal lead exposure on
maternal fluid consumption in 1 ^H1 DAGO binding studies.
Each histogram represents the mean + S.E.M. o f at least 6 observations 
of flu id  consumed prenata lly or postnatally by dams exposed to contro l 
100 ppm £ 3  , 300 ppm Q]J or 1000 ppm ^  lead acetate in drinking water
from  conception to postnatal day 14 (-21 to 14 days), t- te s t lead group vs. 
Oppm *  p>0.05.
Fig. 36. E ffect of perinatal lead exposure on
a) mean pup weight at birth
b) nurqber of pups in litte r  at birth  
( [ H1DAGO binding studies)
Each histogram represents the mean + S.E.M. o f at least 18 
observations o f pup weight or number from  dams exposed to contro l | | ,
100 ppm \ \  , 300 ppm CD or 1000 ppm lead acetate in drinking water
from  conception to postnatal day 14 (-21 to 14 days), t- te s t lead group vs. 
Oppm no s ign ifican t d iffe rence.
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Table 17. Blood lead levels (pg/100 ml) of neonatal rats
used in [ ] DAGO binding studies determined by
atomic absorption spectrophotometry.
Dose of lead 
(ppm)
0
100
300
1000
10
1.48 + 0.88
16.6 + 3.0
21.9 + 3.4
27.6 + 2.4
Age (days) 
21
0.53 + 0.53 
0.90 + 0.42 
7.3+ 2.3
15.8 + 2.8
30
0.14 + 0.10 
1.37 + 0.53 
1.62 + 0.70 
6.30 + 2.2
Each value is the mean + S.E.M. o f at least 10 samples. Lead was 
adm inistered as the acetate in m aternal drinking w ater from  conception to 
postnatal day 14 (-21 to 14 days).
Fig. 37. E ffect of perinatal lead exposure on equilibrium
dissociation constant (Kq) of [ ^H ] DAGO  
binding in rat brain.
Each histogram represents the mean + S.E.M. o f obtained from  6 
Scatchard analyses each saturation curve performed on separate animals 
aged 10, 21 or 30 days from  dams exposed to contro l Q  , 100 ppm
300 ppm Q J or 1000 ppm lead acetate in maternal drinking w ater from  
conception to postnatal day 14 (-21 to 14 days). Saturation curves were 
perform ed in the presence or absence of 1 pM diprenorphine to detect non­
specific  binding at 25°C fo r 40 mins. Analysis o f variance between lead 
groups p>0.05.

(Bmax) was also not s ign ifican tly  altered by perinata l lead exposure (Fig. 38,.39 and 
40) although in 30 day old animals 100 ppm lead trea tm ent caused an increase in 
maximal binding capacity o f approxim ately 30% when expressed per mg wet weight 
or per brain.
3.3.3. 6 -opio id receptor binding using [^H3 DPDPE.
3.3.3.1. Time course o f [ 1 DPDPE binding and s ta b ility  of the 
ligand during incubation.
An in it ia l rapid rise in specific binding w ith  [ ^ H ]  DPDPE was observed
during the f irs t 30 mins. o f incubation in both 13 and 33 day old rats (Fig. 41).
However a plateau was not reached un til 40-60 mins. o f incubation and binding
decreased by 50% from  120 mins to 180 mins. in both 15 and 35 day old animals.
Non-specific binding was higher at both ages than was seen w ith  t^H  1 DAGO
binding (Section 3.3.2.1.). In 15 day old neonates non-specific binding contribu ted
approxim ately 60% of to ta l binding while in 35 day old animals non-specific binding
dropped to 40% of the to ta l binding.
The incubation o f [ ] DPDPE in bu ffe r at 25°C fo r 40 mins. and a s im ila r
incubation in brain homogenate had no e ffe c t on the ligand its e lf (Fig. 42).
3.3.3.2. Saturation curves obtained fo r [ 3 DPDPE binding.
A typ ica l saturation curve fo r [^H ] DPDPE binding is shown in Fig. 43. 
Specific binding showed a hyperbolic curve, non-specific binding was not saturable 
w ith in  the range of concentrations used and showed a linear increase w ith  
increasing concentrations o f labelled ligand in the incubation but constitu ted at 
least 40% of to ta l binding.
The ontogeny o f [^H  1 DPDPE binding is shown in Fig. 44-49. There was no 
change in binding a ff in ity  w ith  age (Fig. 45). However the m axim al binding 
capacity increased 7-fo ld  w ith  age from  1.4 pm ol/brain in 10 day neonates to a 
maximum of approxim ately 10 pm ol/brain at 25-30 days (Fig. 47). The increase
Fig. 38. Effect of perinatal lead exposure on
maximal binding capacity (Bmax) (fmol/mg tissue) of [^H]DAGO
binding in rat brain.
Each histogram represents the mean +. S.E.M. o f maximal binding 
capacity expressed per mg wet weight tissue obtained from  6 Scatchard 
analyses each saturation curve performed on separate animals aged 10, 21 or 
30 days from  dams exposed to contro l | | , 100 ppm ^  , 300 ppm EDI or 
1000 ppm ^  lead acetate in m aternal drinking water from  conception to 
postnatal day 14 (-21 to 14 days). Saturation curves were performed in the 
presence or absence of 1 yM  diprenorphine to detect non-specific binding at 
23°C fo r 40 mins. Analysis o f variance between lead groups p>0.05.
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Fig. 39. Effect of perinatal lead exposure on
maximal binding capacity (Bmgx) (pmol/brain) of 1 ^H] DAGO
binding in rat brain.
Each histogram represents the mean + S.E.M. o f maximal binding 
capacity expressed per brain obtained from  6 Scatchard analyses each 
saturation curve perform ed on separate animals aged 10, 21 or 30 days from  
dams exposed to contro l □  > 100 ppm E3 - 300 ppm □  or 1000 ppm 
lead acetate in m aternal drinking water from  conception to postnatal day 14 
(-21 to 14 days). Saturation curves were perform ed in the presence or 
absence o f 1 jiM  diprenorphine to detect non-specific binding at 23°C fo r 40 
mins. Analysis o f variance between lead groups p>0.05.

Fig. 40. Effect of perinatal lead exposure on
maximal binding capacity (Bmgx) (fmol/mg protein) of 1 ^H] DAGO
binding in rat brain.
Each histogram represents the mean + S.E.M. o f maximal binding 
capacity expressed per mg prote in obtained from  6 Scatchard analyses each 
saturation curve perform ed on separate animals aged 10, 21 or 30 days from  
dams exposed to contro l H )  , 100 ppm [7/| , 300 ppm Q J or 1° 00 PPm 0  
lead acetate in m aternal drinking water from  conception to postnatal day 14 
(-21 to 14 days). Saturation curves were performed in the presence or 
absence o f 1 pM diprenorphine to detect non-specific binding at 25°C fo r 40 
mins. Analysis o f variance between lead groups p>0.05.
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3 2 5Fig. 41. Time course of [ H ] [ D-Pen D-Pen ] enkephalin
binding to rat brain membranes of 15 and 35 day
old rats.
■ 15 day old rats 
•  35 day old rats
Each value is the mean + S.E.M. o f 3 measurements from  separate 
experiments and represent the specific binding, ie to ta l binding -binding in 
presence o f 10 pM naloxone, o f 5 nM [ ^ H ]  DPDPE at incubation tim es of 
between 5 and 180 mins at 25°C.
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Fig. 42. E ffect of temperature and incubation with
rat brain membranes on the elution profile of [ ] DPDPE
O standard [ ] DPDPE
□ [ ] DPDPE incubated in bu ffe r at 25°C fo r 40 mins.
A [ ] DPDPE incubated in brain homogenate at 25°C fo r
40 mins.
Trace shows % rad io a c tiv ity  in each 1 min. frac tio n  eluted from  a C^g 
Vi bondapak reverse phase column eluted w ith  a linear ace ton itrile  gradient 
(15-30% over 30 mins. at 0.5 m l/m in) in 6.25% v/v  acetic acid, 0.25% v /v  
ammonia pH 3.2
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Fig. 43. Typical saturation curves obtained for [ ^H ] DPDPE
binding to rat brain homogenate.
Each point represents the mean of tr ip lic a te  estimates of binding of 
increasing concentrations o f [ ] DPDPE per mg tissue. Non-specific
binding was measured in the presence o f 10 yM  naloxone and specific binding 
is determined by subtracting non-specific binding from  to ta l binding at each 
concentration o f [ ^H ] DPDPE. Incubations were carried out at 23°C fo r 40 
mins.
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Fig. 44. Ontogenetic variation of Scatchard plots foriVflDPDPE
binding in rat brain homogenates.
a 10 day old rats
■ 21 day old rats
a 35 day old rats
•  50 day old rats
Each p lo t represents a typ ica l Scatchard p lo t at each age o f specific 
binding o f [ ^H ] DPDPE to ra t brain homogenate against the ra tio  o f bound 
to free t ^ H ]  DPDPE. Specific binding was calculated as the d ifference 
between to ta l and non-specific binding in the presence o f 10 pM naloxone. 
Incubations were carried out at 25°C fo r 40 mins.
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Fig. 45. Ontogenesis of equilibrium dissociation constant
(Kj-j) for [ 3H ]D P D P E
binding to ra t brain homogenates.
Each histogram represents the mean + S.E.M. o f 4 determ inations o f K n
3from  Scatchard analyses of saturation curves fo r [ H I DPDPE binding on 
separate animals.
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Fig. 46. Ontogenesis of maximal binding capacity
(fmol/mg tissue) for [ ^H] DPDPE binding to rat
brain homogenate.
Each histogram represents the mean + S.E.M. o f 4 determ inations o f
maximal binding capacity (fm ol/m g tissue) from  Scatchard analyses of
saturation curves fo r t^H  1 DPDPE binding on separate animals.
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Fig. 47. Ontogenesis of maximal binding capacity (Bmax)
(pmol/brain) for [ ^H] DPDPE binding to rat
brain homogenate.
Each histogram represents the mean + S.E.M. o f 4 determ inations o f
maximal binding capacity (pm ol/brain) from  Scatchard analyses o f saturation
curves fo r [ ^H l DPDPE binding on separate animals.
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Fig. 48. Ontogenesis of maximal binding capacity (Bmax)
(fmol/mg protein) for t^H ] DPDPE binding to rat
brain homogenate.
Each histogram represents the mean + S.E.M. o f 4 determ inations of
maximal binding capacity (fm ol/m g protein) from  Scatchard analyses of
saturation curves fo r 3 DPDPE binding on separate animals.
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Fig. 49. O ntogenesis o f n o n -sp e c ific  b ind ing  o f [ 3H ] DPDPE
binding to rat brain homogenate.
Each histogram represents the mean + S.E.M. o f non-specific binding 
from  saturation curves fo r ] DPDPE binding on separate animals. Non­
specific  binding was determ ined by incubation in the presence of 10 yM 
naloxone.
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was only 5 -fo ld  when measured per mg tissue (Fig. 46) and only 3 -fo ld  when 
measured per mg prote in (Fig. 48). Brain size increased approxim ately 2-fo ld  and 
prote in concentrations increased 1.5-fold from  10 to 50 days.
Non-specific binding was a particu la r problem in younger animals constitu ting  
over 70% of to ta l binding in 10 day old neonates (Fig. 49), only 50% o f experiments 
produced acceptable Scatchard plots w ith  a linear regression corre la tion  
c oe ffic ie n t greater than 0.82 (p<0.001). In 7 day old neonates specific  binding 
could not be measured.
3.3.3.3. E ffe c t o f lead exposure on l i t te r  parameters and blood lead levels.
M aternal weight gain was s ign ifican tly  increased by lead exposure (Fig. 50).
Neonate weight gain was s ign ifican tly  decreased by lead exposure (Fig. 51). F luid 
consumption and mean pup weight at b irth  also showed no d iffe rence  in lead 
exposed groups (Fig. 52 and 53). The number o f pups per l i t te r  at b irth  was 
s ign ifican tly  increased by 16% in the 300 ppm lead dose group.
Blood lead levels (Table 18) showed a s im ila r pattern  to those presented 
previously in Section 3.3.2.3. A dose re lated elevation in blood lead levels was 
observed at both 15 and 21 days, w ith  higher levels at 15 days. By 30 days only 
1000 ppm lead dose group showed elevated lead levels and by 50 days a ll lead dose 
groups had returned to contro l values.
3.3.3.4. E ffe c t o f lead exposure on [ ] DPDPE binding.
The e ffe c t o f perinata l lead exposure on the binding a f f in ity  fo r 
[ ] DPDPE is shown in Fig. 54. The a ff in ity  o f the binding site fo r t ^ H ]
DPDPE was decreased at a ll ages in the 1000 ppm lead dose group as evidenced by 
increased values. The increase varied from  20% in 21 day old neonates to 52% 
in 50 day old animals. Animals in the 300 ppm lead trea ted group only showed an 
elevation o f a ff in ity  constant (26%) in 15 day old animals.
Maxim al binding capacity was unaffected by perinata l lead trea tm en t (Fig.
Fig. 50. Effect of perinatal lead exposure on maternal weight
gain in [ ] DPDPE binding studies.
Each value is the mean of at least 11 values o f dams exposed to contro l 
( •  ), 300 ppm ( ■ ), or 1000 ppm ( a )  lead acetate in the maternal drinking 
w ater from  conception un til postnatal day 14 (-21 to 14 days). E rror bars are 
om itted  fo r c la r ity  o f graphical presentation. Analysis of variance between 
lead groups was s ign ifican t, p<0 .001 .
F ig. 51. E ffect of perinatal lead exposure on neonate weight 
gain in [ ^H] DPDPE binding studies.
Each value is the mean o f at least 5 values o f neonates weights from  
dams exposed to contro l ( •  ), 300 ppm ( ■ ), or 1000 ppm ( a ) lead acetate 
in the m aternal drinking w ater from  conception to postnatal day 14 (-21 to 14 
days). E rror bars are om itted  fo r c la r ity  o f graphical presentation. Analysis 
o f variance between lead groups p<0.05.
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Fig. 52. Effect of perinatal lead exposure on maternal fluid
consumption in [^H ] DPDPE binding studies.
Each histogram represents the mean + S.E.M. o f at least 11 
observations o f flu id  consumed prenata lly or postnatally by dams exposed to 
contro l [ | , 300 ppm Q J , or 1000 ppm ^  lead acetate in the maternal
drinking water from  conception u n til postnatal day 14 (-21 to 14 days), t -  
test, lead group vs. Oppm not s ign ifican tly  d iffe ren t.
Fig. 53. Effect of perinatal lead exposure on
a) mean pup weight at birth
b) number of pups in litte r  at birth 
( I  1 DPDPE binding studies)
Each histogram represents the mean + S.E.M. o f at least 
19 observations o f pup weight or number from  dams exposed to contro l 
300 ppm Q J , or 1000 ppm^ j  lead acetate in the m aternal drinking water 
from  conception to postnatal day 14 (-21 to 14 days), t- te s t, lead group vs. 
Oppm *p<0.05.
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Table 18. Blood lead levels (pg/100 ml) of neonatal rats
used for [ **H ] DPDPE binding studies determined by 
atomic absorption spectrophotometry.
Dose of lead Age (days)
(ppm)
15 21 35 50
0 1.04 + 0.71 0.26 + 0.26 n.d. 0.75 + 0.75
300 23.9+ 3.0 7.4 + 1.5 1.23 + 1.22 0.42 + 0.42
1000 28.2 + 3.0 14.8 + 3.2 6.5 + 3.6 n.d.
n .d ., not detectable.
Each value is the mean + S.E.M. o f a t least 5 samples. Lead was 
adm inistered as the acetate in the m aternal drinking water from  conception to 
postnatal day 14 ("21 to 14 days).
Fig. 54. E ffect of perinatal lead exposure on equilibrium
dissociation constant (Krvv of [^H] DPDPE binding in rat brain.
Each histogram represents the mean + S.E.M. o f obtained from  5 
Scatchard analyses, each saturation curve perform ed on separate animals 
aged 15, 21, 35 and 50 days from  dams exposed to contro l | | , 300 ppm m
or 1000 ppm ^  lead acetate in m aternal drinking water from  conception to 
postnatal day 14 (-21 to 14 days). Saturation curves were perform ed in the 
presence or absence o f 10 yM naloxone to detect non-specific binding at 
25°C fo r 40 mins. Analysis o f variance between lead groups p>0.001.
( w u )  a »
55-57) w ith  the exception o f 35 day old animals exposed to 1000 ppm lead which 
exhibited elevated maximal binding capacities.
3.4. Plasma corticosterone studies.
The fo llow ing sections describe the e ffe c t o f perinata l lead exposure on the 
general development o f the animals and the e ffec ts  on plasma corticosterone levels 
at 30, 45 and 60 days.
3.4.1. E ffe c t o f lead exposure on l i t te r  parameters and blood lead levels.
There was no s ign ifican t e ffe c t o f lead trea tm ent on m aternal weight gain 
(Fig. 58). Neonate weight gain was s ign ifican tly  a ffected  by lead exposure, 
however in the 1000 ppm dose group this only represented a 10% reduction in 
weight (Fig. 59). This may be due to the lower b irth  weights o f a ll lead treated 
litte rs  (8-15% reduction) (Fig. 61). F luid consumption was not a ffec ted  prenata lly  
by lead exposure but postnatally the 9% reduction in the 1000 ppm dose group was 
s ign ifican t (Fig. 60).
3.4.2. E ffe c t o f lead exposure on plasma corticosterone levels? Basal and saline
in jected groups.
Basal corticosterone levels showed a progressive reduction w ith  age (Fig. 62). 
30 day old animals had the highest basal plasma corticosterone levels fo llowed by 
45 day old animals and 60 day old animals had the lowest basal corticosterone 
levels. The reduction in corticosterone levels was 56% between 30 and 60 day old 
animals.
Saline in jection stress caused an elevation o f plasma corticosterone levels at 
a ll ages (Fig. 63). A 6 -fo ld  increase was observed in 60 day old animals w h ile  30 
and 45 day old animals showed a 2.3-fold increase a fte r in jection stress.
Lead exposure had no e ffe c t on basal corticosterone levels at postnatal day 
30 but at 45 days the 1000 ppm lead dose group caused a 3-fo ld  increase in plasma
Fig. 55. Effect of perinatal lead exposure on
maximal binding capacity (Bmax) (fmol/mg tissue) 
for 1 ‘V llD P D P E  binding in rat brain.
Each histogram represents the mean + S.E.M. o f maximal binding 
capacity expressed per mg wet weight tissue obtained from  5 Scatchard 
analyses each saturation curve perform ed on separate animals aged 15, 21, 35 
or 50 days from  dams exposed to contro l Q  , 300 ppm Q J or 1000 ppm ^
lead acetate in m aternal drinking water from  conception, to postnatal day 14 
(-21 to 14 days). Saturation curves were performed in the presence or 
absence of 10 yM naloxone to detect non-specific binding at 25°C fo r 40 
mins. Analysis o f variance between lead groups p>0.05.
( t_9nss!i6ui |Ouij) XBU,g
Fig. 56. Effect of perinatal lead exposure on
maximal binding capacity (pmol/brain)
for I^H ID PD PE binding in rat brain.
Each histogram represents the mean + S.E.M. o f maximal binding
capacity expressed per brain obtained from  5 Scatchard analyses each
saturation curve perform ed on separate animals aged 15, 21, 35 or 50 days
from  dams exposed to contro l | | , 300 ppm a n  or 1000 ppm lead
acetate in m aternal drinking water from  conception to postnatal day 14 (-21 
to 14 days). Saturation curves were perform ed in the presence or absence of 
10 pM naloxone to detect non-specific binding at 25°C fo r 40 mins. Analysis 
o f variance between lead groups p>0.05.
| O u i j )  x e u i g
Fig. 57. Effect of perinatal lead exposure on
maximal binding capacity (Bmax) (fmol/mg protein)
for [ ^HIDPDPE binding in rat brain.
Each histogram represents the mean + S.E.M. o f maximal binding 
capacity expressed per mg prote in obtained from  5 Scatchard analyses each 
saturation curve perform ed on separate animals aged 15, 21, 35 or 50 days 
from  dams exposed to contro l □  > 300 ppm mi or 1000 ppm lead
acetate in m aternal drinking water from  conception to postnatal day 14 (-21 
to 14 days). Saturation curves were performed in the presence or absence of 
10 pM naloxone to detect non-specific binding at 25°C fo r 40 mins. Analysis 
o f variance between lead groups p>0.05.
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Fig. 58. Effect of perinatal lead exposure on maternal weight
gain in corticosterone studies.
Each value is the mean o f at least 7 values o f dams exposed to contro l 
( •  ), 100 ppm ( O ), 300 ppm ( ■ ), or 1000 ppm ( a ) lead acetate in the 
m aternal drinking water from  conception un til postnatal day 14 (-21 to 14 
days). E rror bars are om itted  fo r c la r ity  o f graphical presentation. Analysis 
o f variance between lead groups p>0.05.
Fig. 59. Effect of perinatal lead exposure on neonate weight
gain in corticosterone studies.
Each value is the the mean o f at least 5 values o f neonate weights from  
dams exposed to contro l ( •  ), 100 ppm ( O ), 300 ppm ( ■ ), or 1000 ppm ( a ) 
lead acetate in the m aternal drinking water from  conception to postnatal day 
14 (-21 to 14 days). E rror bars are om itted fo r c la r ity  o f graphical 
presentation. Analysis o f variance between lead groups p>0.001.
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Fig. 60. Effect of perinatal lead exposure on maternal fluid
consumption in corticosterone studies.
Each histogram represents the mean + S.E.M. o f at least 7 observations 
o f flu id  consumed prenata lly or postnatally by dams exposed to contro l | ] ,
100 ppm [ v ]  , 300 ppm [J J  , or 1000 ppm lead acetate in drinking water 
from  conception u n til postnatal day 14 (-21 to 14 days), t- te s t, lead group vs. 
Oppm. **p<0.01.
Fig. 61. Effect of perinatal lead exposure on
a) mean pup weight at birth
b) number of pups in litte r at birth 
(corticosterone studies)
Each histogram represents the mean + S.E.M. o f at least 12 
observations o f pup weight or number from  dams exposed to contro l | | ,
100 ppm vT  , 300 ppm [JJ] , or 1000 ppm ^  lead acetate in drinking water
from  conception u n til postnatal day 14 (-21 to 14 days), t- te s t, lead group vs. 
Oppm. *p<0.05, **p<0.01.
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Fig. 62. Effect of perinatal lead exposure on basal
corticosterone levels.
Each histogram represents the mean + S.E.M. o f 3-6 observations of 
plasma corticosterone levels in male (M) or female (F) animals at postnatal 
day 30, 45 or 60 from  dams exposed to contro l Q  , 100 ppm !•> , 300 ppm
["HI, or 1000 ppm ^  lead acetate in m aternal drinking water from  conception 
to postnatal day 14 (-21 to 14 days). M u lti-w ay analysis o f variance see Table 
19.
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Fig. 63. E ffect of perinatal lead exposure on plasma
corticosterone levels after injection stress.
Each histogram represents the mean + S.E.M. o f 3-6 observations of 
plasma corticosterone levels 20 mins. a fte r sub-cutaneous in jection o f saline 
in to the sc ru ff o f the neck in male (M) or female (F) animals at postnatal day 
30, 43 or 60 from  dams exposed to contro l Q  , 100 p p m [v ] , 300 ppm Q ] ] , or 
1000 ppm ^  lead acetate in m aternal drinking w ater from  conception to 
postnatal day 14 (-21 to 14 days). M u lti-w ay analysis o f variance see Table 
19.
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corticosterone in male animals and a 3.6-fo ld increse in females (Fig. 62). A t 60 
days a ll lead dose groups had elevated basal cortcosterone levels.
The e ffe c t o f perinata l lead exposure on saline in jection induced rises in 
corticosterone levels were dependent on age, sex and lead dose groups (Fig. 63). In 
30 day old animals there was l i t t le  e ffe c t o f lead in male animals but in females 
300 ppm lead potentia ted the elevation caused by in jection stress while 1000 ppm 
attenuated the corticosterone response by 30%. In A3 day old male animals trea ted  
w ith  1000 ppm lead fa iled  to show stress induced rises in corticosterone whereas in 
females lead exposure caused a po tentia tion  o f the stress induced rise. In 60 day 
old animals perinata l lead exposure only a ffected  corticosterone levels in male 
animals exposed to 1000 ppm lead which resulted in a potentia tion o f stress induced 
rises in corticosterone levels.
3.4.3. E ffe c t o f lead exposure on plasma corticosterone levels: Morphine in jected 
groups.
In male animals morphine potentia ted the in jection stress induced rise in 
plasma corticosterone at postnatal day 30 and 45 but was w ithout s ign ifican t e ffe c t 
at 60 days (Fig. 64-66). The potentia ting e ffe c t o f morphine exhib ited no clear 
dose response relationship. In females morphine did not potentia te  corticosterone 
levels at 30 or 60 days but produced s ign ifican t increases at. day 45 (Fig. 64-66).
The e ffe c t o f perinata l lead exposure on the modulation o f stress induced 
elevation o f plasma corticosterone by morphine was also dependent on age, sex and 
lead dose group as w e ll as the dose o f morphine (Fig. 64-66). In 30 day old male 
animals exposure to 100 and 1000 ppm lead reduced corticosterone levels 
pa rticu la rly  a fte r in jection of the higher doses o f morphine. However 300 ppm lead 
exposure potentia ted the e ffec ts  o f morphine in 30 day old male animals. A s im ila r 
pattern was observed in 30 day old female animals except that. 300 ppm lead 
exposure only potentia ted the e ffec ts  o f the low dose o f morphine (F ig. 64). In 45 
day old male animals lead exposure only a ffected  the response to the high dose o f
Fig. 64. Effect of perinatal lead exposure on plasma
corticosterone levels after injection of 5 mg/kg 
morphine sulphate.
Each histogram represents the mean + S.E.M. o f 3-6 observations o f 
plasma corticosterone levels 20 mins. a fte r sub-cutaneous in jection of 
morphine sulphate in to the sc ru ff o f the neck in male (M) or female (F) 
animals at postnatal day 30, 45 or 60 from  dams exposed to contro l | | ,
100 ppm xT , 300 ppm or 1000 ppm|^Q)lead acetate in m aternal drinking 
w ater from  conception to postnatal day 14 (-21 to 14 days). M ulti-w ay 
analysis o f variance see Table 19.
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Fig. 65. Effect of perinatal lead exposure on plasma
corticosterone levels after injection of 20 mg/kg 
morphine sulphate.
Each histogram represents the mean + S.E.M. o f 3-6 observations o f 
plasma corticosterone levels 20 mins. a fte r sub-cutaneous in jection of 
morphine sulphate in to the sc ru ff o f the neck in male (M) or female (F) 
animals at postnatal day 30,. 45 or 60 from  dams exposed to contro l | | ,
100 ppmf'|»] , 300 ppm Q J], or 1000 ppm ^  lead acetate in maternal drinking 
w ater from  conception to postnatal day 14 (-21 to 14 days). M ulti-w ay 
analysis o f variance see Table 19.
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Fig. 66. E ffect of perinatal lead exposure on plasma
corticosterone levels after injection of 50 mg/kg 
morphine sulphate.
Each histogram represents the mean + S.E.M. o f 3-6 observations o f 
plasma corticosterone levels 20 mins. a fte r  sub-cutaneous in jection o f 
morphine sulphate in to the sc ru ff o f the neck in male (M) or female (F) 
animals at postnatal day 30, 45 or 60 from  dams exposed to contro l | | ,
100 ppm jT v j, 300 ppm [ J j ] , or 1000 ppm ^  lead acetate in m aternal drinking 
w ater from  conception to postnatal day 14 (-21 to  14 days). M u lti-w ay 
analysis o f variance see Table 19.
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morphine, exposure to the high , lead dose causing a potentia tion of the morphine 
induced rise in corticosterone levels. In 45 day old females lead exposure abolished 
any e ffe c t o f 5 mg/kg morphine and reduced plasma corticosterone levels to, or 
below, those seen a fte r saline in jection stress (Fig. 64). A fte r  in jection  o f . 20
mg/kg morphine there was no apparent lead related e ffe c t (Fig. 65) but a fte r
in jection o f 50 mg/kg morphine, lead exposure potentia ted the e ffec ts  o f morphine 
on plasma corticosterone levels. In both male and female 60 day old animals the 
only clear lead re lated e ffec ts  were seen in animals exposed to 1000 ppm lead 
which caused a po tentia tion  o f morphine e ffec ts  on plasma corticosterone levels 
compared to contro l animals (Figs. 64-66).
These observations were supported by m ultiw ay analysis o f variance which 
showed tha t each o f the variables had a s ign ifican t e ffe c t on plasma 
corticosterone. The main variables were the lead dose group, the age o f the 
animals, the trea tm ent group - e ithe r basal, saline or morphine trea tm en t, and the 
sex o f the animal. Accordingly most 2 and 3 way in teractions were also s ign ifican t
(Table 19). Lead s ign ifican tly  altered corticosterone levels but there was also
sign ifican t in teractions w ith  age and trea tm ent group. Age also s ign ifican tly  
a ffected  results and in teracted w ith  a ll other variables. Treatm ent as expected 
s ign ifican tly  a ffected  corticosterone levels and in teracted s ign ifican tly  w ith  most 
other variables but not w ith  sex. Sex its e lf did s ign ifican tly  a ffe c t corticosterone 
levels but showed fewer in teractions than the other variables.
3.5. Locomotor activity studies.
The fo llow ing sections describe circadian varia tion o f locom otor a c tiv ity  and 
how perinata l lead exposure a ffected  the general development o f the animals and 
locom otor a c tiv ity  during the postnatal period.
3.5.1. C ircadian varia tion o f locom otor a c t iv ity .
Locom otor a c tiv ity  showed high exploratory a c tiv ity  during the f ir s t  10 mins.
Table 19. Analysis of variance of lead effects on 
plasma corticosterone.
Source o f va ria tion
Main e ffec ts  
Lead 
Age
Treatm ent
Sex
2 way in teractions 
Lead x Age 
Lead x Treatm ent 
Lead x Sex
Age x Treatm ent 
Age x Sex 
Treatm ent x Sex
3 way in teractions
Lead x Age x Treatm ent 
Lead x Age x Sex 
Lead x Treatm ent x Sex 
Age x Treatm ent x Sex
4 way in teractions
Lead x Age x Treatm ent x Sex
Degree o f freedom f  value
3 4.09
2 16.44
4 492.21
1 77.00
6 14.22
12 3.68
3 0.54
8 5.65
2 7.79
4 0.73
24 2.10
6 1.73
12 0.90
8 2.37
23 1.53
Lead Contro l, 100 ppm, 300 ppm or 1000 ppm lead exposure
Age 30, 45 or 60 days
Treatm ent Basal, Saline, 5, 20 or 50 mg/kg morphine
Sex Male or Female
p value
0.007
0.000
0.000
0.000
0.000
0.000
0.657
0 .0 0 0
0.001
0.570
0.002
0.113
0.551
0.017
0.060
of measurement and then decreased (Fig. 67-69). Both exploratory and to ta l 
a c tiv ity  were a ffected  by the period of the ligh t cycle during which they were 
measured. Maximum a c tiv ity  was measured 1-2 hr in to  the dark cycle ie. between 
20.00 and 21.00 hrs (Fig. 67-69). A c t iv ity  was also found to increase 2.4-fo ld from  
10 to 30 day old rats.
3.5.2. E ffe c t o f lead exposure on l i t te r  parameters and blood lead levels.
M aternal weight and neonate weight gain during the perinata l period was
unaffected by exposure to lead (Fig. 70 and 71). Mean pup weight and l i t te r  size 
were also unaffected by perinata l lead exposure (Fig. 73). F luid consumption was 
s ign ifican tly  decreased in the 300 ppm lead exposed group in the post-natal period 
but was unaffected in 1000 ppm lead group or during the prenatal period (Fig. 72).
Blood lead levels (Table 20) showed a s im ila r pattern  to those presented 
previously. A dose re lated elevation in blood lead levels was seen at a ll three ages, 
highest levels observed in 10 day old neonates. Blood lead levels had returned to 
contro l levels in 30 day old neonates in the 300 ppm dose group but remain elevated 
in 1000 ppm dose group.
3.5.3. E ffe c t o f lead exposure on locom otor a c t iv ity .
The e ffe c t o f perinata l lead trea tm ent on locom otor a c tiv ity  p ro files is 
shown in Fig. 74-76. Morphine trea tm ent supressed both in it ia l and to ta l a c tiv ity  
at a ll ages studied. The 10 day old neonate was 10-fo ld more sensitive to the 
e ffe c t o f morphine than was seen in analgesic studies (Section 3.2 .1.3.). A s im ila r 
sens itiv ity  was seen in 21 and 30 day old animals.
Lead had no s ign ifican t e ffe c t on the normal locom otor a c tiv ity  p ro files  at 
any age studied. In addition lead did not a ffe c t locom otor a c tiv ity  p ro files  a fte r 
morphine trea tm en t in 30 day old neonates (Fig. 76). However in 10 and 21 day old 
neonates high dose lead exposure produced s ign ifican t changes in the locom otor 
a c tiv ity  profiles a fte r the mid dose o f morphine - 0.2  mg/kg in 10 day old neonates
Fig. 67. Circadian variation of locomotor activity profiles
of 10 day old rats.
Each trace represents the mean a c tiv ity  counts in each 2 min. period 
o f a one hour measurement period of 6 animals at postnatal day 10. Error 
bars are om itted  fo r c la r ity  o f graphical presentation. . Dark cycle 
commenced at 19.00 hrs. and during the dark cycle illum ina tion  was by a red 
25 W bulb.
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Fig. 68 . Circadian variation of locomotor activity profiles
of 21 day old rats.
Each trace represents the mean a c tiv ity  counts in each 2 min. period 
o f a one hour measurement period o f 6 animals at postnatal day 21. Error 
bars are om itted  fo r c la r ity  o f graphical presentation. Dark cycle 
commenced at 19.00 hrs. and during the dark cycle illum ina tion  was by a red 
25 W bulb.
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Fig. 69. Circadian variation of locomotor activity profiles
o f 30 day old ra ts.
Each trace represents the mean activ ity , counts in each 2 min. period 
o f a one hour measurement period o f 6 animals at postnatal day 30. E rror 
bars are om itted  fo r c la r ity  o f graphical presentation. Dark cycle 
commenced at 19.00 hrs. and during the dark cycle illum ina tion  was by a red 
25 W bulb.
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Fig. 70. Effect of perinatal lead exposure on maternal weight
gain in locomotor activity studies.
Each value is the mean o f at least 5 values o f dams exposed to contro l 
( •  ), 300 ppm ( ■ ), or 1000 ppm ( a ) lead acetate in the maternal drinking 
w ater from  conception un til postnatal day 14 (-21 to 14 days). Error bars are 
om itted fo r c la r ity  o f graphical presentation. Analysis o f variance between 
lead groups p<0.05.
Fig. 71. Effect of perinatal lead exposure on neonate weight
gain in locomotor activity studies.
Each value is the mean of at least 4 values o f neonate weights from  
dams exposed to contro l ( •  ), 300 ppm ( ■ ), or 1000 ppm ( a ) lead acetate 
in the m aternal drinking water from  conception to postnatal day 14 (-21 to 14 
days). Error bars are om itted  fo r c la r ity  o f graphical presentation. Error 
bars are om itted  fo r c la r ity  o f graphical presentation. Analysis of variance 
between lead groups p>0.05.
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Fig. 72. Effect of perinatal lead exposure on maternal fluid
consumption in locomotor activity studies.
Each histogram represents the mean + 5.E.M. o f at least 5 observations 
o f flu id  consumed prenata lly or postnatally by dams exposed to contro l [ [ , 
300 p p m Q | , or 1000 ppm ^ J lead acetate in drinking water from  conception 
to postnatal day 14 (-21 to 14 days), t-te s t, lead group vs. Oppm, *p<0.05.
Fig. 73. Effect of perinatal lead exposure on
a) mean pup weight at birth
b) number of pups in litte r at birth 
(locomotor activity studies)
Each histogram represents the mean + S.E.M. o f at least 9 observations 
o f pup weight or number from  dams exposed to contro l j  \ , 300 ppm i n  , or 
1000 ppm lead acetate in drinking water from  conception to postnatal day
14 (-21 to 14 days), t- te s t, lead group vs. Oppm, no s ign ifican t d ifference.
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Table 20. Blood lead levels (yg/100 ml) of neonatal rats used
in locomotor activity studies determined by atomic absorption
spectrophotometry.
Dose of lead Age (days)
(ppm)
10 21 30
0 2.0 + 0.2 0.5 + 0.1 0.4 + 0.1
300 32.5 + 1.5 10.9 + 1.1 1.4 + 0.3
1000 43.8 + 2.7 18.6 + 1.4 8.7 + 0.9
Each value is the mean + S.E.M. o f at least 20 samples. Lead was 
administered as the acetate in the m aternal drinking w ater from  conception to day 
14 ("21 to 14 days).
Fig. 74. Effect of perinatal lead exposure on locomotor activity 
profiles of 10 day old rats after injection of saline or 
morphine sulphate.
Each trace represents the mean a c tiv ity  counts in each 2 min. period 
o f a one hour measurement period o f at least 5 animals in jected 
subcutaneously in to  the neck region w ith  saline (a), 0.1 mg/kg morphine 
sulphate (b), 0.2 mg/kg morphine sulphate (c) or 0.4 mg/kg morphine sulphate 
(d). Animals were from  dams exposed to contro l (— ), 300 ppm (— ) or 
1000 ppm (— ) lead acetate from  conception to postnatal day 14 (-21 to 14 
days). Measurements were made between 20:00 hrs and 22:00 hrs during the 
dark cycle which commenced at 19:00 hrs the only illum ina tion  being a red 
25 W bulb. E rror bars were om itted  fo r c la r ity  o f graphical presentation. 
For s ta tis tica l analysis see tex t.
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Fig. 75. Effect of perinatal lead exposure on locomotor activity
profiles of 21 day old rats after injection of saline or morphine sulphate.
Each trace represents the mean a c tiv ity  counts in each 2 min. period 
of a one hour measurement period o f a t least 5 animals in jected 
subcutaneously in to the neck region w ith  saline (a), 1 mg/kg morphine 
sulphate (b), 2 mg/kg morphine sulphate (c) or 4 mg/kg morphine sulphate (d).
Animals were from  dams exposed to contro l (-----), 300 ppm (— ) or 1000 ppm
(— ) lead acetate from  conception to postnatal day 14 (-21 to 14 days). 
Measurements were made between 20:00 hrs and 22:00 hrs during the dark 
cycle which commenced at 19:00 hrs, the only illum ina tion  being a red 25 W 
bulb. E rror bars were om itted  fo r c la r ity  o f graphical presentation. For 
s ta tis tica l analysis see tex t.
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Fig. 76. Effect of perinatal lead exposure on locomotor activity  
profiles of 30 day old rats after injection of saline or 
morphine sulphate.
Each trace represents the mean a c tiv ity  counts in each 2 min. period 
o f a one hour measurement period o f at least 3 animals in jected 
subcutaneously in to the neck region w ith  saline (a), 2 mg/kg morphine 
sulphate (b), 4 mg/kg morphine sulphate (c) or 8 mg/kg morphine sulphate (d). 
Animals were from  dams exposed to contro l (— ), 300 ppm (-— ) or 1000 ppm 
( — ) lead acetate from  conception to postnatal day 14 (-21 to 14 days). 
Measurements were made between 20:00 hrs and 22:00 hrs during the dark 
cycle which commenced at 19:00 hrs, the only illum ina tion  being a red 25 W 
bulb. E rror bars were om itted  fo r c la r ity  o f graphical presentation. For 
s ta tis tica l analysis see te x t.
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(Fig. 74) and 2 mg/kg in 21 day old neonates (Fig. 75). In 10 day old neonates the 
e ffe c t was associated w ith  to ta l a c tiv ity  while in 21 day old neonates the 
supression o f a c tiv ity  was mainly during in it ia l exp loratory a c tiv ity  (Table 21). In 
both cases lead potentia ted the morphine induced hypoactiv ity .
M ultiw ay analysis o f variance o f the a c tiv ity  profiles indicates tha t at a ll 
ages the a c tiv ity  p ro file  is s ign ifican tly  a ffected  by trea tm ent w ith  morphine 
compared to saline. Lead trea tm ent also a ffected  the a c tiv ity  pro files  
s ign ifican tly  but only in 10 and 21 day old neonates.
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4. DISCUSSION.
4.1. Lead dosing model.
4.1.1. L it te r  param eters.
A dm in is tra tion  o f lead to experim ental animals at su ffic ie n tly  high 
levels is recognised to produce signs o f overt to x ic ity  including im paired 
weight gain and at these high levels o f exposure neurochemical to x ic ity  may 
re fle c t undernutrition  (fo r review see Winder and K itchen, 1984).
The lead dosing model used in the experiments described in this thesis 
produced only marginal e ffec ts  on l i t te r  parameters and weight gains in 
agreement w ith  the findings o f Carm ichael e t al. (1981) and Winder et al.
(1984). Some individual s ign ifican t results were observed but these may be 
a ttribu tab le  to the large number o f animals per group and the small standard 
errors involved. The m a jo rity  o f s ign ifican t e ffec ts  o f lead observed in the 
studies reported here constitu ted a change o f less than 10% from  contro ls and 
small d ifferences have been reported by others (Carm ichael et al., 1981 and 
Winder et al., 1984) using s im ila r protocols o f lead adm in istra tion. For 
example, Carm ichael e t al. (1981) observed a decrease in neonate weight gain 
at 21 days o f approxim ately 10% in the 300 and 1000 ppm groups while 
Winder e t al, (1984) observed a s im ilar decrease at 10 days in the 1000 ppm 
group only. The changes described in this thesis include both increased and 
decreased weight gains o f dams and pups which were not re lated to dose o f 
lead or age, thus the doses o f lead used in this study appear to produce only 
m inim al nonspecific weight changes. Higher doses o f lead have been reported 
to have variable e ffec ts  on growth rate but in general high doses o f lead do 
in h ib it growth ra te . High doses o f m e ta llic  lead have been reported to only 
produce small decreases in growth rate (B a rre tt and Livesey, 1983) whereas 
exposure to s im ila r doses o f lead compounds have caused more severe e ffe c ts  
on growth rate in both rats (Modak et al; 1973, Carm ichael et al., 1981 and 
Mykannen et al., 1979) and m ice (Maker et al., 1973). These variations may 
be due to d iffe re n t periods o f exposure or differences in the uptake o f
m e ta llic  lead or lead compounds. Dosing of the dam has been reported to 
reduce exposure to the neonate by up to  1000 fo ld  (Mykannen et al., 1979) and 
when exposure is continued beyond 13-20 days then lead exposure to the pup 
is g rea tly  increased as d irec t access is gained to the source o f exposure. This 
may explain why weight gain is only inh ib ited a fte r weaning in some studies 
(Mykannen et al., 1979; Maker et al., 1975 and Modak et al., 1975). However 
prolonged exposure beyond 3-4 weeks does not resu lt in such a rapid rise in 
lead burden tha t is seen a fte r weaning (Mykannen et al., 1979). This is due to 
the m aturation o f the gastro in testina l tra c t which re s tr ic ts  lead uptake. One 
o f the reasons fo r much o f the work on lead exposure being in neonatal 
an im als 'is  because uptake o f lead from  the gut is much higher in children 
than in adults. S im ila rly  in rats uptake decreases from  55% in 1 week old 
rats to 1% in adults (K osita l et al., 1971), most o f the early uptake occuring 
in the duodenum (Henning and Leeper, 1984).
As lead acetate was used in the studies presented in th is thesis i t  was 
necessary to  contro l fo r the acetate ion which is believed to  contribu te  to 
some of the developmental e ffec ts  o f lead acetate such as weight gain and 
decreased a c t iv ity  (B a rre tt and Livesey, 1982). Sodium acetate (Modak et 
al., 1975, Collins et al., 1982; M ille r a t al., 1984 and Cory-Slechta, e t al.,
1983) is not a suitable contro l as there is an optimum intake o f sodium fo r 
normal development (Farris and G r iff ith ,  1962). Thus throughout the studies 
presented in th is thesis a ll drinking w ater was ac id ified  w ith  acetic  acid and 
a ll lead treated groups were compared w ith  acetic  acid treated controls.
4.1.2. Blood lead levels.
The im portance o f measuring blood lead levels as an index o f lead 
exposure has been emphasized by Grant e t al. (1980) and in the studies 
reported in th is thesis blood lead levels were measured fo r every animal w ith  
the exception of those used in corticosterone assays where the to ta l blood
volume was required. Blood lead levels in 10 day old neonates show l i t t le  
in terstudy varia tion  but at 21 days when exposure was continued un til that 
age blood lead levels were high and exhibited marked individual varia tion. 
This was most like ly  due to the pups gaining access to water bottles before 
weaning. As the aim of the studies presented here was to para lle l sub- 
c lin ica l lead exposure in man, w ith  blood lead levels below the 'safe' level set 
by in te rna tiona l authorities (Royal Commission Report, 1983), dosing was 
term inated at 14 days in subsequent studies and accordingly blood lead levels 
were greatly  reduced at 21 days. Large rises in blood lead levels when pups 
gain d irec t access to the source of exposure have been reported by others 
(Mykannen et al. 1979) and often result in the appearance o f symptoms of 
tox ic  lead exposure.
Throughout the studies presented in th is thesis blood lead levels were 
dependent on dose but were not linea rly  re la ted to dose. Once dosing was 
term inated blood lead levels fe ll,  the greater the lead burden the longer the 
period o f tim e required a fte r te rm ination  o f exposure before contro l levels 
were obtained. By 50 days a ll lead dosed groups had blood lead levels 
equivalent to controls. Blood lead levels obtained in the studies presented 
here were s im ila r at 10 days to those observed by Bailey and K itchen (1985 
and 1986) and Winder e t a l. (1984) using a s im ila r lead dosing.protocol, but 
blood lead levels o f 21 day old animals were somewhat higher when exposed 
un til postnatal day 21. C ontro l blood lead levels throughout the studies 
described in this thesis were below 5 jig /d l in agreement w ith  Bailey and 
K itchen (1985 and 1986), Winder et al. (1984) and Carm ichael et a l. (1981).
Blood lead levels fa ll a fte r cessation o f lead dosing due to excretion via 
several routes including the urine, sweat, hair deposits, teeth  and bile 
(Krigman et al., 1980) as well as red is tribu tion  in the various tissue pools. 
Absorption and excretion from  individual tissue pools is dependent on the 
tissue; bone has been reported to accumulate lead and the ha lf l i fe  o f lead
w ith in  bone is also longer than fo r other tissues in both man (Krigman et al.,
1980) and rats (Bankowska and Hine, 1985; Mykannen et al., 1979 and W igfie ld  
et al., 1986). L ike bone, brain tissue also shows a slower excretion ra te  than 
other tissues so although blood lead levels may re tu rn  close to contro l values 
both brain and bone lead content may remain elevated. Lead also 
p re fe ren tia lly  accumulates in discrete brain regions and is dependent on the 
dose and period o f exposure. The hippocampus is the f irs t  to accumulate lead 
followed by the cortex, stria tum  and mid brain (Collins e t al., 1982).
4.2. Effect of lead on antinociceptive responses.
4.2.1. Nociception and morphine antinociception in young rats using a 
therm al stim ulus.
The nociceptive threshold o f neonate rats in the ta il immersion tes t was 
found to  increase w ith  age in agreement w ith  the results presented by Auguy- 
Va le tte  et al. (1978) who observed an increase in nociceptive threshold 
between 10 and 15 days and is most probably due to a thickening o f cutaneous 
structures w ith  age. However others have fa iled  to  observe changes in 
nociceptive threshold w ith  age in ta il immersion studies at 50°C (Barr e t al., 
1986 and Giordano et al., 1987) although a d iffe re n t strain o f ra t was used 
giving much lower nociceptive thesholds.
Morphine antinociception was present in a ll animals tested and peak 
antinociception was observed 30 mins. a fte r  in jec tion , in agreement w ith  Barr 
et _al. (1986) and Giordano et al. (1987) in the ta il immersion test and by other 
workers using hotp late and ta il f lic k  assays (Schmauss and Yaksh, 1984 and 
Johannesson and Becker, 1973). Peak antinociceptive  a c tiv ity  o f morphine 
has been reported at la te r tim e points p a rticu la rly  in older animals (Auguy- 
Va lette  et al., 1978 and Johannesson and Becker, 1973) although there is some 
disagreement in the lite ra tu re  w ith  adult peak antinociceptive a c t iv ity  also 
reported at 20 mins. (Sewell and Spencer, 1976).
A dose response re lationship fo r morphine was observed at a ll ages 
when measured at peak antinociception but sens itiv ity  to morphine was 
dependent on the age o f the neonate, 21 day old animals were most sensitive 
while 10 day old animals were the least sensitive. A s im ila r ontogenetic 
p ro file  o f morphine antinociception was observed by Auguy-Valette et al. 
(1978) although peak sens itiv ity  to morphine was observed at 15 days ra ther 
than 21 days. In contrast Barr et al. (1986) could not detect morphine 
antinociception in animals younger than 12 days while 14 day old animals 
gave responses s im ila r to adults. However use o f the fro n t paw ra ther than 
the ta il allowed the demonstration of morphine antinociception at 3 days w ith  
no change in sens itiv ity  up to  14 days (Giordano et al., 1987), th is may be due 
to d iffe re n tia l ontogeny o f pain pathways w ith in  the spinal cord. The results 
presented in th is thesis fo r 30 day old rats indicated a s im ila r sens itiv ity  to 
morphine antinociception to tha t reported in adult rats and m ice (Sewell and 
Upton, 1976).
There are several possible explanations tha t could be proposed fo r these 
variations o f nociceptive responses to therm al s tim u li and the ontogenetic 
p ro file  o f morphine antinociception. As stated above the nociceptive 
threshold is like ly  to vary w ith  age fo r purely physical reasons eg. the 
thickness of cutaneous layers. But in addition the pain perception pathways 
may also be im m ature, in the ra t, ce ll p ro life ra tion  w ith in  the CNS is not 
complete un til a fte r day 15 and ce ll growth and m yelination o f nerves 
continue beyond the th ird  postnatal week (H im w ich, 1962). In addition the 
development of the blood brain barrie r plays an im portant part in the 
response to morphine a fte r postnatal day 14. Several groups have studied the 
entry o f morphine in to the CNS and are in general agreement tha t blood : 
brain ratios o f morphine are increased w ith  the development of the blood 
brain barrie r from  day 15 (Auguy-Vale tte et al, 1978; Johannesson and 
Becker, 1973; Kupferberg and Way, 1963 and Zhong-Zhang and Pasternak,
1981). M etabolic inactiva tion  of morphine must also be considered as the 
enzymes involved in glucuronidaton, dem ethylation and esterase a c tiv ity  
appear during the f irs t  two postnatal weeks and may not reach peak a c tiv ity  
un til the fou rth  or f i f th  postnatal week (Yeh and Krebs, 1980). However 
studies by Barr e t al. (1986) and Giordano e t al. (1987), which demonstrate 
tha t d iffe re n t noxious s tim u li and the use o f d iffe re n t limbs or ta il a lte r the 
ontogenetic p ro file  o f morphine antinociception, suggest this va ria tion  not to 
be due to pharm acokinetic development during this period but are re la ted  to 
the ontogenetic p ro file  o f opioid receptor sites. Corre la tion between 
receptor development and analgesia has been reported (Zhong-Zhang and 
Pasternak, 1981; Auguy-Valette  e t al, 1978 and Pasternak e t al, 1980). 
Numbers o f receptor sites are reported to increase rapid ly during the second 
and th ird  postnatal week which would corre la te  well w ith  the increased 
sens itiv ity  o f neonates to morphine during th is period as reported in th is 
thesis. The ontogeny o f opioid receptor sites w ill be discussed more fu lly  in 
Section 4.3.
4.2.2. Nociception and ketocyclazocine antinociception in young ra ts using a 
pressure stimulus.
Kappa-opioid receptor agonists are less active against therm al 
nociceptive s tim u li than y-op io id  receptor agonists (Tyers, 1980) and 
there fo re  a pressure stimulus was used to study the antinociceptive  a c t iv ity  
o f ketocyclazocine. Few studies have been perform ed in neonatal animals 
and d if f ic u lty  was encountered using the com m erical apparatus so the 
m od ifica tion  described by K itchen (1984a) was employed. A lthough repeated 
measurements have been reported in 30 day old ra ts (K itchen, 1984a) paw 
damage and hyperalgesia were observed so only one pre -in jection  test and one 
post-in jection  tes t were made fo r the studies reported in th is thesis.
As was observed fo r the ta il immersion test there was an increase in
nociceptive threshold w ith  age in the paw pressure test. The most probable 
explanation is an increase in thickness o f the paw skin, presence o f hair and 
thickened muscle layers. An increase in nociceptive threshold w ith  age was 
also observed by K itchen (1984a) but not by Giordano et al. (1987) who used a 
pressure stim ulus exerted by a blunt needle at a constant pressure in contrast 
to the increasing pressure model used here.
Ketocyclazocine was antinociceptive in rats at a ll ages studied but peak 
antinociception was dependent on the age o f the animal. In 10 day old 
animals peak antinociception was observed between 5 and 20 mins., in 
contrast 21 and 30 day old animals gave peak antinociceptive a c t iv ity  
between 5 and 10 mins. Reports of ketocyclazocine antinociception in 
neonates have reported antinociception 30 mins. a fte r in jection  (Giordano et 
al., 1987 and Barr et al., 1986). S im ila rly  in adults ketocyclazocine 
antinociception has been measured at 20 mins. (Upton et al., 1983) or 30 
mins. (Konno and Takayanagi, 1984), and there fo re  may not re fle c t peak 
antinociception. A tim e course study of e thylketocyclazocine in adult 
animals using ta il f lic k  and hotplate tests recorded peak antinociception at 10 
mins. Although this ea rlie r tim e point fo r peak antinociception may be 
a ttribu tab le  to  the additional ethyl group compared to ketocyclazocine i t  is 
in agreement w ith  experim ental results reported in th is thesis. The prolonged 
antinociceptive  a c tiv ity  o f ketocyclazocine in 10 day old animals described in 
th is thesis is probably due to a reduced capacity to  metabolise or excrete 
ketocyclazocine compared to  the adult as was reported fo r morphine (Yeh 
and Krebs, 1980 and Kupferberg and Way, 1963).
As was observed fo r morphine antinociception the sens itiv ity  o f the 
neonate to the antinociceptive a c tiv ity  o f ketocyclazocine was dependent on 
age. When the dose o f ketocyclazocine required to increase response la tency 
to 50% of the c u t-o ff  la tency was compared, 21 day old rats were again most 
sensitive while 30 day old rats were least sensitive. There is some
contrad ic tion  in the lite ra tu re  o f the development of ketocyclazocine 
antinociception. Antinociception has been detected at 7 days in a mechanical 
pressure test but l i t t le  increase in sensitiv ity  was observed before postnatal 
day 10 (Giordano et al., 1987) whereas the use o f a therm al stimulus results in 
a slight decrease in sensitiv ity  to ketocyclazocine antinociception between 
postnatal day. 12 and 14 (Barr e t al., 1986). These variations may be due to 
the d iffe re n t types o f antinociceptive test used.
As was described fo r morphine antinociception, the variations in peak 
e ffe c t and sens itiv ity  to ketocyclazocine antinociception w ith  age could be 
a ttribu ted  to the fo rm ation  o f the blood brain barrie r from  day 14 (Davson, 
1972) and the development o f metabolising enzymes (Yeh and Krebs, 1980). 
However the increase in sensitiv ity  observed between 10 and 21 days cannot 
be explained by these facto rs and is most like ly  to  be due to the development 
of the kappa-opioid receptor system. Binding studies have shown peak 
receptor binding fo r e thylketocyclazocine to be between 16 and 35 days 
depending on the study (Barr e t al., 1986; Spain e t al., 1983 and 1985; H ill e t 
al., 1984 and Zhong-Zhang and Pasternak, 1981). The fa ll in sens itiv ity  
observed in 30 day old animals may be due to increased catabolism  of 
ketocyclazocine as tim e course studies indicate a shorter duration o f 
antinociception as w e ll as res tric ted  access in to the CNS.
4.2.3. E ffe c t o f perinata l lead exposure on morphine antinociception in the 
ta il immersion te s t.
Perinatal lead exposure had no e ffe c t on the nociceptive threshold in 
the ta il immersion test at any age. O ther reports have only measured 
nociception in adult animals using the hotp late test. Increased response 
latancies were recorded a fte r short te rm  or single dose o f organic lead 
compounds (Hong et al., 1983; Bondy et al., 1985; Walsh et al, 1984 and 1986) 
and a fte r perinata l exposure to an inorganic lead compound (Baraldi et
al., 1985 and Vickers and Paterson, 1986). The use o f organic lead compounds 
resu lt in very high blood lead levels even a fte r a single dose (Bondy et al., 
1985) which may be the cause of increased latancies observed in addition to 
the age and stim ulus used in these tests.
The lack o f e ffe c t o f lead exposure on nociceptive thresholds described 
in th is thesis ind icate th a t the peripheral and centra l pathways involved in 
the perception and response to  a therm al stimulus are s t i l l  able to  function  
norm ally.
Perinata l lead exposure did have an e ffe c t on the antinociceptive 
a c tiv ity  of morphine in 10 day old neonates. The 300 ppm lead dose group 
exhibited a decreased antinociceptive e ffe c t of morphine but at 1000 ppm the 
antinociceptive a c tiv ity  o f morphine was not fu rth e r im paired as m ight be 
expected but there was a complete lack o f dose response to morphine. This 
may re fle c t a more severe disruption o f the systems which m ediate the 
antinociceptive  e ffe c ts  o f morphine. Both 21 and 30 day old animals show no 
or m inim al e ffe c ts  o f lead. This transien t e ffe c t o f lead early  in
development indicates a capacity of the developing system to compensate fo r 
the early disruption caused by lead exposure. I t  should be noted tha t blood 
lead levels a t 10 days are approxim ately equal to the safety lim its  in man 
proposed by in te rna tiona l authorities (Royal Commission Report, 1983) 
although they do increase above th is level to  a peak a t 21 days when dosing 
was term inated. Thus the suscep tib ility  of the systems involved in morphine 
antinociception to  lead exposure occurs at a specific  tim e point when this 
system is developing, blood lead levels are re la tive ly  low at th is tim e p rio r to  
10 days and continued exposure to  lead beyond this tim e does not cause 
fu rth e r disruption and indeed the system has the capacity to recover despite 
the higher lead burdens. In contrast to the results presented in th is  thesis 
Baraldi e t a l. (1985) reported a po tentia tion  of morphine antinociception in 
rats exposed via th e ir dam from  conception and d ire c tly  from  weaning u n til
postnatal day 40, blood lead levels of these animals were very low (5 yg/d l). 
The varia tion between th e ir study and the results presented here could be due 
to the use of a much lower dose o f lead n itra te  and the stress factors 
involved in adm inistering the dose by oral in tubation or the use o f the 
hotp late test method on older animals.
The most obvious explanation fo r the reduced antinociceptive e ffec ts  of 
morphine at 10 days would be an e ffe c t o f lead on the development o f the 
receptors involved in the m ediation o f the antinociceptive e ffec ts . Morphine 
acts m ainly a t the y-op io id  receptors (James and Goldstein, 1984) and these 
receptors undergo a rapid period o f development between 4 and 21 days 
(Spain e t al., 1985). Thus lead exposure early in development may delay the 
ontogeny o f these receptors such tha t the functioning o f the y-op io id  
receptor system is impaired at postnatal day 10 ; however as w ill be described 
in Section 4.3. the model o f lead exposure used throughout the studies 
described in th is thesis does not a ffe c t y-op io id  receptor binding during th is 
developmental period. Other possible explanations are discussed in Section 
4.2.5.
4.2.4. E ffe c t o f perinata l lead exposure on ketocyclazocine antinociception 
in the paw pressure test.
In the paw pressure test, perinata l lead exposure increased the 
nociceptive threshold in 10 day old neonates but decreased the threshold in 30 
day old rats in contrast to the ta il immersion test where lead had no e ffe c t 
on the nociceptive thresholds. Thus in the studies reported in th is thesis lead 
its e lf causes a hyperalgesia at postnatal day 10 by im pairing the development 
of the pain pathways involved in the perception o f nociception caused by a 
mechanical, stimulus. As lead did not a ffe c t the pain pathways involved in 
therm al s tim u li i t  may be assumed tha t the pain pathway has some 
independent components, specific  fo r the type o f stimulus involved as
described by Schmauss and Yaksh (1984). The impaired response observed at 
10 days has recovered to normal by 21 days and results in a rebound, 
supersensitiv ity to  mechanical s tim u li at 30 days. Although an increase in 
nociceptive threshold is reported in other studies using the hot p late test 
(Hong et al., 1983; Bondy et al., 1985; Walsh et al., 1984 and 1986; Baraldi et 
al., 1985 and Vickers and Paterson, 1986) this was measured in animals at 
least 40 days old.
The e ffe c t o f perinata l lead exposure on ketocyclazocine 
antinociception was s im ila r to tha t observed fo r morphine antinociception in 
the ta il immersion test. Again at 10 days lead exposure reduced the 
antinociceptive e ffec ts  o f ketocyclazocine at both lead dose groups but did 
not produce the loss o f dose response tha t was observed w ith  morphine 
antinociception. In addition although the 300 ppm lead dose group had 
recovered by 21 days the 1000 ppm dose group s t il l exhibited a reduction in 
the antinociceptive e ffe c t of ketocyclazocine, whereas morphine 
antinociception had recovered to normal by 21 days in both lead dose groups. 
The prolonged e ffe c t o f exposure to 1000 ppm lead on ketocyclazocine 
antinociception may be a re fle c tion  o f the higher blood lead levels recorded 
in this study at 21 days.
A more probable explanation is tha t the development o f the k -opioid 
receptor system is a ffected  by lead exposure. Ketocyclazocine exhib its a 
p re fe ren tia l a f f in ity  fo r k -opioid receptors (Magnan et al., 1982) and its  
antinociceptive e ffe c ts  in a mechanical stimulus test are m ainly mediated by 
kappa receptors (Tyers, 1980). Kappa-opioid receptors develop more slowly 
than the p-opioid receptor, peak binding not being observed u n til postnatal 
day 35 in the ra t (Spain et al., 1985). Thus at 21 days the k -opio id receptor 
is s t ill in a developmental phase and may therefore  be sensitive to a tox ic  
e ffe c t o f lead on the development o f ketocyclazocine antinociception, 
whereas at 30 days development is almost complete and the developmental
e ffec ts  o f lead exposure are overcome.
4.2.5. Possible mechanisms o f lead to x ic ity  on opioid antinociception.
A part from  the possible e ffec ts  o f lead exposure on receptor 
development which w ill be discussed more fu lly  in Section 4.3. other 
mechanisms o f lead to x ic ity  may be involved in its  e ffec ts  on 
antinociception. I f  the receptors are not a ffected  by lead exposure or in 
addition to receptor e ffec ts , a post receptor mechanism may be involved in 
lead to x ic ity . This may be in the translation o f the in te raction  o f an opioid 
w ith  its  receptor to the response, which is most commonly observed as a 
depression o f neuronal f ir in g  and an inh ib ition  o f neuro transm itte r release 
(M ille r, 1984). A lte rn a tive ly  i t  may be an e ffe c t o f lead on another 
neuro transm itte r system (see Section 1.8.3.1) which the opioidergic system 
connects to in e ither an inh ib ito ry  or s tim u la tory  capacity. However a study 
using a protocol o f lead adm in istra tion s im ila r to  tha t used throughout this 
thesis found no e ffe c t o f lead on the ontogeny o f noradrenaline, adrenaline 
and dopamine in the ra t s tria tum , only a 50% decrease in y -amino bu tyric  
acid (GABA) levels were observed at 10 days in the 1000 ppm lead dose group 
(Bailey and K itchen, 1986).
The biochem ical events occuring subsequent to opiate receptor 
s tim ula tion is not c learly  understood in adult animals. Some studies have 
indicated tha t morphine inh ib its adenylate cyclase a c tiv ity  in the stria tum  
(Bhoola and Pay, 1986 and Sharma et al., 1975) causing a reduction in ce llu la r 
cyc lic  AMP levels, a well known second messenger system fo r extra  ce llu la r 
s tim u li. Opiates have also been shown to have an e ffe c t on ion channels 
w ith in  nerve cells, in pa rticu la r potassium and calcium ions are involved 
(Michaelson et al., 1984; Konno and Takayanagi, 1983 and North, 1984). 
There is some ind ication tha t lead exposure can also a ffe c t these systems. 
Lead exposure at various doses has e ffec ts  on ce llu la r respiration and various
enzyme systems (fo r review  see Winder and K itchen, 1984) but in pa rticu la r 
brain adenylate cyclase is inh ib ited in v itro  by lead concentrations equivalent 
to those found in the brain o f lead exposed animals (Nathanson and Bloom, 
1975). However as both lead and morphine in h ib it adenylate cyclase a 
po ten tia tion  o f the e ffe c t of morphine may be expected in lead exposed 
animals. Lead has also been shown to bind to calcium  ion binding proteins 
and calmodulin (Goldstein and A rr , 1983 and R ichardt et al., 1986) and has 
been shown in v itro  to  in h ib it the c o n tra c tility  o f longitud inal smooth muscle 
possibly by the im pairm ent of calcium  in flux  or in trace llu la r function  (Walsh 
and H arne tt, 1986). In addition lead has been shown to slow m otor nerve 
conduction ve loc ity , however levels of lead exposure were very high (Maehara 
e t al., 1986).
There is no clear explanation fo r the e ffec ts  of lead exposure on 
antinociception in developing animals. Lead has been shown to have e ffec ts  
on various biochem ical processes tha t may be involved in neural pathways 
some of which are also a ffec ted  by morphine. But comparison o f lead studies 
are d if f ic u lt  due to the large variations in dosing protocols. The tox ic  e ffe c ts  
o f lead on antinociception may be due to a combination o f facto rs  including 
the d iffe re n tia l development of the various components involved in the 
perception and response to a noxious stimulus and the inh ib ito ry  e ffe c ts  o f 
opioids on these systems.
4.3. Effect of lead on the ontogeny of opioid receptors.
The development o f specific  radioligands fo r opioid receptor subtypes 
has allowed the ontogeny o f these receptors to be studied more accurate ly 
w ithou t the use o f suppressing ligands. The ontogeny of both y -  and <S -opioid 
receptors is discussed in the fo llow ing sections and how the ir development is 
a ffected  by perinata l lead exposure. In addition experiments perform ed to  
confirm  su ita b ility  o f test conditions are also discussed.
4.3.1. Radioligand preparation and s ta b ility  during incubation.
The necessity fo r HPLC pu rifica tion  o f radioligands was demonstrated, 
by the variable pu rity  and quantity o f ligand supplied. This was p a rticu la rly  
true fo r [^H  1 [ D-Pen^ D-Pen^] enkephalin (DPDPE) probably due to 
problems in m anufacture o f the labelled form . O ther groups have also found 
i t  necessary to  pu rify  ligands before use by e ither HPLC (Cotton et al., 1985; 
K o s te rlitz  e t al., 1987; Rosenbaum, e t al., 1985; P e tr illo  et al., 1987; Tavani 
et al., 1985 and G illan and K o s te rlitz , 1982), th in  layer chromatography (Pert 
and Snyder, 1973; Coyle and Pert, 1976 and Spain and Coscia, 1987) and gel 
f i lt ra t io n  (Tsang and Ng, 1980a). Variable results between studies may be 
a ttr ib u ta b le  to d ifferences in pu rity  or concentration o f supplied radioligands 
i f  they are not confirm ed.
The s ta b ility  o f the radioligand during incubation has a d irec t e ffe c t on 
the results o f binding assays. Breakdown of the ligand due to tem perature, 
ionic conditions or enzym atic a ttack would resu lt in false estim ations o f free 
concentrations o f ligand and the breakdown product may bind to the
membrane or apparatus in its  own rig h t and so produce false estim ates of 
binding parameters. A m athem atical model of the e ffec ts  o f ligand
degradation is described by Speth et al. (1986), the m ajor e ffe c t being a 
reduction in binding a ff in ity  and a curv ilinear Scatchard p lot.
In the studies presented in th is thesis neither tem perature, ionic
conditions or enzym atic a c tiv ity  a ffe c t the s ta b ility  o f e ither of the ligands,
a ll the ra d io a c tiv ity  cochromatographing w ith  the standard, unincubated
3 2compound. S im ilar results have been presented fo r [ H ] [D -A la  D-
5 3Leu ] enkephalin (DADL) (Spain and Coscia, 1987) [ H] naloxone (Coyle and
Pert, 1976 and Rosenbaum et al., 1984), I ^H I sufentanil (Rosenbaum e t al.,
1984) and [^H  ] etorphine (Rosenbaum et a l., 1985). However many studies
do not report the s ta b ility  o f the ligand and varia tion  of incubation conditions
may adversely a ffe c t the ligand.
4.3.2. Time course o f opioid binding.
The tem perature at which an incubation is carried out fo r a binding 
assay w ill have a s ign ifican t e ffe c t on the tim e at which equilibrium  w ill be 
reached. Assays using lower temperatures to reduce degradation o f the 
ligand also use a longer incubation period (fo r example, G illan e t al., 1980, 
Lord et a l., 1977) although low temperatures may cause conform ational 
changes o f proteins. Temperatures o f 37°C may be used to m im ic conditions 
in the whole animal but may also create problems of ligand degradation 
(Auguy-Vale tte e ta l. ,  1978).
The tim e course fo r [^H  ] [ D -A la^ MePhe G lyol] enkephalin (DAGO)
3' 2 5and [ H ] [ D-Pen D-Pen ] enkephalin (DPDPE) are s im ila r w ith  an in it ia l
rapid rise in binding, a plateau and then a fa ll in binding a fte r 2 hours
incubation. However [^H l DAGO does reach peak binding at 20-30 mins,
s im ila r to  the tim e course o f [^ H l naloxone (Pert and Snyder, 1973), some
10-20 mins. earlie r than l^ H l DPDPE binding. I t  has been suggested tha t
the tim e to  reach equilibrium  should re fle c t the tim e  course o f b io log ica l
e ffe c t (Burt, 1978) and although peak DAGO analgesia occurs approxim ate ly
10-15 mins. a fte r  i.c .v . or i. t .  in jection  (Pazos and F lorez, 1984), the
physico-chem ical variations must be enormous between binding in an
homogenous membrane preparation and in jection  in to the whole animal.
Assays o f in vivo binding use a tim e fo r te rm ination  tha t gives peak brain
levels of the compound (Rosenbaum et al., 1984 and Frost et a l., 1984), and
give a much more re a lis tic  measure of receptor binding as they occur in a
physiological environment identica l to tha t fo r drug action.
Nonspecific binding does not show such marked variations in binding 
w ith  tim e, ind icating tha t i t  is the in te raction  o f the ligand w ith  the receptor 
tha t results in tim e dependent changes in binding and not a change in the 
ligand which continues to bind to nonspecific sites.
4.3.3. Saturation curves.
The saturation curves obtained fo r both l^ H l DAGO and [^H ] DPDPE 
ind icate tha t binding of these ligands is to a receptor site as i t  is possible to 
saturate the specific  binding sites, a c r ite r ia  necessary fo r the id e n tifica tio n  
o f a receptor (Burt, 1978 and Cross and Owen, 1987). Nonspecific binding of 
both ligands increase in a linear re la tion  to increasing ligand concentration 
and is not saturable w ith in  the range o f ligand concentrations used. Thus, 
once saturation o f specific  binding sites has occured to ta l binding increases in 
para lle l w ith  nonspecific binding.
The use o f a displacing compound not chem ically re la ted to  the labelled 
ligand gives a more accurate estim ation of nonspecific binding than an excess 
of unlabelled ligand. The use o f the la tte r  would resu lt in displacement from  
all sites where the chemical nature o f the ligand was the cause o f binding, 
which may not be the binding site of in terest. Use o f another opioid not 
chem ically re la ted would only displace binding o f the radio labelled ligand 
from  opioid sites. An a lte rna tive  method fo r e lim ina ting nonspecific binding 
from  estimates o f binding parameters has been suggested by Mendel and 
Mendel (1985). They propose tha t only to ta l binding should be analysed and 
separated in to  a t least two binding sites one of which is the nonspecific 
binding site . However as DAGO and DPDPE have been shown to  be specific  
to p - and 6 -opio id receptors respective ly (G illan and K o s te rlitz , 1982 and 
Cotton et al., 1985) the use of another, chem ica lly unrelated opioid to  
i measure nonspecific binding was fe lt  appropriate.
The 6 -opio id receptor ligand DPDPE bound to a much higher proportion 
of nonspecific sites than the p-opioid receptor ligand DAGO; this has also 
been observed by other groups (Delay-Goyet et al., 1985 and C otton  et al.,
1985).
The Scatchard plots obtained fo r both t^H  1 DAGO and [^H ] DPDPE 
binding were linear, determined by highly s ign ifican t corre la tion co e ffic ie n ts
from  linear regression analysis, an indication o f only one receptor site 
involved in the specific binding o f these ligands to membrane homogenates. 
As the Scatchard plots were linear estimates of receptor a ff in ity  (K q ) fo r the 
ligand could be made from  the inverse slope o f the p lot and an estim ate of 
the maximal binding capacity could be made from  the in te rcep t o f
the p lot.
4.3.4. Ontogeny o f y-opio id receptor binding.
The para lle l Scatchard plots obtained fo r [^H ] DAGO binding in 10,21 
and 30 day old rats indicate tha t age has no e ffe c t on the a ff in ity  constant 
(K q ) but does result in increased numbers o f receptors ). Peak binding
was observed in 21 day old neonates and although the number o f receptors in 
the whole brain remained constant between 21 and 30 days there were s ligh t 
but not s ign ifican t decreases in the number of receptors expressed per mg 
tissue or per mg prote in. These variations and the variations in the increase 
in receptor number are due to increases in brain size and prote in 
concentrations in the brain during development (see Section 3.3.2.2.).
A s im ila r pa tte rn  o f development was presented by Spain et al. (1983) 
and P e tr illo  e t al. (1987) who both detected peak binding at 21 days. 
However Spain et al. (1983) detected l i t t le  varia tion in maxim al binding 
capacity between 10, 21 and 30 days when expressed per mg prote in  whereas 
a 2 -fo ld  increase was seen between 10 and 21 days in the studies described in 
this thesis in agreement w ith  P e trillo  e t a l. (1987). This may be a re fle c tion  
on the lim ite d  brain area used by Spain et al. (1983). In mice Tavani et al. 
(1983) found y-opio id receptors developed la te r w ith  peak levels not detected 
un til mice were 10 weeks old.
S im ilar ontogenetic patterns have been observed w ith  less specific  
opioid ligands such as morphine (Auguy-Valette et al., 1978) although 
Pasternak et al., (1980) detected biphasic Scatchard plots w ith
[ H] morphine binding, the two sites showing d iffe re n tia l ontogeny. Most 
other ontogenetic studies have used naloxone as the labelled ligand which 
although i t  does show some sp e c ific ity  fo r y-opio id receptors i t  also has some 
binding a c tiv ity  a t <5 - and < -opioid receptors (Magnan et al., 1982 and 
James and Goldstein, 1984). As reviewed in Section 1.3.4. these studies have 
mainly confirm ed peak binding in the th ird  postnatal week although peak 
binding in the cerebellum was shown in the f irs t  postnatal week (Tsang et a l., 
1982b).
4.3.5. Ontogeny o f <5 -opio id receptor binding
C ] DPDPE binding to the 6 -opioid receptor shows a d iffe re n t
developmental p ro file  to the y-opio id receptor w ith  binding not appearing 
un til the second postnatal week and peak binding not observed u n til the 
fourth  postnatal week. The a ff in ity  constant fo r this selective ligand showed
li t t le  change during the developmental period. Studies using the less
3 2 5selective 6 -opioid receptor ligand [ H I  [ D -A la D-Leu 1 enkephalin
(DADL) report a s im ila r lack o f change in a ff in ity  constant w ith  age (P e trillo
et al., 1987) although Spain et al., (1985) report a decrease in a f f in ity
constant u n til postnatal day 14 and suggest tha t th is early low a f f in ity
binding may be due to k -opioid receptor sites.
The earliest tim e point at which 6 -opioid receptor binding can be 
detected is one o f the m ajor differences observed between studies o f <5 - 
opioid receptor ontogeny. In the experiments described in th is thesis specific  
binding o f [ ^ H ]  DPDPE could not be detected before postnatal day 10. 
Studies using the less selective 6 -opioid receptor ligand [ ^ H ]  DADL report 
binding at day 7 (P e trillo  et al., 1987) and a low a ff in ity  DADL binding site 
which can be detected in 1 day old rats (Spain et al., 1985). The varia tions 
between the study presented here and other reported studies may be a 
re flec tion  o f the greater se le c tiv ity  o f DPDPE fo r the 6 -opioid receptors.
The detection o f [ ] DADL binding during the f irs t postnatal week by
Spain et al. (1985) may be due to p-opioid receptor binding as when a higher, 
concentration o f DAGO is used to suppress binding to p-sites binding cannot 
be detected un til postnatal day 7 (P e trillo  et al., 1987). Spain et al. (1985) 
suggest th is early low a ff in ity  binding may be due to new p a rtia lly  
functioning 6 -opioid receptors tha t require the presence o f guanine, 
nucleotides and cations to function norm ally (Szucs et al., 1987).
In addition some differences in the development o f the 6 -opioid 
receptor were observed. Spain e t al. (1985) reported a 3-fo ld  or 1 .5-fo ld  
increase in binding sites fo r [^H  ] DADL between day 10 and day 28 in ra t 
forebra in when expressed per mg wet weight or per mg prote in respective ly 
whereas P e tr illo  et al. (1987) only reported a 2-fo ld  or 0 .2-fo ld  increase in 
binding sites fo r I ^ H l  DADL between day 7 and day 21. In contrast the 
experiments described in this thesis record increases o f 4 .5-fo ld  and 3-fo ld  
fo r [ ] DPDPE binding sites. These variations may re fle c t d ifferences
between the ligands used, the experim ental procedure, brain area studied and 
the ages at which measurements are made. The lower increases in m axim al 
binding capacity observed when expressed per mg prote in are a re fle c tion  o f 
general prote in concentrations w ith in  the brain as shown by experim enta l 
data presented in this thesis. Binding o f less selective ligands such as 
[ 1 DADL w ithou t suppression at other opioid binding sites can be
measured in the f ir s t  postnatal week but in inh ib ition  studies using re la tive ly  
selective cohnpounds the I^H  1 DADL binding is displaced indicating tha t the 
binding is to p-opioid receptors (Leslie et al., 1982 and Wholtmann et al.,
1982). Undisplaceable [ ^ H I D A D L  binding and therefore  6 -opioid binding 
can be detected in the second postnatal week and increases rapid ly in 
agreement w ith  the results presented in this thesis and by P e tr illo  e t al. 
(1987).
A s im ila r ontogenetic pattern o f 6 -opioid receptor development has
been observed in m ice. Binding o f [^H  ] DADL could not be detected in 3 
day old m ice but increased 2-fo ld between 13 days and 10 weeks. There was 
no accompanying changes in a f f in ity  constant (Tavani et al., 1985).
The re la tive ly  low specific  binding o f [ ^ H ]  DPDPE did present some 
problems in younger animals and only reached 50-60% in adult animals. This 
is in accord w ith  the data o f Cotton e t al. (1985) though figures as low as 26% 
have been reported when [^H ] DPDPE was used at incubation temperatures 
of 35°C (Delay-Goyet e t al., 1985). The high nonspecific binding in 10 day 
old animals decreases to adult levels by postnatal day 21, th is may ind ica te  
the presence of a non-opioid site tha t binds [ ] DPDPE during these early
postnatal periods but disappears at la te r ages. As suggested by Spain et al.
(1985) th is binding site may be a newly form ed, non-functional opioid 
receptor tha t is incapable o f binding other opioid compounds in th is im m ature 
fo rm .
4.3.6. E ffe c t o f perinata l lead exposure on [ ^ H ] DAGO binding.
Perinata l lead exposure had no s ign ifican t e ffe c t on e ither the a f f in ity  
constant or maximal binding capacity o f [ ] DAGO binding. This was
surprising as morphine, a re la tive ly  selective agonist fo r the y-op io id  
receptor, showed altered antinociceptive e ffec ts  in lead exposed animals in 
the ta il immersion test suggesting th a t lead has an e ffe c t .on some other 
aspect o f morphine antinociception (see Section 4.2.3. and 4.2.5.).
However lead exposure in the high dose group did cause an increase in 
a f f in ity  o f the binding site fo r the ligand (decreased a ff in ity  constant, K D) o f  
over 30% in 10 and 21 day old neonates. An increase in binding site a f f in ity  
may resu lt in an increased e ffe c t of a pharmacological agent but, as was 
observed in the ta il immersion studies, there was not an increase in the 
antinociceptive e ffe c t o f morphine in 10 day old rats exposed pe rina ta lly  to  
1000 ppm lead. Instead a to ta l lack o f dose response to morphine was
observed possibly suggesting tha t the predominant e ffe c t of the high dose o f 
lead was at a post receptor component of morphine antinociception fo r 
example a delay in the development or an uncoupling of second messenger, 
systems as discussed in Section 4.2.5.
In contrast Baraldi et al. (1985) has reported tha t exposure to  lead 
n itra te  results in a 1.5-fold increase in t ^ H l  naloxone, binding in the 
hypothalamus. This may re fle c t the use o f the n itra te  compound as sodium 
n itra te  also increased the maximal binding capacity (Baraldi et al*? 1985) or i t  
may be a ttr ib u ta b le  to the gastric in tubation route of adm in istra tion which 
may produce compounding problems of stress-related e ffec ts  which have been 
reported to  be d iffe re n t in lead exposed animals (B a rre tt and Livesey, 1985).
4.3.7. E ffe c t o f perinata l lead exposure on l^ H l DPDPE binding.
The values o f a f f in ity  constant and maximal binding capacity from  
contro l animals are very s im ila r to those found in the ontogenetic study using 
[ H 1 DPDPE (see Section 3.3.3.2.). I t  is therefore assumed tha t acetic  acid 
is w ithou t e ffe c t on binding o f [ ] DPDPE despite its  reported e ffec ts  on
behaviour (B a rre tt and Livesey, 1982). This is in contrast to the e ffe c t of 
sodium n itra te  used as a contro l fo r lead n itra te  adm in istra tion which caused 
an increase in a f f in ity  constant and m axim al binding capacity o f naloxone 
binding (Barald i et a l., 1985).
In contrast w ith  the lack o f e ffe c t o f perinata l lead exposure .on- 
[ 1 DAGO binding perinata l lead exposure does a ffe c t [ ] DPDPE
binding. The increase , in a f f in ity  constant o f Ibetween l 20 and 50% in the 
high lead dose group at a ll ages studied indicates th a t the binding site has a 
lower a ff in ity  fo r DPDPE than in contro l animals. This is a persistent e ffe c t 
o f lead tha t is seen in 50 day old rats some 36 days a fte r lead dosing was 
term inated and blood lead levels of exposed animals had fa llen  to  contro l 
levels. Although brain lead levels do not fa ll as rap id ly as blood lead levels
and there is red is tribu tion  of lead w ith in  the body from  tissue pools i t  is 
unlike ly tha t the lead molecule in te rfe res d ire c tly  w ith  the receptor 
conform ation to  a lte r binding. I f  this were the case then i t  would be 
expected th a t the most severe e ffec ts  would be seen in 15 day old neonates 
when blood and therefo re  brain lead levels would be at the ir peak. In addition 
the binding assay involves several washing and preincubation steps and i t  
would be most like ly  tha t any free  lead would be washed out o f the membrane 
preparation.
However lead exposure does not appear to a ffe c t the number of binding
sites in the brain as B values show l i t t le  change from  contro l values w ithmax a
the exception o f the high lead dose group at 30 days where there is an 
elevation of 30-40%. From these observations i t  is apparent tha t lead 
exposure may resu lt in a change in conform ation o f the <5 -opio id receptor 
which decreases the a ff in ity  o f the binding site fo r the ligand DPDPE. I t  is 
un like ly tha t th is e ffe c t o f lead is d irec tly  on the receptor prote in since the 
turnover o f opioid receptors is like ly  to be in the order of days and there fo re  
some recovery o f binding a ff in ity  would be expected when the lead burden 
had fa llen . Another possible explanation is th a t the to x ic ity  is manifested at 
the genetic message fo r the receptor prote in . This may be at transfer RNA 
(t-R N A ) and messenger RNA (m -RNA) levels, lead salts have been shown to 
cleave molecules o f both m -RNA and t-R N A  at conditions of pH and 
tem perature found in liv ing  cells and at low concentrations o f lead (Farkas, 
1975 and Werner et al., 1976). But again recovery may be expected when new 
m -RNA and t-R N A  are produced a fte r lead exposure is term inated and lead 
burden fa lls . Thus perhaps i t  is more like ly  tha t lead exerts its  tox ic  e ffec ts  
on receptor proteins at the DNA level. I f  th is  is true then lead must have a 
pa rticu la r a f f in ity  fo r the gene locus involved in <5 -opio id receptor coding or 
more like ly  this gene locus is pa rticu la rly  sensitive to damage.
Baraldi et al. (1985) have also reported lead e ffec ts  on opioid binding.
Perinatal exposure to low levels o f lead resulted in an increased binding 
capacity fo r [^H  ] naloxone but had no e ffe c t on a ff in ity . I t  was suggested 
th a t th is was due to a super-sensitiv ity of the receptors as a result of 
concom itant decreases in 3-endorphin levels.
O ther receptor systems have also been reported to be a ffec ted  by lead 
exposure and include e ffec ts  on dopamine receptor binding (Winder and 
Lazareno, 1985, Rossouw et al., 1987 and Govoni et al., 1980), m uscurinic 
receptor binding (Rossouw et al., 1987 and Moingeon et al., 1984), and
3-adrenoreceptor, and S2 serotonin receptor binding (Rossouw et al., 1987) 
and GABA receptor binding (Memo et al., 1980). The e ffe c t o f lead exposure 
on receptor binding has been shown to be dependent on the period of 
exposure, e ffe c ts  being seen when exposure is during the period o f ontogeny 
of the receptor, usually the pre- and post-natal periods before weaning 
(Rossouw et al., 1987). In the studies presented in th is thesis exposure to lead 
was during periods o f receptor development however the <5 -opio id receptor 
was found to be more sensitive to  lead expsoure than the p-opioid receptor. 
D iffe re n tia l sens itiv ity  of other receptor systems have been reported. 
Winder and Lazareno (1985) using a s im ila r protocol o f lead exposure to  tha t 
used throughout the studies described in th is thesis found no e ffe c t on 
dopamine (D2) receptors. S im ila rly  Rossouw et al. (1987) found d iffe re n tia l 
e ffec ts  o f lead exposure on receptor systems, 0^  adrenoreceptors were 
unaffected by lead exposure at any tim e  whereas other receptors were only 
a ffected  by lead exposure during a pa rticu la r developmental period.
This d iffe re n tia l e ffe c t of lead exposure on receptor systems is also 
m irrored by d iffe re n tia l e ffec ts  o f lead exposure on neuro transm itte r 
systems. In pa rticu la r the studies by Bailey and K itchen (1985 and 1986) 
using a s im ilar protocol o f lead exposure found no e ffe c t on the development 
o f nor-adrenaline, adrenaline or dopamine levels in the neonate ra t brain. 
GABA levels were decreased by 50% in 10 day old neonates (Bailey and
K itchen, 1986) whereas the opioid peptides were markedly depressed 
pa rticu la rly  at postnatal day 10 when these opioid peptides are v ir tu a lly  
undetectable in lead exposed animals (Bailey and K itchen, 1985). I t  has been 
suggested tha t the tox ic  e ffec ts  o f lead on proenkephalin products may be 
due to an e ffe c t on the processing enzymes as there is some recovery a fte r 
lead exposure is term inated due to synthesis of new enzymes (Bailey and 
K itchen, 1985). These endogenous opioid peptides are considered to  show 
se le c tiv ity  a t 5-opio id receptor sites and may function as physiological 
m ediators at these receptors (Paterson et al., 1983). Thus i t  could be 
proposed tha t the loss o f peptides from  the cleavageof proenkephalin in early 
postnatal development may resu lt in the im paired function ing o f the 5-opioid 
receptor observed in the studies presented in this thesis. However as the 
damage to the 6 -opio id receptors remains a fte r levels o f endogenous 
peptides recover these peptides must play a role in activa ting  sections of 
DNA so tha t the normal 6 -opio id receptor is produced. Lack o f these 
peptides during th is period may result in an incomplete coding fo r the 
receptor remaining in adult animals.
4.4. Effect of perinatal lead exposure on plasma corticosterone levels
4.4.1. Ontogeny o f plasma corticosterone levels.
Basal plasma corticosterone levels were found to fa ll between 30 and 60 
days by approxim ate ly 50%. These results are in contrast w ith  those 
presented hy Bailey and K itchen (1987) which found no varia tion  in basal 
corticosterone levels between 10 and 50 days. S im ila rly  C ritch low  et al. 
(1963) found no varia tion  o f basal levels at a tim e  point corresponding to  tha t 
used in the present study although there were differences between males and 
females as w e ll as circadian varia tion  of corticosterone levels, especially in 
females, between adult and prepubertal (30 day old) rats. There is also 
disagreement in the ontogeny o f basal corticosterone levels at ea rlie r tim e
points; some workers report no varia tion o f basal corticosterone levels 
(Bailey and K itchen, 1987, A llen and Kendall, 1967 and Kakihana et al., 1974) 
whereas others found a marked rise in basal corticosterone levels (Henning 
1978 and Walker et al., 1986). These contrasting results are an ind ica tion of 
the many physiological and environm ental factors tha t can a ffe c t plasma 
corticosterone levels. As described by C ritch low  et al. (1963) and 
Zimmermann and C ritch low  (1967) corticosterone undergoes circadian 
variations and therefore  the tim e at which measurements o f plasma 
corticosterone are made, im pair in terstudy comparisons. The basal
corticosterone levels o f female rats has also been shown to be dependent on 
the stage o f the oestrus cycle (C ritch low  et al., 1963) and may account fo r 
the greater varia tion  observed in results fo r females. Seasonal va ria tion  may 
also a ffe c t basal corticosterone levels despite contro lled conditions. In 
addition corticosterone levels rise in response to stress and even the removal 
of an animal from  a cage is capable o f elevating corticosterone levels 
(Hening, 1978), thus great care is necessary in order to reduce external
factors tha t may give rise to a stress response.
The response to stress is not present from  b irth , i t  is not u n til postnatal 
day 21 tha t a s ign ifican t elevation o f plasma corticosterone levels are seen 
a fte r in jection  stress (Bailey and K itchen, 1987), heat stress (H altm eyer et 
al., 1966), and histam ine in jection in to rats (Butte e t al., 1973) or m ice
(Kakihana et al., 1974). A peak elevation o f plasma corticosterone by
in jection  stress was reported between 30 and 40 days fa lling  to adult levels by 
43 days (Bailey and K itchen, 1987) which is in agreement w ith  the results 
described in th is thesis. Some evidence o f sex re lated differences is also 
evident w ith  levels in female animals at 30 and 60 days being greater than 
males. The elevations o f plasma corticosterone are s im ila r to those reported 
elsewhere (Bailey and K itchen, 1987 and Zimmermann and C ritch low  1967).
4.4.2. E ffe c t o f morphine adm in istra tion on stress induced rises in 
corticosterone levels.
The opioid system has been shown to  have a ro le in neuroendocrine 
regulation, p a rticu la rly  in the hypo tha lam ic-p itu ita ry-adrena l axis (H ow le tt 
and Rees, 1986 and M illan  and Herz, 1985). O f particu la r relevance to this 
study is the common precursor proopiom elanocortin fo r both ACTH which 
controls the release o f corticosterone from  the adrenals and the endogenous 
opioids re la ted to 8-endorphin (fo r review  see K itchen 1984b). There is also 
evidence tha t responses to stress can be modulated by opioids. Stress induced 
secretion o f corticosterone in the ra t has been shown to be modulated by 
acute adm in istra tion o f opioid agonists (Kokka et al., 1973, Eisenberg, 1985 
and Pechnick e t al., 1985) and opioid antagonists (Eisenberg, 1980, Siegel et 
al., 1982 and Jezova et al., 1982). As described previously (Section 4.4.1.) 
stress responses do not appear un til the th ird  postnatal week, the po tentia ting  
e ffe c t o f opioids on stress induced rises in corticosterone appear even la te r, 
s ign ifican t elevations are not reported un til postnatal day 40 (Bailey and 
K itchen, 1987). However in the results described in th is thesis some 
po tentia tion  by morphine of stress induced rises in corticosterone were 
observed in male 30 day old rats but not in female animals. The po ten tia tion  
by morphine was not s ign ifican t and may re fle c t the lower responses o f 30 
day old male animals to in jec tion  stress, both male and female corticosterone 
levels a fte r morphine in jection  being s im ilar. The lack o f e ffe c t o f morphine 
in 30 day old animals recorded by Bailey and K itchen (1987) may be due to a 
masking o f changes in male animals by not analysing results from  each sex 
independently. By 45 days morphine po tentia tion  o f in jection stress was 
observed in both sexes, results being s im ila r to  those obtained by Bailey and 
K itchen (1987). This elevation was also observed at 60 days but a s ign ifican t 
sex d iffe rence was observed at all doses of morphine. This sex d iffe rence  is 
most like ly  due to group housing o f males and females during a period when 
sexual a c tiv ity  is increasing. As there was no sex d iffe rence in basal
corticosterone levels the females appear to have a greater capacity fo r 
response to stress in terms o f corticosterone levels. Although housing o f both 
sexes together is not normal p ractice  i t  probably re flec ts  a more natural 
situation and was fe lt  appropriate in lead dosed animals fo r relevance o f 
l i t te r  data. No female was pregnant at the tim e of experim ent. An 
a lte rna tive  explanation fo r the observed sex differences could be the 
d iffe re n t circadian varia tion  observed between sexes (C ritch low  et al., 1963), 
depending on the tim e of day there . is a greater varia tion between 
corticosterone levels from  male or fem ale animals.
This la te  development o f opioid a c tiv ity  on the hypo tha lam ic-p itu ita ry - 
adrenal function is unusual compared to the development p ro files o f other 
aspects of the opioid system. p-Opioid receptor development and CNS 
peptide levels reach m a tu rity  by postnatal day 21 (Spain et al., 1985, Bailey 
and K itchen, 1985) along w ith  morphine analgesia (Auguy-Vale tte e t al., 1978) 
and even 6 -opio id receptors which appear la te r in postnatal development 
peak by day 30 (Spain et a l., 1985; this thesis). Thus other facto rs  must 
influence the contro l exerted by opioids on the hypotha lam us-p itu ita ry- 
adrenal axis and may involve a reduced capacity in younger animals to 
respond in excess of in jection stress, however when stress induced rises are 
lim ite d  by habituation there is s t i l l  l i t t le  ind ica tion of opioid m odulation 
(Bailey and K itchen, 1987).
4.4.3. E ffe c t o f perinata l lead exposure on basal and stress induced 
corticosterone levels.
E ffec ts  of perinata l lead exposure on basal corticosterone levels was 
only observed in 45 and 60 day old rats. In 45 day old rats exposure to 1000 
ppm lead resulted in elevated basal corticosterone levels but at 60 days a ll 
lead dose groups showed elevated plasma corticosterone levels. An elevated 
basal corticosterone level may ind icate a stressed state and accordingly i t
appears tha t perinata l lead exposure may produce a stressed state la te r in 
development and in adult animals. This e ffe c t o f perinatal lead exposure 
occurs some 30-46 days a fte r te rm ination  o f lead dosing when lead levels 
would be fa lling  or at contro l levels. This la te  developmental e ffe c t o f lead 
may be an ind ication of the la te  development o f th is system (Bailey and 
K itchen, 1987) but due to the low levels o f lead at th is tim e would ind icate 
th a t lead has a tox ic  e ffe c t much earlie r. Thus lead may cause some 
neurophysiological damage early in development but which does not m anifest 
its e lf as a stressed state un til the animal has com plete ly developed ie. 
postpubertal.
Perinata l lead exposure both potentia ted and inh ib ited the 
corticosterone response to  in jec tion  stress and was dependent on age and sex. 
I f  the e ffe c t o f saline in jection  stress is corrected fo r the lead induced 
changes in basal corticosterone levels then only m inim al e ffec ts  o f lead were 
observed. Perinata l exposure to  1000 ppm lead did depress corticosterone 
levels in 30 and 43 day old male animals, an e ffe c t reversed at 60 days.
4.4.4. E ffe c t o f perinata l lead exposure on morphine modulation o f stress 
induced rises in corticosterone levels.
The most marked e ffec ts  of perinata l lead exposure on morphine 
po tentia tion  o f stress induced rises o f corticosterone levels was seen in the 
high lead dose group at 60 days. Lead exposure resulted in upto a 30% 
elevation o f corticosterone levels compared to contro l animals, these rises 
were not so marked at lower lead doses in 60 day old animals. Thus lead 
exposure not only increases the basal stress state o f these animals but also 
increases the sens itiv ity  to  the e ffe c t o f morphine. This is in (contrast to the 
e ffec ts  o f lead exposure on morphine antinociception (Section 3.2.1.) where 
lead exposure decreases the e ffe c t of morphine indicating tha t a d iffe re n t 
mechanism of action o f lead may be involved. Stress during the postnatal
period or in adults has been reported to increase the sensitiv ity  o f adult 
animals to nociceptive s tim u li and morphine antinociception (Larson, 1982 
and Applebaum and Holtzm an, 1983). Therefore the stressed state caused by 
lead exposure in these animals as evidenced by elevated basal corticosterone 
levels may its e lf resu lt in an increased sens itiv ity  to the m odulatory e ffec ts  
of morphine on corticosterone levels. Indeed i t  has been reported tha t 
perinata l lead exposure does result in a greater behavioural response to stress 
(B arre tt and Livesey, 1985).
In 45 day old female rats morphine modulation o f corticosterone levels 
is com plete ly abolished in lead treated animals a fte r in jection o f the low dose 
o f morphine. Corticosterone levels remain at those seen a fte r saline 
in jection stress and in the 1-000 ppm lead dose group the corticosterone levels 
are reduced to the elevated basal corticosterone levels. Thus lead exposure 
having elevated basal corticosterone levels 3.6-fo ld above contro l levels has 
abolished the capacity fo r fu rthe r increases in corticosterone levels a fte r 
stress and the morphine po ten tia tion  seen in contro l animals. This could be 
a ttr ib u te d  to a decreased sensitiv ity  o f the opioid receptors involved,
although this is d if f ic u lt  to reconcile w ith  the e ffe c t o f lead on binding, or a 
decreased capacity o f the hypo tha lam ic-p itu ita ry-adrena l axis to release 
higher levels o f corticosterone. However when higher doses o f morphine are 
used there is a reversal o f this e ffe c t. Lead exposure appeared to have no 
e ffe c t on the rises seen w ith  the mid dose o f morphine and increased the rises 
seen in contro l animals a fte r in jection o f the high dose of morphine. Thus i t  
appears tha t lead exposure has decreased the sens itiv ity  of th is system to the
e ffec ts  o f morphine and therefore much higher doses o f morphine are
required to e lic it  a response. This pattern  o f lead e ffec ts  was only observed 
in 45 day old females which may indicate an increased stress state in females 
as discussed previously.
In 30 day old animals exposure to 1000 ppm lead depresses the
corticosterone levels in morphine trea ted rats at a ll morphine doses in both 
male and female animals ind icating tha t at this age lead exposure may have 
inh ib ited the mechanisms by whch morphine potentiates stress induced 
corticosterone levels. In te resting ly this e ffe c t is also m irrored in the 100 
ppm lead dose group but not the 300 ppm group. A possible explanation is 
tha t low doses o f lead may in h ib it the mechanisms involved, higher doses 
resu lt in a fu rth e r depression capable o f e lic itin g  feedback mechanisms that 
w ill compensate fo r the e ffe c t o f lead, while exposure to the high lead dose 
may depress levels below which any compensatory system can re tu rn  them to 
normal or may in h ib it the compensatory mechanism itse lf.
4.4.3. Conclusions.
A lthough corticosterone responses to stress are present by postnatal 
day 21 the hypotha lam ic-p itu ita ry-adrena i system is s t il l in a stage o f 
development and adult responses are not seen u n til postnatal day 45. The 
e ffe c t o f lead exposure early in development appears to have a la ten t e ffe c t 
on the response to stress. A t 30 days perinata l lead exposure results in a 
depression o f the e ffe c t o f morphine on stress induced rises in corticosterone 
while at 45 days there is recovery in male animals but in females the 
sens itiv ity  to morphine induced e ffec ts  are reduced. A t 60 days exposure to 
lead results in an increased stressed state evidenced by elevated basal 
corticosterone levels and in addition there is an increased sens itiv ity  to the 
e ffe c ts  o f morphine in jection  on corticosterone levels.
As was seen w ith  other opioid systems lead exerts its  e ffe c t during 
development even though in th is case lead exposure has been term inated and 
lead burden is fa lling . Early in development lead depresses the system 
involved in morphine modulation of stress responses and as the system 
matures so the e ffec ts  o f lead diminish. Lead exposure results in a rebound 
sensitiv ity  o f this system when i t  reaches m a tu rity .
4.5. E ffect of lead on locomotor activity.
4.5.1. C ircadian variations and ontogeny o f locom otor a c t iv ity .
A du lt ra ts being nocturnal animals exh ib it marked increases in a c tiv ity  
during the dark phase o f a lig h t cycle (Aschoff, 1981). In the studies 
described in this thesis this was also seen in neonatal, and prepubertal rats, 
the increase in a c tiv ity  seen during the f irs t few hours o f the dark phase. 
This was due to increases in both the exploratory a c tiv ity  during the f ir s t  ten 
minutes in the test apparatus and the to ta l a c tiv ity  during the hour long 
measurement period. I t  is in teresting to note that some form  o f circadian 
rhythm  evidenced by increased a c tiv ity  in the dark phase is present in 10 day 
old neonates which have not yet opened the ir eyes. Thus i t  appears tha t the 
m other influences the neonate by patterns of nursing and a c tiv ity  to fo llow  
normal ligh t/d a rk  cycle changes in locom otor a c tiv ity  (Honma e t.a l., 1987). 
The influence o f m aternal rhythms on development o f circadian rhythm s in 
neonates is also discussed by Davis (1981).
The a c tiv ity  level at a ll periods o f circadian rhythm  studied increased 
w ith  age. 30 day old rats having the highest exploratory and to ta l a c tiv ity . 
S im ilar increases in a c tiv ity  have been reported (A lieva et al., 1987, F ilibeck 
et a l., 1982. Caza and Spear, 1980 and K a tz, 1980), although there is some 
disagreement as to the age at which peak or adult a c tiv ity  can be recorded. 
F ilibeck et al. (1982) found a peak in a c tiv ity  at 21 days and a fte r a fa ll to 26 
days some recovery in a c tiv ity  levels was seen u n til adult levels were reached 
by 60 days, in agreement w ith  Katz (1980). However Caza and Spear (1980) 
report a c tiv ity  at postnatal day 24 to be lower than at day 17. These 
variations in results re fle c t the many variables tha t can influence locom otor 
a c tiv ity  measurements. As discussed above circadian variations can resu lt in 
a 3-fo ld  d iffe rence in a c tiv ity  as described in th is thesis, in addition 
experim ental protocol can also influence a c tiv ity  measurements. The f ir s t  
ten minutes represent a period o f more intense a c tiv ity  associated w ith
exploring the new environment and attem pts to escape, habituation w ith  the 
test environment can reduce th is in it ia l exploratory a c tiv ity  (Katz, 1980). 
Uncontro lable variables such as operator handling and extraneous noise can 
also influence a c tiv ity  and the type o f recording apparatus used can also 
make comparisons between laboratories d if f ic u lt .
4.5.2. E ffe c t o f morphine on locom otor a c t iv ity .
Morphine produced hypolocomotion at a ll ages studied, an e ffe c t also 
observed in adults (Olson e t al., 1985) and at some ages in neonates (A lieva  et 
al., 1987 and Caza and Spear, 1980) although there is disagreement, in the 
lite ra tu re  as to the e ffec ts  o f morphine on locom otor a c tiv ity  in the neonate. 
In the studies presented in th is thesis the 10 day old neonate was 10-fo ld 
more sensitive to the e ffects  o f morphine on locom otor a c tiv ity  than the 
response to therm al s tim u li (see Section 3.2.1.). Depression o f locom otor 
a c tiv ity  w ith  s im ila r doses o f morphine in 10 day old neonates was also 
observed by Caza and Spear (1980). This high sens itiv ity  o f 10 day old 
neonates is surprising as p-opioid receptors fo r which morphine is re la tive ly  
selective (Paterson et al., 1983) is s t i l l  developing, adult com plim ent of 
receptors not being present in the brain u n til postnatal day 21 (Spain e t al., 
1985 and th is thesis). In addition, m axim al responses to morphine 
antinociception are also not seen un til postnatal day 21 as described in th is 
thesis (Section 3.2.1.).
There * also appears to be a d iffe re n tia l e ffe c t o f morphine on 
exp loratory and to ta l a c tiv ity  in the studies reported in th is thesis. In 21 and 
30 day old animals low doses of morphine have a greater e ffe c t on 
exploratory a c tiv ity  than to ta l a c tiv ity , higher doses of morphine being 
required to  a ffe c t to ta l a c tiv ity  over the whole hour. These varia tions may 
provide an explanation fo r the variable e ffec ts  o f morphine reported in the 
lite ra tu re , in additon the present studies were perform ed in the dark phase
whereas other reports have stated recordings in the ligh t phase (Katz, 1980 
and Locke and Hoitzman, 1986). Some reports were conducted in the dark 
phase (Caza and Spear, 1980 and A lieva et al., 1987) and morphine induced 
stereotyp ic behaviours have also been reported to be increased during the 
dark cycle (Charness et al., 1975). The p re fe ren tia l e ffec ts  o f low doses o f 
morphine on exploratory a c tiv ity  may be a ttribu ted  to a quicker clearance o f 
low doses o f morphine and therefore a shorter duration o f action. I f  this 
were the case i t  would be in contrast to the tim e course o f morphine 
antinociception.
4.5.3. E ffe c t o f perinata l lead exposure on locom otor a c t iv ity .
The e ffec ts  o f lead on locom otor a c tiv ity  have been reported as hypo 
and hype ractiv ity  in addition to no e ffec ts  (see Section 1.8.2.1.). Locom otor 
a c tiv ity  measurements are a ffected  by many variables as decribed above and 
these are compounded by the variable lead dosing protocols used. The 
perinata l lead dosing model used in the studies described in th is thesis 
produced a selective e ffe c t in 10 day old neonates, hypoactiv ity  being 
observed during the exploratory phase o f a c tiv ity  in the high lead dose group. 
However this decrease in a c tiv ity  was not re flec ted  in to ta l a c tiv ity  
ind icating a possible hype ractiv ity  a fte r the in it ia l 10 min. exp lora tory 
a c tiv ity . Some indication o f hypoactiv ity  in lead dosed animals at postnatal 
day 11 was reported by Jason and Kellogg (1981), although blood lead levels 
were somewhat higher than those reported in the studies in this thesis. In 
adult animals R e ite r e t al. (1975) also reported hypoactiv ity  during the dark 
phase.
There was no lead e ffe c t on locom otor a c tiv ity  at other ages studied, in 
agreement w ith  McCarren and Eccles (1983) and Jason and Kellogg (1981). 
Most studies do not measure a c tiv ity  o f neonates but tha t o f adults a fte r 
perinatal lead dosing. The ontogenetic p ro file  o f a c tiv ity  in lead trea ted
animals reported by Jason and Kellogg (1981), re fle c ts  a delayed development 
o f a c tiv ity  resulting in hype rac tiv ity  at day 18 a s im ilar pattern  to tha t 
reported fo r s tr ia ta l enkephalin levels (Winder e ta l. ,  1984).
The influence o f the ligh t/d a rk  cycle on the e ffects  o f lead exposure 
has been reported by several groups (R e ite r et al., 1975, Collins et al., 1984 
and Dolinsky et al., 1981), however results were also contrad icto ry. R e ite r et 
al. (1975) reported hypoactiv ity  during the dark phase while Collins et al.
(1984) reported a hype rac tiv ity  p rim arily  during the ligh t phase o f the 
ligh t/d a rk  cycle, although some ind ication of hype ractiv ity  was recorded 
during the dark phase.
4.5.4. E ffe c t o f perinata l lead exposure on morphine modulation 
o f locom otor a c t iv ity .
Morphine adm in istra tion produced a dose dependent decrease in both’ 
exp loratory and to ta l a c tiv ity  as discussed in Section 4.5.2. However lead 
exposure m odified these e ffec ts  in both 10 and 21 day old neonates exposed 
during the perinata l period. In 10 day old neonates exposure to 1000 ppm lead 
depressed exploratory a c tiv ity  but i t  also abolishes the depression of 
exp lora tory locom otor a c tiv ity  induced by morphine, but th is e ffe c t was not 
observed in the 300 ppm lead dose group. However, exposure to 1000 ppm 
lead also potentia ted the morphine induced hypoactiv ity  a fte r in jec tion  o f 
the m id dose o f morphine. Thus in 10 day old neonates lead appears to  delay 
the e ffec ts  o f morphine on locom otor a c tiv ity  to beyond the in it ia l 10 mins. 
exploratory period. The a c tiv ity  p ro file  fo r the remaining 50 mins. show a 
potentia ted e ffe c t o f morphine pa rticu la rly  w ith  the mid dose o f morphine. 
The low dose o f morphine is very close to the bottom  of a dose response 
curve while the high dose is close to the top of the curve and there fo re  
e ffec ts  at these doses may be masked. However between approxim ate ly 35 
and 50 mins. exposure to 1000 ppm lead does reduce a c tiv ity  below tha t o f
contro l animals at a ll doses of morphine.
In 21 day old rats lead trea tm ent no longer inh ib its the e ffe c t of 
morphine during the exploratory period but does potentia te  the hypoactiv ity  
caused by morphine again pa rticu la rly  w ith  the mid dose o f morphine. Lead 
exposure also increases the hypoactiv ity  of to ta l a c tiv ity  induced by 
morphine, however th is does occur during earlie r periods o f recording 
compared to tha t observed in 10 day old neonates.
4.5.5. Possible mechanisms of action o f lead on locom otor a c t iv ity .
The e ffe c t o f lead exposure on morphine modulation o f locom otor 
a c tiv ity  is d iffe re n t to tha t seen on morphine antinociception in the ta il 
immersion test, although using the protocol described in th is thesis there 
appears to be no e ffe c t o f lead exposure on the p-opioid receptors fo r which 
morphine is re la tive ly  selective (Paterson e t al., 1983). Lead exposure was 
shown to  depress exploratory a c t iv ity  at the high dose, only in 10 day old 
neonates. As a c tiv ity  levels over the to ta l hour long recording period were 
not a ffected  th is is unlike ly to  be a d irec t e ffe c t o f lead on locom otion but 
more like ly  to be an e ffe c t on the em otional state of the animal, depressing 
its  desire to explore or escape from  a novel environment. A s im ila r e ffe c t of 
lead exposure on the reaction o f rats to a novel environment was reported by 
B a rre tt & Livesey (1985).
The e ffe c ts  of lead exposure on the morphine induced depression of 
locom otor a c t iv ity  may be as a result o f th is early modulation o f em otional 
state. However there are several other a lternatives tha t should be 
considered. As described in th is thesis the p-opio id receptors fo r  which 
morphine is re la tive ly  selective are unaffected by this protocol o f lead 
exposure and therefore the a ffe c t o f lead must be a post receptor e ffe c t. As 
morphine inh ib its locom otor a c tiv ity  i t  is like ly  tha t the opioid system 
impinges on the m otor system in an inh ib ito ry  capacity. As lead ions have
been shown to depress neurally evoked release o f acetylcholine from  m otor 
nerve term ina ls (Kolton and Yaari, 1982) fu rthe r inh ib ition  of neural a c tiv ity  
may result in the po tentia tion  o f morphine induced hypoactiv ity  observed in 
these studies. The e ffec ts  o f lead on locom otor a c tiv ity  in the experiments 
described in th is thesis fo llow  blood lead levels, the greatest a ffe c t being 
seen in 10 day old animals when lead levels are highest. Therefore e ffe c ts  o f 
lead on locom otor a c tiv ity  may be a d irec t e ffe c t o f lead ions at the 
neuromuscular junction  and as lead levels in the body fa ll so the e ffe c ts  o f 
lead on locom otor a c tiv ity  and morphine modulation o f locom otor a c t iv ity  
decrease.
A lte rn a tive ly  lead may be a ffec ting  other neuro transm itte r systems, 
although the pro toco l o f lead adm in istra tion used throughout th is thesis did 
not a ffe c t noradrenaline, adrenaline or dopamine levels (Bailey & K itchen,
1986) although it  has been shown tha t low levels o f lead exposure may 
d iffe re n tia lly  a ffe c t neuro transm itte r receptor development (Rossouw et al.,
1987). A like ly  neuro transm itte r system to be involved w ith  the e ffec ts  o f 
lead on locom otor a c tiv ity  would be the dopamine system. The dopamine 
system is found p a rticu la rly  in the nucleus accumbens, an area o f the brain 
which plays an im portan t role as an in te rface  between lim b ic  structures and 
the m otor system (Yim  and Mogenson, 1982). Opioids have been shown to 
in te rac t w ith  the dopamine system in this area (Havemann and Kuschinsky, 
1985, Swerdlow et al., 1987 and Schoffelmeer e t al., 1987). D e lta-op io id  
receptors in ra t s tria tum  have been shown to  a ffe c t release o f dopamine in 
this area (P e tit et al., 1986) and in the studies reported in th is thesis 
perinata l lead exposure has a ffec ted  the development of 6 -opioid receptors. 
Perinata l lead exposure has also been shown to a ffe c t dopamine receptors 
(Lucchi e t ' a l., 1981 and Rossouw et al., 1987) although there is some 
disagreement in the lite ra tu re  (Winder and Lazareno, 1985). The circadian 
varia tion  reported fo r the e ffec ts  o f lead on locom otor a c tiv ity  (R e ite r et al.
1975; Collins et al., 1984 and Dolinsky et al., 1981) may also be a ttribu ted  to 
circadian variations in receptor binding indeed [ ] spiroperidol, a
dopamine receptor agonist, does show increased binding early in the dark 
phase as do some other receptors including opiate receptors (W irz-Justice,
1987).
4.6. General discussion and future experimental studies.
I t  appears tha t the opioid system is pa rticu la rly  sensitive to perinata l 
lead exposure. Blood lead levels produced by the lead dosing model discussed 
in this thesis during the postnatal period are s im ila r to those observed in 
children and below the 'safe lim its ' set fo r human blood lead levels by several 
in te rna tiona l authorities (Royal Commission Report, 1983). S im ilar exposure 
models have been shown not to produce e ffec ts  on levels o f other 
neurotransm itters (Bailey and K itchen, 1986) or on dopamine receptors 
(Winder and Lazareno, 1985). In addition the perinata l period o f exposure is 
im portant as development of the opioid system is occuring during this tim e. 
E ffec ts  o f lead exposure on antinociception and locom otor a c tiv ity  occured 
only during the developmental period indicating a capacity fo r recovery once 
development was com plete. Other tox ic  e ffec ts  were shown to persist in to  
adulthood, despite the re tu rn  to normal blood lead levels,, as was seen w ith  
<5-opio id receptor binding and corticosterone levels in basal, stressed and 
morphine trea ted animals.
A lthough blood lead levels were m onitored throughout the studies and 
did not reach levels associated w ith  overt to x ic ity  they are only an index of 
recent exposure. Most of the opioid linked e ffec ts  of lead exposure are 
re la ted to the CNS and may persist long a fte r blood lead levels had fa llen  and 
i t  would there fo re  be o f value to have a para lle l measure o f brain lead levels.
Perinatal lead exposure was found to depress both morphine and 
ketocyclazocine antinociception but this e ffe c t was only observed in the
early neonatal period w ith  recovery by 21-30 days. However the e ffe c t on 
morphine antinociception was not accompanied by an e ffe c t on the p-opioid 
receptors fo r which i t  shows se lec tiv ity  (James and Goldstein, 1984). This 
may suggest a post receptor e ffe c t o f lead which may involve a second 
messenger system such as adenylate cyclase or calcium  ions and channels. 
Some work has been reported on the e ffec ts  o f lead on these systems 
(Nathanson and Bloom, 1975; Goldstein and A rr, 1983; R ichardt et al., 1986, 
and Walsh and H arnett, 1986) but comparisons are d if f ic u lt  due to variations 
in lead exposure models. Further studies using the model o f perinata l lead 
exposure used in th is thesis on such systems may shed some lig h t on the 
mechanism o f action o f lead. As perinata l lead exposure also a ffec ted  
ketocyclazocine antinociception in the paw pressure test, a re la tive ly  k -  
opioid selective system (Tyers, 1980), the newly developed k -opio id selective 
ligands could be used to study k -opioid receptor binding in lead exposed 
animals to see i f  development o f these k-op io id  receptors are a ffected .
As stated above, perinata l lead exposure did not a ffe c t p-opioid 
receptor binding. To confirm  tha t this lack o f e ffe c t was not due to a d irec t 
e ffe c t o f the lead ion, which may be removed during the washing phases o f 
membrane preparation, i t  would be necessary to measure levels o f lead in 
both brain and membrane homogenate fo r comparison. The lack o f e ffe c t o f 
perinata l lead exposure on p-opioid receptor binding may also be a re fle c tio n  
o f gross measurements on the whole CNS. Measurements o f p-opio id 
receptor binding in discrete brain regions may produce d iffe ring  results. I t  
has been shown previously tha t both opioid binding (Bardo e t al., 1981; Recht 
et al., 1985 and Garcin and Coyle, 1976) and lead accum ulation (K le in  and 
Koch, 1981; Collins e t al., 1982 and Mykkanen et al., 1982) are dependent on 
the brain region studied.
In contrast to the lack o f e ffe c t o f perinata l lead exposure on the p- 
opioid receptor the 6 -opioid receptors had a decreased a f f in ity  fo r
[^H ID P D P E  throughout development and persists to adulthood. As these 
receptors are a ffected  by lead exposure the use o f 6 -opioid specific  agonists 
and antagonists may reveal e ffec ts  of lead in the whole animal. I t  has been 
postulated tha t the mechanism by which perinata l lead exposure a ffec ts . 6 - 
opioid receptors reported in th is thesis and opioid peptide levels (Bailey and 
Kitchen, 1985) is due to an e ffe c t on the proteins produced e ithe r fo r the 6 - 
opioid receptor or fo r the cleavage enzymes involved in peptide synthesis. 
Whether th is e ffe c t o f lead is at the prote in, RNA or DNA level can only be 
speculated but w ith  current advances in sequencing o f the receptor proteins 
and cleavage enzymes some progress in elucidating the site o f action o f lead 
may be made.
Perinata l exposure to  lead elevates plasma corticosterone levels 
p a rticu la rly  in 45 and 60 day old animals in addition lead exposure reduces 
morphine m odulation o f stress responses in 30 day old rats but th is e ffe c t is 
reversed by 60 days w ith  an increase in morphine m odulation o f stress 
induced rises in corticosterone levels. The mechanism of action o f perinata l 
lead exposure on corticosterone levels is com plicated as not only is the 
release o f corticosterone contro lled by various release hormones from  the 
hypothalamus and p itu ita ry  but a ll the hormones involved have feedback roles 
resulting in fu rthe r contro l o f the system. To elucidate the mechanism of 
action o f lead on this system its  e ffec ts  on each o f these contro l hormones 
would need to  be studied as w e ll as any e ffe c t on the feedback mechanisms. 
Even then changes in levels o f hormones may indicate e ffec ts  on production, 
release or metabolism of these hormones and not the specific  a c t iv ity  o f the. 
hormone w ith in  the system being studied.
Exp loratory locom otor a c t iv ity  is depressed in 10 day old neonates 
exposed perina ta lly  to 1000 ppm lead. In addition exposure to 1000 ppm lead 
potentia tes the hypoactiv ity  a fte r in jection  o f morphine in 10 day old 
neonates. This e ffe c t o f lead exposure on locom otor a c t iv ity  in 10 day old
neonates has been associated w ith  an a lte ra tion  o f the emotional state o f the 
animal. Measurement o f plasma corticosterone levels in these animals would 
indicate a stressed state although i t  has been reported that the response to 
stress such as in jection or exposure to ether is not present un til the th ird  
postnatal week (Bailey and K itchen, 1987; Haltm eyer et al., 1966 and 
Kakihana et al., 1974). As a stressed state, as evidenced by elevated plasma 
corticosterone levels, is observed in 45 and 60 day old animals trea ted w ith  
lead perina ta lly , i t  would be in teresting to measure possible variations in 
locom otor a c tiv ity  of these animals. Many other studies reported in the 
lite ra tu re  measure locom otor a c tiv ity  in adult animals a fte r  perinata l 
exposure to lead and find hyper- and hypo a c tiv ity  as w e ll as no e ffe c t 
(Section 1.8.2.1.).
Thus perinata l lead exposure pa rticu la rly  during periods o f development 
does a ffe c t the opioid system. These e ffec ts  may be long lasting and because 
o f the com plexity o f the opioid system are wide ranging. The mechanisms by 
which lead produces these e ffec ts  require fu rthe r studies and may be due to 
m u ltip le  e ffec ts  on various systems.
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S U M M A R Y
Administration of lead (at 300 and 1000 ppm) in the maternal drinking water from conception to wean­
ing impaired the antinociceptive activity of morphine in 10-day-old neonatal rats. Blood lead levels in 
these animals were below 50 /zg/100 ml in the high lead dose group and below 35 ^ g/100 ml in the low 
lead dose group. The differences in the antinociceptive potency of morphine between normal and lead- 
exposed animals were not observed at later time points (21 and 30 days). It is suggested that lead disrupts 
the development of opioid receptor systems in the central nervous system and that this disruption occurs 
early in development.
I N T R O D U C T I O N
The possibility that some neuropsychological disorders of childhood may result 
from environmental exposure to lead has received close scrutiny in recent years. 
That this neurotoxicity might occur due to an impairment of the development o f 
neurochemical systems in the brain has also been under investigation and we have 
recently reported that the development o f enkephalin levels is depressed and delayed 
in the striatum o f neonatal rats exposed to low levels o f lead (1]. We have extended 
these studies by measuring morphine antinociception in the normal and lead- 
exposed neonate as an indirect measure o f opioid receptor system development.
M E T H O D S
Lead (as the acetate) was administered in the maternal drinking water from con­
ception to weaning ( — 21 days to +21 days) as previously described [2]. Two virgin 
female Wistar albino rats (Charles River) o f equivalent starting weights were housed
0378-4274/84/$ 03.00 ©  Elsevier Science Publishers B.V.
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with 1 male/cage, and conception was determined by the presence of sperm in 
vaginal smears. Lead was administered (as the acetate, in distilled water) at two 
doses: 300 and 1000 ppm. The control groups received acetate (28 m M, pH 3.3) in 
the drinking water. The postnatal rats were weaned at Day 21 and subsequently 
maintained on tap water. Levels o f lead in tap water were below the limit o f detect­
ability. Blood lead levels in neonatal rats were determined after experimental pro­
cedures were complete. Trunk blood was collected and sonicated and lead determin­
ed by atomic absorption spectrophotometry [1].
Antinociceptive testing was carried out at 10, 21 and 30 days using the tail immer- 
’ sion test. Rat pups were held upright in the hand and the terminal 3 cm of the tail
(in 10-day rats) and 5 cm (in 21- and 30-day rats) was immersed in hot water main- 
\  tained at 50°C. Nociceptive reaction times were determined by a hand-held stop
watch and were taken as the point when the tip o f the tail was just withdrawn from 
the surface of the water. A maximum cut-off time o f 10 s was employed to prevent 
tissue damage. All animals were pretested 15 min before injection, and 15, 30 and 
60 min after injection of 0.9% saline or morphine sulphate. Doses of morphine 
sulphate used were 4, 8 and 16 mg/kg, 1, 2 and 4 mg/kg and 2, 4 and 8 mg/kg for 
10-, 21- and 30-day-old animals, respectively. A ll injections were subcutaneous in 
a volume of 0.05 ml (10-day rats) or 0.1 ml (21- and 30-day rats).
R E S U L T S  A N D  DISCUSSION
Table I shows the blood lead levels observed in neonatal rats. Although peak 
blood lead levels (21 days) were higher than the limits o f safety (35-40 n g / d l )  pro­
posed by several international authorities [3] for children, levels at 10 days after 
birth wepe below this limit in the lower lead dose group. In common with our 
previous studies [1 ,2 ] neonate and maternal weight gain was not impaired by lead 
treatment.
Fig. 1 shows the time course for the antinociceptive effects of morphine in 10-day- 
T A B L E  I
B L O O D  L E A D  L E V E L S  IN P O S T N A T A L  R A T S  ( j ig /1 0 0  ml) D E T E R M I N E D  BY A T O M I C  A B ­
S O R P T I O N  S P E C T R O P H O T O M E T R Y
Each value is the mean ± S.E.M. of at least 30 samples. Lead was administered in the maternal drinking 
water from conception to weaning ( - 2 1  to +21 days).
Dose of lead (ppm) Age (days)
10 21 30
0 1.2 ± 0.7 3.4 ± 1.2 n.d.
300 34.7 ± 1.3 118.6 ± 8.8 26.0 ± 2.7
1000 47.5 ± 2.5 163.5 ± 15.4 35.1 ± 2.6
n.d., not detectable.
121
10
38
8 25
6
4
2
10
8
6
4
2
10
2010
40
20
6030P r e
T i m e  A f t e r  I n j e c t i o n  ( m i n s j
Fig. 1. Antinociceptive effects of morphine in 10-day-old neonatal rats determined by the tail immersion 
test, (a) Control treated groups; (b) 300 ppm lead-dosed groups; (c) 1000 ppm lead-dosed groups. Each
graph shows tail immersion response time at 15, 30 and 60 min after injection of: •--- • , 0.9% saline;
■— ■ , 4 mg/kg morphine sulphate; A A ,'8 mg/kg morphine sulphate; or O  O, 16 mg/kg morphine
sulphate. Each point is the mean ± S.E.M. of at least 8 observations and each time course study was car­
ried out on separate animals. Figures alongside standard error bars refer to the %  of animals which show­
ed response times >  10 s. For graphical presentation response times >  10 s are denoted as 10 s. Statistical 
comparison of peak antinociceptive activity using repeated measurements analysis assuming WeibuII 
distribution for data to account for censored values (i.e. values >  cut-off time) 0 vs. 300 ppm data, 16 
mg/kg morphine P  <  0.05; 0 vs. 1000 ppm data 16 mg/kg morphine P  <  0.05.
122
old normal and lead-exposed rats. In the 300-ppm dose group (Fig. lb) there was 
a marked impairment o f the antinociceptive activity o f morphine. At 16 mg/kg mor­
phine, the peak response latency was reduced from 7.2 ±  1.1 s to 4.3 ±  0.9 s. Since 
tests that employ heat as the nociceptive stimulus are selective for ^-opioid receptor 
agonists (4] it seems likely that this effect o f lead is due to depression o f the on­
togeny o f /i-receptors in the neonate. In the higher lead dose group the antinocicep­
tive activity of morphine was not further impaired as might have been expected. In­
stead a complete lack o f dose-related responses to morphine was observed (Fig. lc). 
This may well reflect a more severe disruption o f the opioid receptor systems which 
mediate the antinociceptive effects o f morphine. Receptor binding studies should 
confirm if  this is the case and these are currently in progress.
No significant difference in the antinociceptive potency of morphine was observ­
ed in the 300-ppm lead-dosed animals 21 or 30 days after birth (Table II)  suggesting 
that the toxic effects of lead occur early in development and that responses of opioid 
systems at later stages are unaffected. Dose-related antinociceptive activity of mor­
phine was also restored in the 1000-ppm lead-dosed groups at 21 and 30 days. Only 
one dose o f morphine (4 mg/kg at 30 days) produced a significantly lower peak an­
tinociceptive response.
Most studies of the ontogeny o f /x-opioid receptor systems show that high affinity 
binding and morphine analgesia increase up to day 15 in the rat [5-7] and that 
development during this period is extremely rapid. Lead therefore appears to disrupt 
this development at a critical period and although morphine antinociception returns 
to normal by day 21 the pathophysiological consequences o f the earlier impairment 
o f the system might well be more serious. Similarly we have shown that striatal
T A B L E  II
TAIL I M M E R S I O N  R E S P O N S E  TIMES. 15 M I N  A F T E R  INJECTION O F  M O R P H I N E  S U L P H A T E  
IN 21- A N D  30-DAY-OLD N O R M A L  A N D  L E A D - E X P O S E D  R A T S
Values are the mean +  S.E.M. of 8 observations. Values >  cut-off time are included as the cut-off time.
Age (days) Dose of mor­
phine (mg/kg)
Response times (s) 
Dose of lead (ppm)
0 300 1000
21 1 3.5 ± 0.5 3.8 ± 0.2 3.5 ± 0.6
21 2 4.8 ± 0.7 6.6 ± 0.7 5.2 ± 0.4
21 4 8.6 ± 0.5 8.0 ± 0.5 8.5 ± 0.8
30 2 3.7 ± 0.3 4.6 ± 0.5 4.0 ± 0.7
30 4 6.5 ± 0.6 5.6 ± 1.0 5.5 ± 0.7
30 8 6.6 ± 1.2 6.9 ± 0.7 8.0 ± 0.8
Wilcoxon non-parametric rank test 0 vs. 300 ppm and 0 vs. 1000 ppm: no significant difference. C o m ­
parison of peak antinociception using complete dose-response curves (see legend to Fig. I) 0 vs. 300 ppm: 
no significant difference; 0 vs. 1000 ppm: P  >  0.05 (4 mg/kg at 30 days).
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enkephalin levels are significantly depressed by lead exposure up to day 21 [1] and 
thus there appears to be an impairment of both opioid neurotransmitter and recep­
tor development. It is becoming clear that opioid peptide systems are very sensitive 
to the toxic effects of lead.
R E F E R E N C E S
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Toxic Effects of Perinatal Lead Exposure on the Development of 8-Opioid receptors in Rat
Brain
J. McDowell & I. Kitchen
Department of Biochemistry, Division of Pharmacology &  Toxicology. University of Surrey, Guildford, Surrey, 
G U 2  5 X H . U K
W e  have previously reported that perinatal exposure to low levels of lead markedly impairs the development of 
the opioid peptide products of proenkephalin without exhibiting toxicity on other neurochemical systems.1-2 
W e  have addressed the question of whether disruption of these peptide neurotransmitters results in disruption of 
the receptors which mediate their effects and may accordingly produce disruption in behaviour. Our recent 
studies have shown that the development of p-opioid receptors is unaffected by perinatal lead exposure.3 W e  
report here studies on the development of 8-opioid receptors in lead exposed animals which may be more 
important in mediating the action of proenkephalin products.
Lead (as the acetate) was administered in the maternal drinking water (at 300 and 1000 ppm) from conception 
to postnatal day 14. Neonates were killed at 15. 21 and 35 d and 8-receptor functioning characterised using 
ligand-binding 'tudies employing the highly selective 8-site ligand [D-Pen2, D-PensJenkephalin. Receptor 
binding was carried out in Tris HC1 (pH 7.4) at 25°C for 40 min after preincubation to remove endogenous 
opioids. Ten concentrations of ligand were used in each assay to produce saturation curves with or without 10|jlm 
naloxone to determine non-specific binding. Scatchard analysis was used for determining K D and B max, and each 
value is the mean of 4 analyses. In control animals the number of 8-binding sites increased 2Vi fold between day 
15 and 35 (Bm;1* values: 15 d, 2.7 ±  0.3: 21 d. 4.9 ± 0.2: 35 d. 6.4 ± O.o fmol/mg tissue, results x  ±  s.e.m.). In 
common with our findings for the p-receptor the number of sites was not significantly altered by perinatal lead 
exposure at these ages. However in animals exposed to 1000 ppm Pb. 8-receptor affinity was increased by
30-50% at all ages (Kp values: 15 d, 12.8 ±  1.6 vs 16.6 ± 0.6:21 d. 11.3 ± 0.8 vs 14.8 ± 1.4; 35 d. 12.0 ±  1.5 vs 18.1 
± 2.2 nxt. results x ± s.e.m.). These results provide evidence that opioid receptor function can be disrupted by 
lead exposure. The toxicity appears to be selective to the 8 and not p. receptors.
This work was supported by The Wellcome Trust.
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ONTOGENY OF p-OPIOID RECEPTOR BINDING IN  RAT BRAIN AND 
THE EFFECTS OF PERINATAL LEAD EXPOSURE 
I. K itchen and J. M cDowell, Departm ent of B iochem istry, D ivision o f 
Pharmacology and Toxicology, University o f Surrey, G uildford, 
Surrey. GU2 5XH. U.K.
Studies in our laboratory have shown tha t the development o f 
s tria ta l proenkephalin products is markedly impaired in animals 
exposed to low levels of lead. In addition these animals show 
abnormal responses to the antinociceptive e ffects  of morphine and 
keto'cyclazocine. To investigate fu rthe r the lead induced disruption 
o f opioid ontogeny we have studied the development o f p-opioid 
binding using ( H) Tyr-D -A la-G ly-M ePhe-G ly-o l (DAGO). Lead (as 
the acetate) was administered in the m aternal drinking water (a t 100 , 
300 and 1000 ppm) from  conception to postnatal day 14. Neonates 
were k illed  at 10, 21 and 30 days and whole brain rapid ly removed. 
Receptor binding was carried out in T ris-H C l (pH 7.4) at 25 C fo r 40 
mins a fte r preincuJ^ation to remove endogenous opioids. 12 
concentrations of ( H) DAGO were used w ith  and w ithout lp M  
diprenorphine for determ ination o f non-specific binding. Scatch^rd 
analysis was used fo r determ ining and Bmax. The binding o f ( H) 
DAGO in 21 and 30 day old neonates is not a ffected by perinatal lead 
exposure. However pre lim inary experiments suggest tha t in 10 day 
old animals lead exposure may cause a reduction in K n  suggesting 
tha t opioid receptor functioning is altered in early postnatal 
development. Peak blood lead levels in neonates were w ith in  the 
range recognised to represent sub-clin ical lead to x ic ity .
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LOW LEVEL LEAD EXPOSURE ALTERS THE DEVELOPMENT OF MORPHINE 
ANT I NOCICEPTION IN THE RAT
I. Kitchen, J. McDowell, J.M. Wilson and C. Winder, Department of Biochemistry, 
University of Surrey, Guildford, Surrey, G U 2  5 X H
S o m e  neuropsychological disorders of childhood m a y  result from environmental exposure 
to lead and w e  have recently shown that low-level exposure to this metal depresses and 
delays the development of enkephalins in the striatum of neonatal rats (Winder et al. 
1983). W e  have extended these studies by measuring morphine antinociception in the 
normal and lead-exposed neonate as an indirect measure of opioid receptor system 
development.
Lead was administered at two doses (300 and 1000 pp m )  in the maternal drinking water 
from conception to weaning as previously described (Carmichael et al., 1982). 
Antinociceptive testing was carried out at 10, 21 and 30 days using the hot water tail 
immersion test at 50°C. The nociceptive end point was taken as the time of withdrawal 
of the tip of the tail from the water bath and a m a x i m u m  cut-off time of 10 seconds was 
employed. Animals were pretested 15 minutes before injection and 15, 30 and 60 minutes 
after injection of 0.9% saline or morphine sulphate (at three dose levels) subcutaneousty. 
After experimental procedures were completed trunk blood was collected and blood leads 
determined by atomic absorption spectrophotometry.
In the 300 p p m  lead dosed groups there was a significant impairment of the 
antinociceptive activity of morphine in 10 day old rats only at 16mg/kg where the peak 
response latency was reduced from 7.2 + 1 . 1  sec to 4.3 + 0.9 sec. In the 1000 p p m  lead 
dose group antinociceptive activity of morphine was observed but this was not dose 
related. Blood lead measurements at 10 days were 34.7 + 1.3 and 47.5 + 2.5pg/100 ml for 
the 300 and 1000 p p m  lead dosed groups respectively. The differences in the 
antinociceptive potency of morphine in normal and lead-exposed animals at 10 days were 
not observed at later time points (21 and 30 days).
It is suggested that lead m a y  disrupt the ontogeny of opioid receptor systems which 
mediate the effects of morphine, and that this disruption occurs early in development. It 
is becoming clear that opioid peptide systems are very sensitive to the toxic effects of 
lead. Whether this neurochemical toxicity is responsible for the behavioural disorders 
associated with lead exposure remains to be studied.
Carmichael, N.G., Winder, C. and Lewis, P.D. (1982) Toxicology, 21, 117-128.
Winder, C., Kitchen, I., Clayton, L.B., Gardiner, S.M., Wilson, J.M. and Lewis, P.D. (1983) 
Toxicol, appl. Pharmac., in press.
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~ DEVELOPMENT OF tf^OPIOIDJ^CEPTORS H  RAT BRAIN
CHARACTERISED BYCH ]- [D-Pen , D-Pen ] 
ENKEPHAUN BINDING
Ian Kitchen and Julia McDowell
Department of Biochemistry, Division of Pharmacology &  Toxicology, 
University of Surrey, Guildford, Surrey, G U 2  5XH, U.K.
A B S T R A C T
The development of rat brain 6 -opioid receptors has been studied in the 
postnatal period using the highly selective 6 -site ligand [ H ]  - [D-Pen , D- 
Pen ] enkephalin (DPDPE) in binding studies. Between day 10 and day 25 there 
was a three-fold increase in the number of binding sites (expressed per m g  
protein) and the K-. was constant throughout the postnatal period. Specific 
binding could not be detected earlier than day 10.
I N T R O D U C T I O N
There is good evidence that there is differential development of p, 6- and tc- 
opioid binding sites (Spain et al. 1985)The understanding of this heterogeneity has 
been hampered, however, because of the lack of selective ligands for the 
receptor subtypes.
With the recent availablity of ^ H - D P D P E  which has been shown to be a highly 
selective binding ligand for the 6 -opioid receptor (Cotton et al. 1985) an 
gccurate determination of 6 -site ontogeny has become possible. W e  report here 
H - D P D P E  binding in the postnatal period and reveal inconsistencies with 
previous ontogenetic studies using less selective ligands.
M E T H O D S
Wistar albino rats of mixed sexes were used in all experiments and receptor
binding assays (in Tris HCI, p H  7.4 at 25°C for 40 mins) were,carried out as
described by Cotton et al. (1985) in whole brain homogenates. H - D P D P E  (25-
27Ci/mmoI, Amersham) was purified by H P L C  prior to use. Scatchard analysis
of saturation curves was used to determine K ~  and B
U  m a x
R E S U L T S  A N D  DI S C U S S I O N
Table 1 shows the maximal binding capacities and affinities for ^ H - D P D P E  
during postnatal development. Specific binding was absent in animals less than 
10 days old and this contrasts with data forC H)- OD-Ala , D-Leu ] enkephalin 
(DADL) where binding was reported during the first postnatal week (Spain et al. 
1985). In addition the three-fold increase in number of binding sites between the 
^econd and fourth postnatal week is of a greater magnitude than reported for 
H - D A D L .  In r o m m o n  with all ontogenetic binding studies using opioid ligands 
the affinity of H - D P D P E  remains constant during postnatal development.
In conclusion this study is the first report of <5-receptor ontogeny using a ligand 
highly selective for this receptor and confirm that the major development of 6 - 
receptors occurs between the second and fourth postnatal weeks. It should be 
pointed out however that difficulties were encountered in obtaining acceptable 
Scatchard plots in young animals due to the low specific binding of H - D P D P E  
and this poses problems in the use of this ligand for ontogenetic studies.
i *  — TABLE 1- Binding characteristics of ?H] - [D-Pen^, D-Pen^ J 
enkephalin In the developing rat brain
Age
(days)
Dissociation constant 
(Kd , nM)
Binding capacity 
(Bm a x » fmol/mg protein)
10 10.5 +1.9 34.5 + 6.2
15 10.2 + 1.7 49.3 + 4.6
21 9.7 + 1.1 78.6+ 7.5
25 12.7 + 2.7 102.8 + 13.6
30 9.7 + 0.9 107.6 + 6.1
35 9.7 + 1.4 111.8 + 15.2
40 8.5 + 0.5 103.3 + 11.5
45 11.1 + 1.8 119.4 + 11.2
50 7.2 + 0.4 99.9 + 12.0
Values' are the m e a n  + s.e.m. of 4 Scatchard plots.
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The ontogenesis of 8-opioid receptors has been studied in the postnatal period up to day 50 using the highly selective 
8-site ligand [3H][D-Pen2,D-Pen5]enkephalin ([3H]DPDPE) in binding studies. Analyses of saturation curves revealed 
marked increases in binding capacities between the second and fourth postnatal week with little change in affinity. In 
contrast to findings with [3 H][D-Ala2,D-Leu5 jenkephalin binding could not be detected before postnatal day 10 which 
may be associated with the low affinity and specific activity of DPDPE. A low specific binding for [3H]DPDPE poses 
methodological problems in the use of this ligand for ontogenic studies.
[D-Pen2,D-Pen5 jenkephalin; Opioid ontogeny; 8-Receptor binding
1. Introduction
Both ligand binding studies and autoradiogra­
phy have been employed to study opioid receptor 
development in foetal and neonatal animals. There 
are clear indications that there is differential post­
natal development of ju-, 8- and /c-opioid binding 
sites, from both binding studies (Spain et al., 
1985; Tavani et al., 1985) and autoradiography 
(Loughlin et al., 1985). However the understand­
ing of the heterogeneity of opioid receptors has 
been hampered because of the lack of selective 
ligands for the receptor subtypes, in particular for 
the 8- and /c-sites.
The introduction and availability of [3H][D - 
Pen2,D-Pen5 jenkephalin ([3H]DPDPE) which has 
been shown to be a selective binding ligand for the 
8-opioid receptor (Mosberg et al., 1983; Cotton et 
al., 1985) has raised the possibility of providing a 
clearer picture of the development of this receptor 
subtype. To this end we have studied the ontogen­
* To w h o m  all correspondence should be addressed.
esis of 8-opioid binding sites in rat brain using 
[3H]DPDPE for comparison with the previously 
reported ontogeny of this receptor using far less 
selective ligands.
2. Materials and methods
Wistar albino rats of mixed sexes were used in 
all experiments. Animals were equilibrated in a 
quiet laboratory 24 h before experimentation and 
experimental procedures begun between 8 :30 and 
9 :30  h. Pre-weanling pups were removed from the 
maternal cage immediately before killing.
Wistar albino rats of mixed sexes were used in 
all experiments. Receptor binding assays were car­
ried out as described by Cotton et al. (1985) and 
Gillan and Kosterlitz (1982) in whole brain homo- 
genates from neonates age 10, 15, 21, 25, 30, 35, 
40, 45 and 50 days. For neonates up to 21 days 
pooled brain tissue was used for each binding 
assay and for animal >  21 days a single brain was 
employed. [3H ]DPDPE (25-27 C i/m m ol, Amer- 
sham) was purified by HPLC (Bailey and Kitchen,
0014-2999/86/$03.50 ©  1986 Elsevier Science Publishers B.V.
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1985) prior to use. Ten concentrations of ligand 
(0.2-25 nM ) were used in each assay (in Tris HC1, 
pH  7.4 at 25 °C  for 40 min) to produce saturation 
curves with or without 10 jaM naloxone to de­
termine non-specific binding. Scatchard analysis 
was used to determine the equilibrium dissociation 
constant (K D) and maximal binding capacity 
(Bmax)- Values of Bmax were calculated per g wet 
weight of tissue, per brain and per mg protein 
after determination of protein concentrations in 
brain homogenates by the method of Lowry (1951). 
Linear Scatchard plots with correlation coeffi­
cients (r) >  0.82 were considered suitable for data 
inclusion.
3. Results
Table 1 shows the binding capacities and affini­
ties for [3H]DPDPE during postnatal develop­
ment. Specific binding was absent in animals less 
than 10 days old and it was not possible to obtain 
acceptable Scatchard plots. Even in 10 days old 
neonates non-specific binding represented over 
70% of the total. Between day 10 and day 25 there 
was a 6.9-fold increase in the number of binding 
sites for [3H]DPDPE when expressed per whole 
brain. This increase was 4.5-fold and 3-fold when 
expressed per mg wet weight tissue or per mg 
protein respectively (table 1). Brain protein con­
centrations increased 1.5-fold during this period.
Binding affinities for [3H ]DPDPE were not sig­
nificantly different throughout the postnatal 
period.
Specific binding for [3H]DPDPE between day 
21 and day 30 was 50-60%but at ages below 21 
days the specific binding was greatly reduced. 
Indeed in 50% of experiments at 10 days linear 
Scatchard plots were not obtained.
4. Discussion
The characteristic of the development of 5- 
opioid binding sites using [3H]DPDPE as a bind­
ing ligand are broadly speaking similar to those 
reported for [3 H ][D -A la2,D -Leu5 Jenkephalin 
(D A D L ) when the ju-binding of this ligand is 
suppressed using an excess of unlabelled [D- 
Ala2,G ly5ol]enkephalin (Spain et al., 1985). There 
are some differences worthy of note which may 
reflect the greater selectivity of [3H]DPDPE for 
6-sites. For example the lack of binding for 
[3H]DPDPE before day 10 contrasts with data for 
[3H [D A D L  where binding was reported, albeit at 
a low level during the first postnatal week, when a 
small number of low affinity sites could be de­
tected (Spain et al., 1985). In  addition only a 
3-fold or 1.5-fold increase in binding sites for 
[3H ]D A D L  is observed between day 10 and day 
28 in rat forebrain when expressed per mg wet 
weight tissue or protein respectively (Spain et al.,
T A B L E  1
Dissociation constants, binding capacities and specific binding ratio of [3H][D-Pen2,D-Pen5]enkephalin in the developing rat brain. 
Values for K D and Bmax are the means ±S.E. of 4 Scatchard plots.
Age
(days)
Dissociation 
constant 
( Kd , nM)
Binding capacity (B 
pmol/brain
'max )
pmol/g wet wt. fmol/mg prot.
Specific binding ratio
(mean -Pec^*c bound) 
total
10 10.5 +  1.9 1.4+ 0.2 1.3 +  0.2 34.5 ±  6.2 0.28
15 10.2 +  1.7 3.3+ 0.3 2.3 ±0.2 49.3 ±  4.6 0.39
21 9.7 ±1.1 7.3 +  0.6 4.8 ±0.4 78.6 ±  7.5 0.52
25 12.7 +  2.7 9.6+ 0.9 5.9 ±0.7 102.8 ±13.6 0.54
30 9.7+ 0.9 10.2 +  0.7 5.8 ±0.6 107.6 ±  6.1 0.57
35 9.7+ 1.4 11.4±0.8 6.7 ±0.5 111.8±15.2 0.59
40 8.5+ 0.5 11.1 +  1.1 6.1 ±0.5 103.3 ±11.5 0.57
45 11.1 +  1.8 14.5 +  1.1 7.7 ±0.5 119.4±11.2 0.58
50 7.2+ 0.4 11.9 +  1.6 6.3 ±0.7 99.9 ±12.0 0.61
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1985). This contrasts with a 4.5-fold and 3-fold 
increase in sites for this study with [3H]DPDPE. 
The lower increases in maximal binding capacities 
when expressed per mg protein is recognised as a 
reflection of increases in general protein con­
centrations within the brain and this was borne 
out from experimental data. In  common with 
ontogenic studies using [3H ]D A D L  binding affini­
ties remain constant from postnatal day 10 and 
the full development of 5-sites occurs at around 
the fourth postnatal week.
The problem of a relatively low specific binding 
for [3]DPDPE has been addressed by other 
workers. Specific binding of 50-60% in our adult 
animals accords with the data of Cotton et al. 
(1985) though figures as low as 26% have been 
reported when [3H]DPDPE is used at incubation 
temperatures of 35 °C  and this leads to a large 
experimental variation (Delay-Goyet et al., 1985). 
The high non-specific binding observed at early 
postnatal ages may be due to a relatively low 
affinity of [3H]DPDPE compared to other 5- 
ligands combined with a smaller proportion of 
sites at these ages. Alternatively there may be 
other high affinity non-opioid sites present in brain 
homogenates prepared from early postnatal rats to 
which [3H ]DPDPE binds.
In  conclusion, this study is the first report of 
5-receptor ontogeny using a ligand highly selective 
for this receptor. It  confirms that the major devel­
opment of 5-receptors occurs between the second 
and fourth postnatal week and that receptor affin­
ity is constant during development. In  addition 
[3H]DPDPE binding could not be detected before 
postnatal day 10.
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S U M M A R Y
The development of ketocyclazocine antinociception has been measured in lead-exposed rats as an in­
direct determinant of x-opioid receptor system development. Perinatal lead administration (at 300 and 
1000 ppm) in the maternal drinking water from conception to weaning, impaired the antinociceptive ac­
tivity of ketocyclazocine (using the paw pressure test) in 10-day-old rats. Lead caused a dose-dependent 
impairment of ketocyclazocine antinociception, the paw pressure threshold for 0.4 mg/kg being reduced 
from 207 g to 135 g in the 1000 ppm lead dose-group. Ketocyclazocine antinociception was impaired in 
the high-lead dose-group at 21 days, but unaffected at 30 days. Blood lead levels in 10-day-old animals 
were below 35 g g /1 0 0 ml in the low-lead dose-group and below 50 g g /1 0 0 ml in the high-lead dose-group. 
It is suggested that lead may disrupt the development of x-opioid receptor systems in the central nervous 
system and that this disruption occurs early in development.
I N T R O D U C T I O N
Some of the neuropsychological disorders of childhood that have been associated 
with environmental exposure to lead may be due to impaired neurochemical func­
tion [1]. We have been studying the development of opioid peptide systems in rats 
exposed to low levels of lead, and have recently reported that the ontogeny of 
striatal enkephalin is depressed and delayed by lead [2]. In addition, the develop­
ment of morphine antinociception is also impaired in lead-exposed animals [3]. We 
have extended these studies by measuring ketocyclazocine antinociception as an in­
direct index of x-opioid receptor system ontogeny.
0378-4274/85/$ 03.30 ©  Elsevier Science Publishers B.V.
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M E T H O D S
L e a d  d o s in g  a n d  b l o o d  l e a d  d e t e r m i n a t i o n s
Lead was administered in the maternal drinking water from conception 
( - 2 1  days) to weaning ( +  21 days) as previously described [4]. In  brief, lead was 
administered (as the acetate, in distilled water) at 2 doses, 300 and 1000 ppm, and 
the control groups received acetate (28 m M , pH 3.3) in the drinking water. A t birth, 
litters were weighed, culled to 8 per litter and cross-fostered within experimental 
groups. Rat pups were weaned at day 21 and subsequently maintained on tap water.
Body weight and maternal fluid intake were monitored throughout lead ad­
ministration. Trunk blood was collected when experimental procedures were com­
plete and stored at -  20°C for later analysis. Blood samples were sonicated and lead 
levels determined by atomic absorption spectrophotometry, as previously described 
[21.
A n t i n o c i c e p t i v e  t e s t in g
All animals were equilibrated in a quiet, constant light-cycle laboratory (lights on 
07:00-19:00 h) 24 h before experimentation. A ll antinociceptive testing was carried 
out between 13:30 and 16:00 h in 10-, 21-, and 30-day-old neonatal rats. 10-Day-old 
pups were removed from their mother 5 min before injection and testing and return­
ed afterwards, to minimise stress-related responses. To eliminate inter-litter varia­
tions and variability between testing days, litters of 8 were divided so that on each 
occasion 2 animals were used for each dose of ketocyclazocine and saline. Each 
point on the dose-response curves therefore represents the mean of 8 animals tested 
on 4 separate days. Testing of control and lead-treated groups of different ages was 
randomly distributed throughout the study. Drug injections were carried out blind 
to remove operator bias.
The antinociceptive effects of ketocyclazocine were determined in neonates using 
the paw pressure test with a modified analgesy-meter [5]. This modification applies 
pressure to the paw from a 3-mm-diameter bar placed across the full width of the 
neonate paw. A  nociceptive response was taken as paw withdrawal or body flinch. 
A  maximum cut-off weight of 250 g, 500 g and 750 g was used for 10-, 21-, and 
30-day-old rats, respectively, to prevent paw damage.
A ll animals were pretested 10 min before injection of 0.9% saline or 
ketocyclazocine, and only once after drug administration. A ll injections were sub­
cutaneous (in the neck region) in a volume of 0.05 ml for 10-day-old neonates and 
0.1 ml for 21- and 30-day-old rats. The dose range employed for ketocyclazocine 
was 0.1-0.8 mg/kg for 10- and 30-day-old rats and 0.05-0.4 mg/kg for 21-day-old 
rats. These dose ranges gave pressure thresholds close to the cut-off values for the 
top dose. 10-Day-old rats were tested 30 min after injection, and 21- and 30-day-old 
animals at 10 min after injection. These times corresponded to the peak antinocicep­
tive activity of ketocyclazocine. Both hind-paws were tested and the mean of these 
2 results used as a single observation.
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S t a t i s t i c a l  p r o c e d u r e s
Maternal weight gain and fluid intake was analysed by the Minitab statistical 
package with analysis of variance (Pennsylvania State University).
Dose-response curves for ketocyclazocine were analysed by straight-line regres­
sion. A D 50 values (defined as the dose required to increase antinociceptive responses 
to half the cut-off weight) were computed from the full dose-response curves.
R E S U L T S  A N D  DISCUSSION
Lead produced a small but significant increase in the threshold at which nocicep­
tive responses were elicited 10 days after birth, but had the opposite effect in 30-day- 
old animals (Table I). This might suggest that lead impairs the development of pain 
pathways, which later compensate for this depression. However, in our previous 
study using the tail immersion test, lead was without effect on nociceptive thresholds 
[3] though in adult rats exposed to lead an increase in latencies in the hot-plate test 
has been reported [6].
Table I I  shows the antinociceptive activity of ketocyclazocine determined from 
full dose-response curves. A t 10 days, lead caused a significant dose-dependent im­
pairment of the antinociceptive activity of ketocyclazocine. A t 0.4 mg/kg, the 
pressure required to elicit a nociceptive response was reduced from 230 ±  11 g in 
control rats to 135 ±  9 g in 1000 ppm lead-treated animals. A t 21 days, the an­
tinociceptive activity o f ketocyclazocine was restored in the low-lead dose-group but 
still impaired in the high-lead dose-group. A t 30 days, antinociceptive responses in 
both lead-dosed groups were restored to the control level. The impairment of 
ketocyclazocine antinociception probably reflects an impaired development of the 
K-opioid receptor system, since it is likely that ketocyclazocine mediates its effects 
via K-rather than ^-receptors in the paw pressure test [7]. In addition, the effect of 
lead on antinociceptive responses to the /^-agonist morphine is dissimilar [3] and this
T A B L E  I
E F F E C T  O F  L E A D  O N  N O C I C E P T I V E  R E S P O N S E S  IN U N T R E A T E D  N E O N A T E  R A T S  U S I N G  
T H E  P A W  P R E S S U R E  TEST
Dose of lead (ppm) Paw pressure response weight (g)
Age (days)
10 21 30
0 41 ± la 97 ± 3 162 ± 5
300 46 ± 2* 95 ± 3 134 + 4***
1000 49 _i_ 2*** 93 ± 3 132 ± 4***
a Each value is the x  ± S E M  of at least 40 observations. The data represent pretest values for animals 
subsequently treated with 0.9% saline or ketocyclazocine. There were no significant differences between 
saline treated and naive neonates.
* P<0.05, *** P < 0.001 (t-test, control vs. lead-treated).
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TABLE II
E F F E C T  O F  L E A D  O N  K E T O C Y C L A Z O C I N E  A N T I N O C I C E P T I O N  IN N E O N A T E  R A T S
Dose of lead (ppm) AD50 values3
Age (days)
10 21 30
0 0.23 ± 0.021 0.16 ± 0.013 0.42 ± 0.039
300 0.31 ± 0.020* 0.20 ±  0.023 0.40 ± 0.025
1000 0.34 ± 0.016*** 0.25 ± 0.019** 0.34 ± 0.033
a A D 50 values are the mean doses (mg/kg) ± S E M  required to increase paw pressure response to half 
of the cut-off weight (125 g for 10-day; 250 g for 21-day and 375 g for 30-day). Values are computed 
from the full dose-response curves (see statistical procedures). Lead was administered in the maternal 
drinking water from conception to weaning.
* P<0.05, ** P<0.01, *** P<0.001. (/-test, vs. 0 ppm control groups).
may reflect differences in the toxic effect of this metal on the 2 opioid receptors, 
since there is a differential development of these 2 systems [8]. However, it should 
be stressed that different antinociceptive tests were employed for the morphine and 
ketocyclazocine studies, and that this too may be a factor in the differential effects 
o f lead. The possibility of an effect of lead on the pharmacokinetics of 
ketocyclazocine cannot as yet be discounted, but levels of morphine in the brain are 
unaltered after perinatal lead exposure (Kitchen and McDowell, unpublished).
Peak blood lead levels (21 days; Table I I I )  were much higher than in our previous 
studies employing the same lead-dosing protocol [2-4]. However, levels at 10 days 
corresponded very well with previous measures. Preliminary studies into the 
variability of lead levels in 21-day-old neonates suggest that neonates may be obtain­
ing lead directly from the drinking water in addition to the maternal milk supply, 
since the water bottles are accessible from an age of about 15 days. Despite the 
relatively high lead levels in 21-day-old animals, there were no indications of overt 
toxicity, since neonate weight gain and maternal fluid intake were not significantly 
altered by lead administration at either 300 or 1000 ppm. It  should be noted that 
the major effects on opioid responses occur in 10-day-old animals whose blood lead
T A B L E  III
B L O O D  L E A D  L E V E L S  IN P O S T N A T A L  R A T S  Oig/100 ml) D E T E R M I N E D  B Y  A T O M I C  
A B S O R P T I O N  S P E C T R O P H O T O M E T R Y
Dose of lead (ppm) Age (days)
10 21 30
0 3 ± 0.3a 1 ± 0.2 0.4 ± 0.1
300 33 ± 1 91 ± 12 19 ± 1
1000 49 ±  2 230 ± 19 34 ± 1
a Each value is the mean ± S E M  of at least 30 samples. Lead was administered in the maternal drinking 
water from conception to weaning.
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levels are around the limits of safety proposed by several international authorities 
[91.
In  conclusion lead appears to disrupt the development of antinociceptive response 
to ketocyclazocine, and this impairment differs from the effects on morphine an­
tinociception [3]. Although it is too early to gauge the importance of this disruption 
it is becoming clear that opioid peptide neurotransmitters and their receptors are 
very sensitive to lead. Whether this neurochemical toxicity is responsible for the 
behavioural disorders associated with lead exposure remains to be studied.
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P e r i n a t a l  l e a d  e x p o s u r e  a l t e r s  t h e  d e v e l o p m e n t  o f  / -  
b u t  n o t  ^ o p i o i d  r e c e p t o r s  i n  r a t  b r a i n
Julia M cD ow e ll &  1 Ian K itchen
Department of Biochemistry, Division of Pharmacology &  Toxicology, University of Surrey, Guildford, 
Surrey, GU2 5XH
1 Low level lead exposure has been shown to impair the development of opioid peptide levels in 
the brain, and to impair antinociceptive responses to opioid drugs. We have now studied the effects 
of lead exposure on the development of opioid receptors using ligand binding studies.
2 The ontogenesis of //- and 6-opioid binding sites was studied using rat whole brain membranes 
and [ 3H]-[D-Ala2MePhe*-Gly-ol]enkephalin and [ 3H]-[D-Pen2,D-Pen3]enkephalin as binding 
ligands. Rats were exposed to lead during development by addition of lead acetate (at 100- 
1000 p.p.m.) to the maternal drinking water from conception to postnatal day 14.
3 Perinatal lead exposure had no significant effects on the binding affinity (K D) or binding capac­
ity ( B ^ J  for the //-opioid receptor measured at postnatal days 10, 21 and 30. Lead exposure (at
1000 p.p.m.) increased the K D for the 6-opioid receptor at postnatal days 15, 21, 35 and 50 but had / .
no effect on the binding capacity. No indications of overt toxicity were observed and blood/levels L . '
were in the ranges considered to represent subclinical lead toxicity in man. t--
4 The lack of effect of lead on //-receptor binding contrasts with previously described impairment 
of antinociceptive effects of //-agonists suggesting that the toxicity is not manifested at the //-binding 
site. However, the 6-opioid receptor appears to be more sensitive to lead exposure and the persist­
ent changes in 6-site affinity after cessation of lead exposure suggest irreversible damage in the 
production of the receptor protein.
Introduction
Certain behavioural abnormalities have been associ­
ated with environmental exposure to lead in children 
(Royal Commission Report, 1983) and the possible 
mechanisms underlying this behavioural toxicity has 
been the subject of several experimental animal 
studies over the last 20 years (for review see Winder 
& Kitchen, 1984). The dopaminergic system has been 
identified as being sensitive to low level lead expo­
sure and, recently, in our laboratory we have shown 
disruption of endogenous opioid systems using an 
experimental model of lead exposure which gives 
blood lead levels in neonatal rats corresponding to 
levels representative of sub-clinical lead toxicity 
(Royal Commission Report, 1983). This disruption is 
indicated by delayed ontogeny of striatal proenkep­
halin products which can be reduced by 96-100% in 
lead-treated animals at postnatal day 10 (Bailey &  
Kitchen, 1985). These toxic effects appear to be selec­
tive, since monoamines and y-aminobutyric acid are
1 Author for correspondence.
unaffected by the same lead treatment (Bailey &  
Kitchen, 1986). Other indications of toxic effects on 
opioid systems include impaired responses to the 
antinociceptive actions of the opioid drugs morphine 
(Kitchen e t a l . , 1984) and ketocyclazocine (Kitchen 
& McDowell, 1985).
In the light of impaired peptide function and anti­
nociceptive effects of opioids, we have entertained 
the possibility that the ontogeny of opioid receptor 
sites in the brain may be altered by perinatal expo­
sure to lead. We describe here the ontogeny of //- 
and 6-opioid receptors, using ligands highly selective 
for these sites, in lead-treated rats. ,
M e th o d s
A n im a ls  a n d  le a d  d o s in g
Lead (as the acetate in distilled water) was adminis­
tered to female Wistar albino rats (University of 
Surrey strain) in the drinking water as described by
©  The Macmillan Press Ltd 1988
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Table 1 Effect of perinatal lead exposure on the ontogenesis of //-opioid receptor binding capacity
L e a d l 3H ] - D A G O L
A g e dose B ind ing  c a p a c ity (B,nu)
(days) (p.p.m.) pmol/brain fmolmg -1 wet wt. fmolmg -1 protein
10 0 3.5 ±  0.46 3.1 ±  0.37 56.2 ±  7.1
100 3.2 ±0.26 3.2 ±  0.29 61.5 ±  6.8
300 3.8 ±  0.42 3.7 ±  0.40 69.4 ±  5.3
1000 3.6 ±  0.29 3.7 ±  0.28 68.6 ±  5.9
21 0 14.2 ±  1.50 9.4 ±  1.03 134 ±  15.9
100 15.6 ±  0.60 10.2 ±  0.30 141 ±  4.1
300 12.6 +  1.94 8.1 ±  1.19 118 +  17.8
1000 12.9 ±  0.97 8.4 ±  0.70 129 ±  9.8
30 0 14.8 ±  1.48 8.8 ±  0.79 120 ±  9.8
100 19.0 ±  0.85 11.5 ±0.42 150 ±  10.7
300 16.6 +  1.30 10.1 ±  0.90 127 +  12.9
1000 15.4 ±  0.77 9.6 ±  0.44 125 ±  7.7
Lead was administered in the maternal drinking water from conception to postnatal day 14. //-Receptor binding 
was determined using [3H]-[D-Ala2-MePhe4-Gly-ols]enkephalin ([3H ] - D A G O L )  as the binding ligand. Specific 
binding was > 8 0 %  in all determinations. Each value represents mean ±  s.e. mean of at least 5 Scatchard analyses. 
One-way analysis of variance for lead groups at each age - no significant differences.
Carmichael e t a t. (1982), with modifications of the 
dose and duration of administration. Control groups 
were treated with acetic acid and lead groups were 
given lead acetate made up in acetic acid. For this
Age (days)
Figure 1 Effects of perinatal lead exposure on the 
ontogenesis of //-opioid receptor affinity. Lead (Pb) was 
administered in the maternal drinking water from con­
ception to postnatal day 14. Open columns, 0 p.p.m. 
Pb; stippled columns, 100p.p.m. Pb; hatched columns, 
300p.p.m. Pb; cross-hatched columns, lOOOp.pan. Pb. 
//-Binding was determined using [3H]-[D-Ala2- 
MePhe4-Gly-ol3]enkephalin as the binding ligand and 
each value represents mean of dissociation constants 
determined from at least 5 Scatchard analyses; vertical 
lines indicate s.e. mean. One-way analysis of variance 
for lead groups - no significant difference.
study 3 doses of lead were employed: 100, 300 and 
1000p.p.m. and were administered from conception 
( — 21 days) to postnatal day 14. Maternal weight 
gain and fluid intake were monitored throughout, 
and litter size and neonate weight gain measured in 
the postnatal period. Neonates were killed at 10, 21 
and_30_days for studies of //-receptor-development 
and at 15, 21, 35 and 50 days for studies of 6- 
receptor development. Trunk blood was collected for 
determination of blood lead levels as previously 
described (Bailey & Kitchen, 1985) and brain tissue 
rapidly removed for use in receptor binding assays.
R e c e p to r  b in d in g  a ssays
Whole brain homogenates were prepared as 
described by Gillan and Kosterlitz (1982). For neon­
ates up to 21 days, pooled brain tissue was used for 
each binding assay and for animals >21 days jn a 
single brain were employed. For //-receptor binding 
[3H]-[D-Ala2MePhe4Gly-ol]enkephalin (DAGOL, 
57-60Cimmol-1, Amersham) was used as a binding 
ligand, and for 6-receptor binding [ 3H]-[D-Pen2,D- 
Pen5]enkephalin (DPDPE, 25-27Ci mmol-1 , Amer­
sham) was used. Both ligands were purified by h.p.l.c. 
(Bailey & Kitchen, 1985) before use.
Twelve concentrations of DAGOL (40pM-llnM) 
and ten concentrations of DPDPE (0.2-25 nM) were 
employed in each assay. Binding incubations were 
carried out in Tris HC1, pH 7.4 at 253C for 40min to 
produce saturation curves; 1 /zm diprenorphine and 
10 /zm naloxone were used to determine non-specific 
binding of DAGOL and DPDPE, respectively. Scat-
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Table 2 Effect of perinatal lead exposure on the ontogenesis of <5-opioid receptor binding capacity
A g e
(days)
L e a d
dose
(p-p-m.) pmol/brain
[ 3H ] - D P D P E  
B in d in g  c a p a c ity (Bm„) 
fmol m g -1 wet wt.
\b in d ina  
fmolmg -1 protein
, Specific  
 ^ ra t io
15 0 3.7 ±0.34 17 +  0.26 47.5+ 3.6 0.33
300 3.6 ±  0.41 17 +  0.25 55.3 ±  5.8 0.30
1000 3.6 ±  0.31 2.8 ±  0.23 49.8 ±  4.5 0.29
21 0 7.4 ±  0.32 4.8 +  0.23 79.0 ±  3.9 0.48
300 6.3 ±  0.62 4.2 ±  0.46 73.4 ±  12.7 0.42
1000 7.4 ±  0.36 4.9 ±  0.17 75.8 ±  3.2 0.45
35 0 10.7 ±  0.77 6.2 ±  0.49 93.1 ±  8.9 0.53
300 10.5 ±  0.39 6.4 ±  0.13 94.2 ±  5.1 0.53
1000 14.0 ±  0.51 8.1 ±  0.40 127.2 ±  14.2 0.51
* \ 0 12.1 ±  1.25 6.4 +  0.62 102.5 ±  11.0 0.53
300 10.7 +  0.71 5.9 ±  0.35 92.7 ±  3.9 0.49
1000 12.2 ±  1.60 6.6 ±  0.79 97.7 ±  9.9 0.47
Lead was administered in the maternal drinking water from conception to postnatal day 14. ^ -Binding was deter­
mined using [3H]-[D-Pen245-Peni]enkephalin ([3H]-DPDPE) as the binding ligand. Specific binding ratio rep­
resents the mean of specific binding divided by total binding. All values represent mean ±  s.e. mean of at least 5 
Scatchard analyses. One-way analysis of variance for lead groups at each age - no significant differences.
chard analysis was used to determine the equilibrium 
dissociation constant (KD) and maximal binding 
capacity ( B ^ J .  Values for B ^  were determined per 
mg wet weight tissue and per mg protein after deter­
mination of protein content by the method of Lowry 
e t a l . (1951).
Results
receptor affinity remaind constant during postnatal 
development but the  ^number of binding sites 
increased 2-3 fold between day 15 and day 35 
(Table 2, Figure 2). The number of 5-sites measured 
throughout the postnatal period and up to 50 days 
was not significantly altered by perinatal lead expo­
sure and in animals treated with 300 p.p.m. lead 
DPDPE affinity was also not altered. However, in 
the 1000p.p.m. lead-treated groups the' K D -for 
DPDPE was increased by up to 50% at all ages 
studied (Figure 2).
E f fe c t  o f  le a d  o n  r e c e p to r  o n to g e n y
/i-Opioid receptor affinity remained constant during 
postnatal development but the number of binding 
sites increased 2-3 fold in the third postnatal week. 
Perinatal lead exposure had no significant effects on 
either K D or for [3H]-DAGOL binding at any 
of the ages studied (Table 1, Figure 1). 5-Opioid
B lo o d  le a d  le v e ls  a n d  e ffe c ts  o n  b o d y  w e ig h t
Blood lead levels are shown in Table 3. Peak blood 
leads were observed at postnatal day 15 immediately 
after cessation of lead administration to the mother. 
Thereafter blood lead levels fell and reached control 
levels by day 30. There were no significant correla­
tions between blood lead levels and DPDPE K D in
Table 3 Blood lead levels (^g 100ml" *) in postnatal rats determined by atomic absorption spectrophotometry 
Dose o f  lead  A g e (days)
(p.p.m.) 10 15 21 3 0 3 5 5 0
0 1.5 ±  0.9 1.0 ±  0.7 0.39 ±  0.29 0.14 +  0.1 N D 0.8 ±  0.8
100 16.6 +  3.0 — 0.90 ±  0.4 1.4 +  0.5 — — :
300 219 ±  3.4 23.9 ±  3.0 7.4 +  1.3 1.6 ±  0.7 1.2 ±  1.2 0.4 +  0.4
1000 27.6 ±  2.4 28.2 ±  3.0 15.0 ±  2.1 6.3 ±  2.2 6.5 ±  3.6 N D
Each value represents the mean ±  s.e. mean of 5-24 determinations. Lead was administered in the maternal drink­
ing water from conception ( —  21 days) to postnatal day 14. N D  =  non detectable.
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Figure 2 Effect of perinatal lead exposure on the onto­
genesis of 5-opioid receptor afiinity. Lead (Pb) was 
administered in the maternal drinking water from con­
ception to postnatal day 14. Open columns, 0p.p.m. 
Pb; stippled columns, 100p.p.im-Pb; hatched columns, 
300p.p.m. Pb; cross-hatched columns, lOOOp.p.m. Pb. 
[3H]-[D-Pen2,D-Pen5]enkephalin was used as the 
binding ligand and each value represents mean of disso­
ciation constants determined from at least 5 Scatchard 
analyses; vertical lines indicate s.e. mean. One-way 
analysis of variance for lead groups *  P  <  0.05.
those groups where lead caused changes in site affin­
ity.
There were no significant effects of lead on maternal 
or neonate weight gain or maternal fluid intake (data 
not shown).
Discussion
The profile of postnatal development of both f i -  and 
5-sites in the control groups (0 p.p.m.) was essentially 
similar to that obtained by ourselves (McDowell &  
Kitchen, 1986) and others (Spain e t  a l . , 1985) pre­
viously. Thus, with respect to opioid receptor 
binding, the acetic acid component is without toxic 
effect. Despite suggestions that this component may 
in some instances adversely affect behaviour (Barrett 
& Livesey, 1982), it is clearly preferable to chronic 
administration of sodium nitrate which has been 
shown to increase the number of opioid binding sites 
(Baraldi e t  a l. , 1984). DPDPE non-specific binding 
was high in both control and lead-treated groups, a 
problem in the use of this binding ligand for devel­
opmental studies (McDowell &  Kitchen, 1986).
The failure of perinatal lead exposure to alter 
binding characteristics at the ,u-opioid site is sur­
prising, since opioid-mediated responses such as 
antinociception are impaired at ages equivalent to 
those used in this study (Kitchen e t  a l . , 1984; 
Kitchen & McDowell, 1985). This perhaps indicates 
that the toxic effects on antinociceptive response to 
opioids are manifested at a site other than the jt- 
opioid receptor; an obvious possible candidate is the 
second messenger systems coupled to the [ i -site. It is 
noteworthy that this protocol of perinatal exposure 
severely suppresses the development of peptide pro­
ducts of proenkephalin (Bailey & Kitchen, 1985) and 
at ages where these opioid peptides are virtually 
undetectable after lead exposure (day 10), /t-opioid 
peptide function does not result in disruption of /i- 
opioid binding. There are indications, however, from 
this study that the ontogeny of 5-opioid sites is sus­
ceptible to lead exposure, as affinity for DPDPE is 
decreased. This effect persists into adult animals and 
abnormal K D values were recorded 5 weeks after 
cessation of lead treatment. Since the time for turn­
over of opioid receptors is likely to be in the order of 
days, it is probable that the toxicity is manifested at 
the level of the genetic message for the receptor 
protein. This effect appears irreversible and is of par­
ticular concern, since blood levels of lead correspond 
to the lower limit for sub-clinical lead poisoning in 
man (Royal Commission Report, 1983). It is conceiv­
able that the toxic effects oi 5-receptors result from 
the loss of proenkephalin peptide in early postnatal 
development, since these ligands are considered to 
show selectivity at 5-sites and may function as 
physiological mediators at these receptors (Paterson 
e t a l. , 1983).
One other study of the effects of lead on opioid 
receptor development has been presented in the liter­
ature (Baraldi e t  a l . , 1985) and in this study [ 3H]- 
naloxone was used as a binding ligand. A significant 
increase in the number of sites was observed without 
a change in affinity. The disparity of this data may 
reflect the use of the nitrate salt of lead given by 
gastric intubation since the nitrate salt itself causes 
changes in B ^  (Baraldi e t a l. , 1985), and intubation 
may produce compounding problems of stress- 
related effects which have been shown to be different 
in lead-exposed animals (Barrett &  Livesey, 1985).
In conclusion, perinatal lead exposure does not 
alter the ontogeny of /t-opioid receptors but doses of 
1000p.p.m. in the maternal drinking water decrease 
the affinity of 5-opioid receptors. This change in 
5-sites persists after cessation of lead exposure, poss­
ibly suggesting irreversible damage in the production 
of receptor protein.
The work was supported by a project grant from the Well­
come Trust.
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